•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

•Why must I use this?

•When will I use this?

I first realized the importance of fluorescent proteins as tech when I began working on circadian clock research, focusing on the role of BMAL1. My project has required seeing how BMAL1 colocalizes with other clock proteins inside living cells. At that point, I recognized that traditional biochemical methods, though useful, could not fully capture the spatial and temporal dynamics of protein interactions. This was my first when the moment I needed a tool that could allow real-time visualization of proteins within their natural cellular context.

Later, during my work on the dengue virus, I had the opportunity to apply this technology more directly. I worked with two different subtypes of DENV-2, one of which carried a GFP marker. This allowed us to compare cytopathic effects (CPE) and viral protein expression between the two strains, providing insights that would have been difficult to obtain with conventional assays alone.

To understand how this tech works, I studied the basic principles of fluorescent proteins such as GFP. In essence, the gene encoding GFP or its variants can be fused to the gene of a target protein, creating a fluorescently tagged version. When this construct is expressed in cells, the protein emits light under specific wavelengths, making it possible to track its localization and dynamics under a microscope. While I did not perform the genetic modifications myself, I had received the model from my previous senior mates; reading and learning about these steps, which gave me the foundation to interpret experimental outcomes.

Through these experiences, I came to understand why fluorescent proteins are so powerful. They are invaluable when studying processes that demand live, real-time monitoring, such as viral replication, protein trafficking, or immune cell activation. Beyond virology and circadian biology, I believe that they are also essential in broader areas like developmental biology, where following gene expression and cell fate decisions over time provides a deeper understanding of life processes.

How can I use this?

In practice, I would use fluorochrome-conjugated antibodies to label B cells. These antibodies target both surface markers (such as CD19, CD38 for human and B220 and CD138 for mouse) and intracellular metabolic proteins (such as PHGDH). After B cells are purified and stained, the samples are analyzed using a flow cytometer. Gating strategies are then applied to identify distinct B cell subsets and quantify their metabolic marker expression.

Why I must use this?

Flow cytometry offers the advantage of high-throughput, single-cell resolution, enabling simultaneous measurement of multiple spectra (I perform staining with at least 8 different fluorochromes in every experiment). This technique allows the correlation of B cell subsets with metabolic protein expression, thereby unveiling heterogeneity in metabolic reprogramming.

When will I use this?

In addition to detecting the enzymatic activity of metabolic proteins in B cells, I can design experiments that involve supplementing or depleting specific metabolites within a pathway of interest. Following these interventions, I would analyze B cell surface markers to determine whether the metabolic pathway influences B cell activation or development.

Conclusion

Flow cytometry was the first fluorescence-based technique I was introduced to. It serves as a powerful method for analyzing protein expression across different cell types, and it has greatly enhanced my proficiency in conducting experiments involving immune cells.

I worked out some roles they can act in the cell biology field:

1. Observing dynamic cell processes, for example, cell movement, intracellular trafficking(proteins, mRNAs), and mitosis/meiosis, all of these may not be easily seen even with a optical microscope(except the cell cycle)

2. A marker in detecting material movement in an individual's body, although most of the time we solve this problem by labeling with radioactive elements.

3. A checking marker in technologies such as gene transfer, when the goal characteristics are uneasy to notice, fluorescent can a rather noticeable feature to detect.

Well, is there anything we can achieve only by implementing fluorescent marker?

It turns out that fluorescent technique dominates when it comes to living-cells physiology because traditional stains or antibodies often require dead cells.

I can implement the fluorescent technique mainly when I want to observe originally invisible cell actions or when I want to label cells optionally, I have also found that some fluorescent proteins are specially designed to act towards environmental changes, easy to observe cell response.

1. How can I use this?

   • I can use this technology to measure host responses towards certain probiotics. When testing probiotics as chemotherapy for cancer, fluorescent conjugates (ex., Annexin V–FITC and PI or Propidium Iodide) can be used to measure how many cancer cells undergo apoptosis and the stage of it, leading to necrosis. These markers will be combined, and using flow cytometry, I can quantify the percentage of live, early apoptotic, and late apoptotic cancer cells.

2. Why must I use this?

   • By using fluorescent markers, I can accurately quantify the proportion of cells undergoing apoptosis (both early and late stages) and necrosis. On the other hand, other methods typically measure only overall cell death without distinguishing the specific stages of apoptosis. The data will be more comprehensive and reliable if I utilize this technology.

3. When will I use this?

   • Generally speaking, I can use this technique when I need to visualize and track specific molecules, cells, or processes in real time. In my current study, this can be applied to monitor how probiotics interact with cancer cells, to follow the expression of apoptosis-related genes, or to see where a probiotic’s therapeutic protein goes inside a cancer cell and watch how it moves around.

How can I use this?
I can construct promoter–fluorescent protein reporter strains (e.g., adeB-GFP, carO-GFP) to directly observe how these genes are expressed under tigecycline induction. I can also use fluorescent labeling to visualize biofilm formation and bacterial distribution.

Why must I use this?
Because fluorescent proteins provide live, dynamic, and visual data. Unlike MIC or qPCR that give only endpoint results, fluorescence lets me confirm whether resistance-related genes are activated in real time, and it makes the data easier to present.

When will I use this?
I will use it after identifying candidate resistance genes from MIC, qPCR, or WGS. At that stage, I can validate their expression with reporter assays, and also use fluorescent imaging to compare biofilm development between parental and tigecycline-induced resistant strains.

Currently my research surrounds bacterial antibiotic resistance and the current protocols I use don't use fluorescent tagging techniques. However, I believe this technology can be valuable in certain situations.

How I can use this:

I can use next generation sequencing (e.g. Nanopore) to sequence the whole genome of my bacterial samples, leveraging its fast sequencing speeds by rapidly recording the florescent signals let out by the incorporation of florescent tagged nucleotides to the to-be sequenced nucleotide chain, giving me several reads that can be assembled into the complete genome of my sample. With the whole genome of the bacteria sequenced, it can allow me to analyze the resistance, virulence and other profiles of the given samples, gaining insights in the properties of the said strain.

Why I must use this:

Using whole genome sequencing is a relatively efficient way of comprehensively learning about a given bacterial sample, and sequences can be further analyzed in silico, reducing the need for biochemical tests. For instance, the antimicrobial resistance profiles of a bacterial strain can be simply analyzed through Resfinder where traditionally several rounds of antimicrobial susceptibility tests and PCRs may be performed to learn about its susceptibility to certain antibiotics and the genes contributing to it, which can result in being time-inefficient.

When I will use this:

I will use whole genome sequencing when I wish to comprehensively learn about a certain bacterial strain of interest, or when I wish to perform an in-depth analysis of a small number of strains, in which that performing large amounts of traditional biochemical tests to gain the needed data is not efficient enough.

I can use fluorescence because it provides a living, renewable way to observe cells. Unlike dyes or stains that often kill the sample, fluorescent proteins allow continuous observation without harming cell integrity by fusing with the target gene.  In my last hands-on experience, dTomato was not just pretty red colonies; it was a practical tool to confirm that my cloning experiment had worked and that the gene was expressed

I will use fluorescence whenever I need to study events that are invisible or unclear under a normal light microscope. For example, while basic microscopes allow me to see general cell shape or division, fluorescence enables me to track specific proteins (such as GFP or mCherry), nuclei (DAPI), or signaling pathways in real time, and it is also applied in techniques such as flow cytometry and FACS. There are also dye-based types of fluorescence, which are widely applied in methods like next-generation sequencing (NGS). In my own course, dTomato served as a reporter by producing red colonies in E. coli, which confirmed the success of my cloning experiment. A practical research example I connect with is in Huntington’s disease: in one study, AAV-shRNA fused with a fluorescent marker was injected into the brain, and the fluorescence signal was then used to observe its distribution and effectiveness across eight brain regions, allowing researchers to directly monitor the knockdown of a Huntington-related gene. Even though I have not yet carried out such experiments, this shows me how fluorescence can bridge my classroom knowledge and the real work in my lab’s disease research concentration.

Application of fluorescent proteins in cell biology

How can I use it?

Choose the right fluorescent wavelength (color)

Clone fluorescent proteins into cells

Detect with: fluorescence microscopy, FACS

Analyze: localization, intensity, co-localization, time-lapse dynamics

 Why must I use it?

Fluorescent proteins allow you to:

Visualize processes inside living cells

Use a non-invasive and genetically encoded method

Measure changes in intensity, localization, or interactions over time

 When will I use it?

Studying protein function

Studying dynamics (e.g., cell migration, signaling)

Tracing cell fate

Checking gene expression

Testing interactions or pathways

How can I use this?

In my mouse model (K8-Cre; RFP/+), I use fluorescent staining and FACS to isolate and analyze specific cell populations from tumor tissues. Fluorescent markers allow us to sort cells based on their expression. For example, selecting K8-Cre (linked to GFP marker) and RFP-positive cells post-dissection for establishing organoid cultures. I also use immunofluorescent staining to visualize protein markers in tissue sections, which helps us better characterize different tumor types and investigate the potential roles of selected genes in ovarian cancer development.

Why must I use this?

FACS enables accurate, high-throughput isolation of target cells, which is important when working with more complex tissues or rare cell populations. Immunofluorescent staining offers clearer and more specific localization of protein markers compared to standard immunohistochemistry, making it very useful for observing lineage markers and analyzing tumor heterogeneity.

When will I use this?

I already use both fluorescent staining and FACS in my work with the K8-Cre; RFP/+ mouse model to isolate tumor samples after dissection and identify key markers in tissues. They are important tools for my research, and I will continue using them for future experiments.

How can I use this? 

Fluorescent proteins can be used in cell biology to vizualize cells components or track molecular processes in living cells. These proteins emit light when it is exited by specific wavelengths which allows researchers to observe the bodies they are linked to. 

Why must I use this? 

Fluorescent proteins are used because they offer high sensitivity, spatial and temporal resolution, and they also allow to quantify molecular interactions. It allows to study proteins localization and cells dynamics without disrupting the cell’s natural environment

When will I use this? 

For live cell imaging, during studies of proteins or of cell mechanics.

Email: ltmtrang.ls14@nycu.edu.tw

After today’s class, I can see how this technique connects physics, chemistry, and biology into tools that are actually useful for studying immune cells.

When will I use it?

I will use it first to confirm that the engineered cells are expressing what I expect. Later, I can apply it in experiments that test how these cells perform during phagocytosis, and compare them with normal cells as part of the project on lupus.

Why must I use it?

Fluorescence allows me to track the changes directly, so I can evaluate whether the enhanced phagocytes really work better, which is important if I want to think about therapy for lupus.

How can I use this technique?

I can use fluorescent proteins to check if the cells I am working with really express the molecules I introduce, and to see their position inside the cell.

1. How can I use this?

In my research, fluorescent proteins could be used as reporters to track the expression of metabolic genes in probiotic strains. For example, I could clone a fluorescent protein gene under the control of a promoter that responds to a specific metabolic pathway. This would allow me to visualize when and where the pathway is active under the microscope. I could also use different colors of fluorescent proteins simultaneously to study multiple pathways in the same bacterial population.

2. Why must I use this?

Since my goal is to design a probiotic that can respond to specific signals and regulate certain metabolic pathways, I need to observe how efficiently when the genes are activated to regulate metabolism. (I haven’t decided which pathway to focus on yet) Fluorescent proteins allow me to monitor gene expression in real time, without harming the cells. This means that I can track the changes over hours or days, and compare different designs to see which ones work best. This information is critical for building a probiotic that functions reliably inside the host.

3. When will I use this?

I would probably use fluorescent proteins when I’m testing my probiotic designs to see whether they work or not. The use of fluorescent proteins would let me easy to track which design will work on after receiving the right signals. And in animal experiments, I would like to use them to track where the probiotic function well in the gut

How can I use this?

I use fluorescent tools to track monocytes in my research. With bi-transgenic CCR2-CreER; R26R-GFP mice, I can label CCR2⁺ monocytes with GFP. This lets me follow how they move into the brain after tau injection. I also use immunofluorescence to check tau pathology in brain slices, and fluorescence-activated cell sorting (FACS) to sort out GFP+ monocytes for further experiments like RT-qPCR.

Why must I use this?
I need to use the Cre-LoxP system to label CCR2⁺ monocytes, because once these cells infiltrate into the brain, some of them differentiate into microglia-like or macrophage-like cells, then lose CCR2. If I only stained for CCR2, I would miss these cells and not know they actually came from the blood. With GFP labeling, I can still trace their origin even after they change.

When will I use this?
I use fluorescence at several stages: right after tau injection to see GFP⁺ monocytes entering the brain, several months later when staining brain slices to follow tau spread, and also when I isolate GFP⁺ cells with FACS to study their gene expression.

Since this class is one of the first steps in my studies, I did not have much experience to share. However, during my undergrad project, I had the chance to work with cells and was given the opportunity to work with an inverted microscope and a few basic techniques. Among all these, the most familiar technique I once worked with was the fluorescent-based technique called flow cytometry.

At that time, my previous research group was at the first step of constructing an in vitro model to analyze the protective effects against aging agents of an in vitro-cultured plant in Vietnam. Although many studies had been carried out on different types of plants, the difficulty of our project at that time was due to the rarity of this plant in nature, and it was also considered an endangered species, that was why we could not take out the natural sample, as well as previous studies for reference. Back then, the team had to carry out experiments to measure the viability of cells when treated with the ROS-inducing reagent, or IC50 measurement. Although we had implied the resazurin dying assay, the data presented showed a slight to no significant difference in the data comparison. The project leader then came to the decision to apply flow cytometry to analyze the apoptosis percentage of the cell line.

At first, we dyed the cell population with Annexin V and Propidium Iodide staining solution. Before flow cytometry, this staining step aims to label specific cellular components or markers with fluorescent dyes or antibodies to enable their detection and quantification as cells pass through the cytometer. In our case, we want to detect the rate of healthy cells per apoptotic cells per population, as well as whether they were in an early apoptosis or late apoptotic/ necrotic phase, and flow cytometry is a standard technique used to detect and differentiate apoptotic and necrotic cells based on the externalization of phosphatidylserine and membrane integrity.

The results did not disappoint us when, finally, after tonnes of failed experiments, we finalized the IC50 concentration to introduce cells with the targeted aging-inducing reagent. Based on these results, we could later carry out the EC50 concentration to further establish an analysis of the plant's properties. This took us one step closer to this project's first and foremost aim. It was a tough moment, yet it created chances for me to learn and practice another new method, and I could apply my knowledge to the new project ahead.

1. How can I use this?
   Fluorescent proteins can be used in several ways in cell biology. First, they can be employed to observe living cells by fusing the gene of a fluorescent protein (such as GFP) with the gene of the protein of interest, allowing visualization of these cells by fluorescence. They can also be combined to simultaneously track several proteins within the same cell by using multi-color labeling. Finally, they can be used to quantify proteins or cellular structures in vivo.

2. Why must I use this?
   Fluorescent proteins enable specific and stable labeling of the target protein because they are genetically encoded. They have high sensitivity and resolution, which even allows the detection of low-abundance molecules. This makes it possible to directly observe various cellular processes, for example in living organisms. Moreover, they can be adapted to many cell types and model organisms and are non-invasive to them.

3. When will I use this?
   Fluorescent proteins are used when one wants to work in vivo in order to visualize a cellular phenomenon. They can be used to study the localization of organelles or signaling pathways directly in living cells, to monitor responses to treatments, or to follow the behavior of infectious agents in cellular or animal models.

I can use fluorescent proteins as a way to actually see what’s happening inside living cells. By tagging proteins of interest, I can track their movement, interactions, and expression in real time. This helps me connect what I read in theory to what I can visualize in the lab.

Why must I use this?

I must use this because many modern studies in cell biology rely on visual evidence. If I want to really understand processes like signaling pathways, protein localization, or cell division, fluorescent proteins give me the most direct and convincing way to observe them. Without this tool, it would be very difficult to study these processes dynamically.

When will I use this?

I will use this whenever I need to monitor how cells behave under different conditions, such as during stress, drug treatment, or genetic modification. It’s especially useful in future research projects where I may need to prove not just that a protein exists, but where it goes and how it acts inside the cell.

How can I use it? 

Cell fluorescence can be used for different purposes such as cell tracking and cell identification, which are very useful for any type of experiment in biology. In addition, cell fluorescence is applied in many techniques such as: 

FRAP (Fluorescence Recovery After Photobleaching), which measures the mobility of proteins or lipids inside the cell. 

Immunostaining, which uses antibodies to detect a specific protein in a sample. 

Fluorescence microscopy, including confocal and TIRF microscopy, to visualize proteins and structures in cells. 

Flow cytometry and FACS, which are used to analyze and sort cells based on their fluorescent properties. 

DNA microarray and next-generation sequencing (NGS), which use fluorescent labeling to study gene expression and genomes. 

Why must I use this? 

Because fluorescent labeling makes cell identification possible, and it also provides preliminary results when studying the role and function of a protein. It helps to understand protein localization, dynamics, and interactions. 

When will I use this? 

I will use cell fluorescence when I need to identify, track, or analyze cells and proteins, or when I want to study their function, location, or dynamics in biological experiments. It is also used when working with techniques such as FRAP, immunostaining, fluorescence microscopy, flow cytometry, FACS, or genomic tools like DNA microarray and NGS 

How can I use this?  

First, it is useful to locate the target sequence and repair DNA damadge buy generating new DNA strands, using a DNA repair system. Different technologies make this possible: Zinc Finger Nuclease and TALEN, which combine DNA binding domains with a FolkI nuclease to create a break in the double strand. Also, CrispCas9 is a technology which uses a guide RNA and a nuclease to cut at a precise location. These technologies allow to do knock out, mutation or insertions, depending on the experimental goal. 

Why must I use this? 

Because it is really powerful to identify the protein function. By creating knock outs, we can identify the role of the protein. We can also create mutations to try to cure a disease or repair the damaged DNA using HDR. Gene editing allows to control the genome, something that random mutagenesis can’t like chemicals or radiation. 

When will I use this? 

I can use this to identify the function of a gene or a protein, repair defective genes, modify or regulate gene expression, for example using Crispr not only for editing, but also for transcriptional activation, repression, or even cell reprogramming

How can I use this?

I can use CRISPR/Cas9 technology to knock out or regulate key enzyme genes involved in serine biosynthesis, such as PHGDH. By designing specific sgRNAs and introducing the CRISPR system into primary human or mouse B cells, I can achieve targeted gene knockout. After these edits, I would evaluate how the changes affect B cell development, differentiation (using flow cytometry), proliferation, and function. This evaluation would include analyzing surface markers, measuring metabolic products, and testing functional antibody production.

Why must I use this?

CRISPR is seen as a revolutionary tool because it is simple, inexpensive, can target multiple genes at the same time, and is highly useful. Compared with traditional gene editing methods, it is generally more efficient and practical for both research and potential therapeutic applications. Using this approach can help us better understand the underlying molecular mechanisms and also provide support for developing future therapeutic strategies that focus on metabolic pathways in immune-related diseases.

When will I use this?

I would apply this approach in several situations:

During functional experiments that investigate the metabolic role of B cells throughout their developmental stages, from progenitors to mature cells.

When confirming the critical role of specific metabolic enzyme genes in regulating B cell phenotype and metabolism.

When long-term and stable regulation of a target gene is required, combined with testing its function in both in vitro and in vivo models.

These applications are supported by recent studies and experimental evidence using CRISPR-based gene editing in primary human and mouse B cells (In fact, I’ve done it before!). And they provide effective strategies to address unresolved questions about how the serine biosynthesis pathway contributes to B cell development.

1. How can I use this?
I can use CRISPR-Cas9 to knockout or modify resistance-related genes (for example, efflux pump genes like adeABC or regulators) in A. baumannii. This allows me to directly test how these genes contribute to antibiotic resistance and phenotype switching in the bacteria.

2. Why must I use this?
I must use gene editing because conventional methods like random mutagenesis cannot precisely target specific resistance genes. Gene editing gives me a direct and reliable way to establish cause-and-effect relationships—for example, proving whether the increased tigecycline resistance is due to overexpression of a pump or mutation in a regulator. This accuracy is essential for developing strategies to overcome multidrug resistance.

3. When will I use this?
I will use gene editing when I need to:

• Validate candidate resistance genes identified from sequencing or transcriptomic data.

• Construct isogenic mutant strains (e.g., adeABC knockout) to study phenotypic changes.

• Investigate cross-resistance or collateral sensitivity by introducing or deleting specific mutations.

•How can I use this?

Fluorescent proteins can be used in almost any situation researchers can think of. In the past I had worked on a mouse cancer model in which a mouse pancreatic cancer cell line was established and transfected with the gene to produce a variant of GFP, along with the gene to produce luciferase. The two genes were linked so that if a cell is seen to have GFP, it is assumed that it is also producing luciferase. In this way the cancer cells can be tracked using both GFP fluorescence and luminescence (when the cells are treated with a solution containing luciferin). The model our lab had produced involved injecting these GFP/luciferase producing cancer cells into mice to induce tumor growth. The growth of the tumor can then be monitored in vivo using luminescence signals. And afterwards the tumor tissue can also be analyzed under a fluorescent microscope or using flow cytometry.

•Why must I use this?

There other ways to attach a fluorescent signal to a target cell of interest. For example staining with fluorescence-tagged antibodies or with fluorescent dyes that are known to bind to certain structures in cells. However, there are instances when this is not practical or convenient. In the case of flow cytometry, maybe the protein of interest resides within the cell and not on the surface, so staining would require perforating the cells' membrane. This adds an extra step to the experiment which may or may not be feasible. In other cases, the cells might be required to maintain viability for downstream experiments and so the membrane must be kept intact. In such an experiment, it would be more ideal for the cell to simply be carrying an endogenous fluorescent signal such as GFP, right at the beginning, rather than require staining afterwards.

•When will I use this?

In a hypothetical experiment, there is a specific type of anti-cancer drug that specifically targets cancer cells by supposedly inducing a process called autophagy. But autophagy is also known to promote cell survival in different contexts. By using genetic engineering techniques to establish a cancer cell line that produces fluorescently labeled proteins, I can use fluorescent microscopy to monitor a cancer cell's internal process when undergoing autophagy, and then when this cancer cell is treated with the above mentioned anti-cancer drug, I would be able to do time point monitoring of the cancer cell's response to this drug, all while keeping the cell alive so that different time points can be taken throughout the process of autophagy. This would be one of the typical ways for researchers curious about how autophagy affects cancer cells to obtain insights into what happens during this phenomenon.

Gene editing might be the technique that separates "classic biology" from modern molecular biology. In the early days of gene editing, one of the main uses of this tool was to produce gene knockouts in order to study the function of a specific gene. For example, in developmental biology, researchers who wanted to know what role a gene played in the normal development of mouse embryos, they can use gene editing to excise a gene suspected to play a crucial role for embryonic growth. If the result is that the embryo grows abnormally, then they can further investigate how the gene functions. Today, gene editing is usually used to insert a gene with a desirable function into cells for specific experimental goals. For example, in my lab, we had previously tried to produce CAR-T cells using gene editng (lentivirus transduction, later Crispr-CAS9). In this scenario, the gene for the desired artificial antigen receptor, that would allow the CAR-T cells to recognize and attack the specific cancer cells which the CAR-T cells are designed against, are inserted into the cell's genome, allowing it to produce the antigen receptor, and when these CAR-T cells, expand in population, all descendants will also carry this antigen receptor.

•Why must I use this?

There are times when a gene needs to be permanently edited, such as in the above example where CAR-T cells need to be cultured and expanded, for use in therapy. In this situation, clonal expansion is required, so the gene modification needs to be fixed into the genome of the cells. To ensure a stable supply of consistent cells, all with the same altered gene, it is necessary to perform genetic editing on parent cells.

•When will I use this?

In my current field of research, I may be trying to culture cells specifically to produce exosomes with certain traits. This will require establishing a cell line with stable genetic modification. One example of gene editing in regards to the field of exosomes is to upregulate the genes related to exosome production, thus increasing the yield of exosomes produced by cell culture. Another example is to upregulate, or even insert into a cell, a specific sequence for generating microRNAs, which are then packaged into exosomes and then secreted by the cell.

I think gene editing isn't a rare topic for everyone, when that statement is only for knowing the CrisprCas9. I listened to the ZFNs and TALEN the first time in my life, well I find it rather hard to understand, perhaps because of lack of experience in labs.

So how can we use this? The answer is also unbelieveing simple, to correct or modify genes, before the technology came out, we only know RNA inhibiting and protein inhibiting, that quite come in handy when we want to observe temporary changes in cells,but how about cancelling out a mutation, alternating RNA doesn't solve the problem from the root. Imagine if we can add codons deplete codons on the gene arbitrarily(well in fact there are still limits in lab practices), we may solve a lot of diseases including cancer or inherited diseases.

And why do we must use it, for a simple reason, it is cost effective and time saving compared to other nowaday technique. And I think we can only use gene editing to deplete DNA codons, DNA silencing by appling methylation or phosphorylation might do the trick, but we still need the gRNA or ZFN to get the position.

When will I use it? Maybe one day when I am diving into cancer and inherited disease research. I may apply CrisperCas9 to prove my theory and as a solid result.

How can I use this?
I can use fluorescent proteins to track how Bifidobacterium interacts with host cells. For example, I can tag probiotic strains or specific proteins to see how they colonize the gut environment or affect host cell responses.

Why must I use this?
Fluorescent proteins allow me to visualize living processes in real time. This gives more precise and dynamic information than traditional staining methods, such as seeing where probiotics attach, how they influence cell signaling, or how they change host metabolism related to weight control.

When will I use this?
I will use this technique when studying the effect of probiotics on host cells, especially when I need to follow colonization, protein expression, or molecular pathways. In weight-control research, it can help me monitor how Bifidobacterium influences host fat metabolism at the cellular level.

Why must I use this?
I would need CRISPR because it gives me a very direct way to test whether certain genes are truly driving the disease. Other methods, like drugs, can have side effects, but gene editing would let me clearly confirm the role of CCR2 or Syk.

When will I use this?
I would probably use CRISPR at the beginning, to build mouse models with specific knockouts or reporters. Later, I could use it again to test new targets I find, for example, checking if removing a signaling gene helps slow tau transmission or improves memory in the mice.

How can I use it?

After creating a guide RNA for a certain DNA location (next to a PAM like NGG), I introduce Cas9 and the guide into cells, and Cas9 cuts. If NHEJ is used for repair, I knock off the gene. If I provide HDR a donor template, it will replace or insert the sequence (knock-in). Additionally, I am able to make accurate point modifications without double-strand breakage using Base or Prime editors.

Why must I use it?

I can test gene function, create disease models, confirm medication targets, investigate therapeutic repair of mutations, and design cells or microorganisms for beneficial products thanks to my accurate, quick, and scalable gene control.

 When will I use it?

When I need to demonstrate the function of a gene by turning it on or off, replicate a patient mutation, do pooled screens while a patient is receiving therapy to identify targets or resistance mechanisms, or construct isogenic cell lines, organoids, or animals that closely resemble human genotypes, I employ gene editing. I always take delivery constraints, off-target hazards, and legal or ethical obligations into consideration.

Gene editing can be applied by first identifying the correct genomic location, then introducing a DNA break, and finally relying on the cell’s repair systems to modify the sequence. These edits are carried out mainly through non-homologous end joining (NHEJ), which often produces insertions or deletions, or through homology-directed repair (HDR), which allows more precise modifications when a donor template is present

Why must I use it?

This approach is considered the most powerful method to study protein function because it enables direct connections between genotype and phenotype, offering more specificity than random mutagenesis or chemical mutagens

When will I use it?

I will use gene editing when studying diseases in which regulating gene expression provides insights into molecular mechanisms. My lab focuses on working with Huntington’s disease, and recently I came across a paper discussing a gene editing tool: CRISPR-Cas9. Because the wild-type HTT protein still has essential functions for cells, directly cutting and permanently disrupting the gene is not ideal. In this study, the researchers used CRISPRoff, a modified version of Cas9 fused with DNMT3A/L and KRAB, to silence the gene epigenetically instead of producing double-strand breaks. However, in the context of Huntington’s disease, this approach faces several limitations. First, the repression is not durable: HTT mRNA levels recover after about seven weeks, so the silencing cannot be maintained long-term. Second, the effect is not allele-specific; CRISPRoff reduces total HTT expression rather than selectively silencing the mutant allele, which risks harming normal cellular functions that depend on HTT. Third, delivery relies on viral transfection, and repeated viral injections every few weeks are neither practical nor safe for clinical application. Therefore, although CRISPRoff is a powerful and promising tool for studying gene function in general, within the specific context of Huntington’s disease it is not yet a truly viable therapeutic strategy.

I can use this technique to perform gain or loss of function experiments on bacterial clinical isolates, gaining insights on how this particular gene might affect its virulence or resistance to antimicrobial substances. First, I have to locate and sequence the target sequence for my CRIPSR/cas9 setup, then I can either knockout the gene, swap it with another similar gene, or give it an extra gene to determine the function of the gene in my strains.

Why must I use this?

Sometimes it is hard to find two strains nearly identical except for the gene of interest, or all the strains tested all have the gene, which is especially true if clinical isolates are the subject of the study. Thus, I must use gene editing to construct a specific mutant that is only one gene different from my target strain, so that I can observe the difference the gene brings without any other interference. It will also be especially convenient if my genes of interest are located in the chromosome instead of plasmids, making it harder to manipulate with other techniques.

When will I use this?

I can use this technique when I want to compare the virulence and toxicity of a virulence gene in a certain strain, without locating a similar strain to compare with. I can construct a mutant without the virulence gene and another mutant with another similar virulence gene replacing the original one (e.g. replacing the siderophore gene entB with iucA, another virulence gene), then assess the virulence and toxicity of these mutants compared to the original strain.

I can utilize CRISPR-Cas9 gene editing to study the function of candidate genes like TBX3, which is a potential IOR marker in mouse ovaries. We are exploring IOR as a possible origin of HGSOC, so knocking out TBX3 in vitro or in vivo would help us to investigate whether it plays a role in tumor initiation or suppression.

Why must I use this?

CRISPR offers more efficiency, specificity, and long-term gene manipulation compared to our current siRNA, which tends to be transient and incomplete. To study TBX3’s role in IOR and HGSOC progression, a more reliable and permanent gene modification method is necessary.

When will I use this?

I hope to use CRISPR in future experiments to knock out TBX3 in our organoid models, and eventually also in our mouse models. This will help us to analyze the early tumor development and could be used to generate reporter lines for lineage tracing or fluorescence-based tracking.

I first encountered genome editing during my master’s research when I studied the role of Galectin-3 in dengue virus infection. To answer that question, we worked with THP-1 cells where Galectin-3 was knocked down, and with Galectin-3 knockout AG86 mice to investigate how this protein influences viral replication and immune responses. That was my when: the moment I saw how genetic modification could be used to directly dissect the function of a single host factor in the middle of a complex infection process. Later, in another project on human cytomegalovirus (HCMV), I was also involved in knocking down certain intracellular proteins in HFF cells that play roles in viral entry, which gave me another perspective on how gene editing tools can uncover virus–host interactions.

The how of genome editing is based on a simple principle: identify the gene of interest, introduce a targeted break in its DNA, and then allow the cell’s repair machinery to make changes. Depending on the method used, the gene can be disrupted, modified, or even replaced. While I did not perform the entire process of designing or delivering the editing systems myself, I learned the essential steps. For example, a guide sequence can be designed to bring an editing enzyme like Cas9 to the correct DNA location, where it introduces a cut. The cell then repairs that cut either by error-prone pathways that knock out the gene, or by precise repair if a template is provided. Understanding this logic allowed me to connect the technical details with the biological outcomes I was analyzing in the lab.

The why became clear from my own results. Genome editing gave me a direct way to test hypotheses about the role of Galectin-3 and other host proteins in viral infection. Without such tools, it would have been impossible to move beyond correlations and actually see what happens when a single factor is removed from the system. More broadly, genome editing is valuable because it enables us to ask and answer very precise questions about gene function, immune regulation, and host–pathogen interactions. It provides a way to observe real-time biological consequences of genetic changes, whether in cultured cells or in animal models.

I can use what I learned in the “Gene Editing in Molecular Biology” lecture to understand how genome editing tools like CRISPR-Cas9 can be applied to bacteria such as Lactobacillus. For example, if I want to knock out or modify certain genes involved in stress resistance, adhesion, or metabolite production, gene editing would allow me to study their exact function. This can directly support my thesis work on screening and evaluating probiotics for colitis.

Why I must use this:

Gene editing is essential because traditional mutagenesis methods are less precise and often time-consuming. By using modern gene editing approaches, I can generate targeted mutants and clearly link specific genes to probiotic traits. This not only strengthens the scientific validity of my experiments but also makes my findings more impactful for developing therapeutic probiotics.

When I will use this:

I will use this knowledge when I design experiments to study how certain genetic modifications influence bacterial survival in acid/bile conditions or adhesion to intestinal cells. Later, I may also apply it if I need to create engineered probiotic strains with improved anti-inflammatory effects for colitis models. Beyond my thesis, I’ll use gene editing skills in any future research that involves functional studies of microbial genes.

How can I use this?

I haven't did gene modifying in the past, but take the homework as example. We want to get glucagon, and in a large scale. It does make sense that getting it from humans may be costly and time-consuming. We can use E. coli, which is easy to culture and implement the process.

Why must I use this?

Costly and time-consuming may be a point, but the more important idea is that the process may not be ethical, and by reviewing history, we used to extract glucagon from pigs before the recombinant technology has been widespread, the yield may be deemed unsafe.

When will I use this?

In labs, I will apply this technology when I want to research on some kind of protein in a large scale, then applying the method can increase efficiency.

I can use recombinant protein design and purification to study protein-protein interactions and to validate the expression of recombinant proteins in specific tissues, especially when studying newly established and yet uncharacterized marker proteins in ovarian cancer. This technique enables us to produce tagged proteins for pull-down assays, fluorescent labeling, and antibody validation in our organoid models.

Why must I use this?

Recombinant proteins are important when studying specific interactions, testing antibodies, or performing assays with proteins that have a low or inconsistent endogenous expression. This is because tagged proteins enable cleaner immunoprecipitation, clearer Western blot detection, and a more controlled experimental setting, which is especially helpful when exploring the function of new marker proteins.

When will I use this?

I am not sure if I will use this technique soon, however, I have used it extensively in the past, during my bachelor's thesis, where I studied the interaction of polyadenylation components with the U1 snRNP in Arabidopsis thaliana. We co-expressed tagged proteins in Nicotiana benthamiana and used immunoprecipitation followed by Western blotting to test their interactions.

How can I use this? 

For me, I can use recombinant protein technology when I need to study or produce a protein that is hard to collect in nature. By inserting the gene into e. coli or yeast, the cells will make the protein for me. After that, I can purify it using standard lab methods like chromatography. This way, I can get enough protein for my experiments without depending on rare or expensive sources. 

Why must I use this? 

I think this method is necessary because it solves both ethical and practical problems. In the past, proteins such as glucagon or insulin were taken from animals, but the process was expensive and sometimes unsafe for humans. Using recombinant technology, I can produce the same protein in a controlled system with better quality and stability. It also allows scientists to improve the protein if needed, for example making it more effective as a drug. 

When will I use this? 

I will probably use this in the lab when I need large amounts of protein to analyze. For example, I could use it to test how a protein interacts with other molecules or to check its structure and function. I also see this as useful if I work in the biotechnology industry, because many medicines, enzymes, and vaccines today are made with this technology. 

How can I use this?

I can express and purify subunits of ATP synthase, such as the β-subunit and c-ring, as high-purity tag-free recombinant proteins. These subunits can then be reconstituted into a functional complex to test ATP synthesis activity and measure proton transport. This allows me to analyze oxidative phosphorylation capacity in activated B cells and plasmablasts.

Why must I use this?

As B cells differentiate, oxidative phosphorylation is strongly upregulated, and plasmablasts basically depend on ATP synthase to produce antibodies. Germinal center B cells also remodel their mitochondria and assemble more ATP synthase. By using purified recombinant proteins, I can avoid the noise from mixed cell systems and focus directly on the biochemical changes. This is important for understanding normal B cell metabolism and also for studying diseases like multiple sclerosis and lymphoma, where oxidative phosphorylation is often abnormal.

When will I use this?

I would use this when looking at how B cells switch from glycolysis to oxidative phosphorylation (around 48–72 hours after activation), during germinal center formation (about 1–2 weeks after immunization), or when testing how ATP synthase inhibitors affect antibody production. It’s also useful in disease models like autoimmune disorders or B cell cancers, where OXPHOS serves as a potential therapeutic target.

1. How can I use this?
I can use recombinant protein expression to produce resistance-related proteins from A. baumannii, such as efflux pump components or regulatory factors. By purifying these proteins, I can study their biochemical properties and interactions, which helps me link genetic changes to actual protein function.

2. Why must I use this?
Because understanding resistance at the molecular level requires sufficient and pure protein. Clinical isolates don’t give me enough protein for structural or functional studies. Recombinant expression is the only way I can get stable, analyzable amounts, and this is crucial if I want to confirm how specific mutations or regulatory pathways contribute to drug resistance.

3. When will I use this?
I will use it once I identify candidate genes linked to resistance in my A. baumannii strains. At that point, I need to clone, express, and purify the corresponding proteins to test their activity—for example, whether a modified efflux pump really changes substrate specificity, or whether a regulator directly affects gene expression.

I could use gene editing to engineer probiotic strains with modified genetic circuits that detect specific signals and control targeted metabolic pathways. For example, I could knock out genes that interfere with the pathway which I want to control or insert new genes under specific promoters to make the pathway turn on at the right time. With gene editing, I can make precise changes that would allow me to test different designs of my engineered probiotic.

Why must I use this?

If my goal is to build a probiotic that can really control metabolism, I can’t just rely on wild strains. With gene editing, I can design the precise circuits required for my probiotic. This technique would able to test different versions of the probiotic design more directly and see which one works better. Without gene editing, I would only be observing what probiotics normally do instead of guiding how they react to signals.

When will I use this?

I think I would use gene editing mostly at the beginning of my project when I’m building the engineered probiotics. That’s the stage where I need to add or remove certain genes and see which design works the best. Later on, I might use gene editing again to optimize the strain especially if I want it to be more stable and safer before moving into animal experiments.

Recombinant protein production starts with cloning the target gene into an expression vector, introducing it into a suitable host such as E.coli, and then inducing expression. The expressed protein can be tagged for easier purification and separated using methods like affinity chromatography, ion-exchange, or size-exclusion, depending on the needs of the experiment. Finally, the purified protein is stabilized for storage and downstream applications.

Why can I use this?

because it provides a reliable way to obtain proteins in large amounts and high purity, which are difficult to extract directly from native sources. It allows me to analyze biological activity, study structure–function relationships, therapeutic candidates, generate antibodies, developing target-specific drugs, or produce vaccines. In the context of my own research on Huntington’s disease, recombinant huntingtin fragments can be produced to study aggregation mechanisms and to test therapeutic approaches.

When will I use this?

I’ll use recombinant protein design and purification whenever I need defined, purified protein for biochemical assays such as enzyme kinetics or binding. In the summer course, I cloned and expressed dTomato in E.coli, saw red colonies, purified the protein by Ni-NTA, and confirmed it on SDS-PAGE. This experience gave me my first direct visualization that the process works. In future research, such as studying Huntington’s disease, I could apply the same principles to produce huntingtin fragments or related proteins to investigate their aggregation and potential therapeutic targets.

I can use recombinant proteins to test whether my engineered probiotics are producing the enzymes or regulatory proteins I designed. For example, I plan to engineer a probiotic to produce a protein that activates a pathway involved in short-chain fatty acid (SCFA) production and I could purify the recombinant protein and measure its activity in vitro. Recombinant proteins could also serve as markers to check whether the probiotic is responding correctly to specific signals, such as changes in nutrient levels or pH level.

Why must I use this?

Recombinant proteins allow me to measure directly whether my probiotics are producing the target proteins instead of relying on indirect indicators like metabolites or gene expression. This is crucial for verifying that the engineered pathways are functional or not. They also make it possible to compare different designs or strains under controlled conditions which help me to determine which genetic modifications are most effective for regulating metabolism.

When will I use this?

I would use recombinant proteins after I generate my engineered probiotic strains. They would allow me to quantify protein expression levels using techniques like SDS-PAGE or Western blot. I could also evaluate protein stability over time or under different environmental conditions and measure enzymatic activity through specific biochemical assays. In later in vivo studies, recombinant proteins could serve as molecular markers to track the probiotics localization in the gut and to verify that the target proteins are delivered and functional within the host environment.

The how relies on combining genetic engineering with biochemical purification. A gene of interest is cloned into an expression vector and introduced into a suitable host system, such as E. coli, yeast, insect, or mammalian cells. The expressed protein is often fused with tags that improve solubility and facilitate purification. Once produced, the protein is isolated using chromatography techniques such as affinity, ion-exchange, or size exclusion, yielding a stable and functional product for downstream analysis.

The why lies in the versatility of recombinant proteins. They are indispensable for exploring protein structure and function, testing drug interactions, raising specific antibodies, and even developing vaccines or therapeutic agents. In research on viral infections, for example, recombinant host and viral proteins allow direct investigation of binding, entry, and immune activation, bridging genetic information with functional understanding.

I can use the knowledge of “Recombinant Protein Design” to understand how it can be applied in probiotic research, particularly in studying and modifying functional proteins that contribute to gut health. For example, if I identify a beneficial protein from a Lactobacillus strain—such as an anti-inflammatory peptide, antioxidant enzyme, or adhesion-related protein—learning how to design and express it recombinantly will allow me to further characterize its activity, stability, and therapeutic potential. By learning techniques like vector design, restriction digestion/ligation or Gibson assembly, transformation, protein expression, affinity purification (His-tag/Ni-NTA), and SDS-PAGE/Western blot confirmation, I will be able to produce and study these proteins in isolation.

Why I must use this?

I must learn this because recombinant protein design provides a way to validate the mechanisms of action of probiotic strains beyond just whole-cell assays. It enables me to isolate and test specific protein factors that may play a role in colitis protection, making my findings more precise and mechanistically clear.

When I will use this?

I will likely use this knowledge when I move from strain-level screening to molecular-level characterization during my project, or later in follow-up studies when exploring the bioactive proteins secreted by promising probiotic candidates. This skill will also be valuable in my future research career if I pursue probiotic-derived therapeutic development.

In the study of induced Pluripotent Stem Cells (iPSC), the use of defined media is sometimes necessary for the culturing and maintenance of such cells. There are also certain other cell lines where the culturing and growth of said cells requires using growth medium that does not contain any animal products, such as bovine fetal serum. This means that the growth factors and other necessary signaling molecules all must be derived from a single verifiable and non-animal source. In such an application, recombinant protein technology can be used to derive and mass produce proteins, growth factors, and signaling molecules, etc, that can then be highly purified and used as a component in the derived media used for culturing iPSC and other cell lines requiring such culture conditions.

•Why must I use this?

For complex macromolecules such as proteins, it is impossible with today's technology to chemically synthesize from scratch. Therefore, the use of cell lines, yeast, or bacteria cultures, and employing recombinant protein technology, is one of the viable methods for mass producing synthetic proteins, for research, medicine, or industrial use.

•When will I use this?

When I need large amounts of purified proteins, or in some cases modified proteins for experimental use. For example, as a research tool, maybe I want to produce an antibody to recognize a specific protein target, in order to do experiments such as immunoflourescent microscopy or flow cytometry. The antibody might normally be produced by human B cells. The genes for producing this protein can be isolated and using genetic engineering methods, inserted into the genome of a cell line such as CHO cells. The CHO cells can then be used to help produce large quantities of the desired antibody. The gene for producing this antibody can also be modified genetically, to produce a protein with desirable traits, such as an antibody with higher specificity, for example.

I can use this technique to get large amounts of a certain protein for further analysis, such as carbapenemases, efflux pumps or porins from carbapenem resistant Klebsiella pneumoniae strains, which aligns with my current research. I can first acquire the sequence of a certain resistance gene I am interested in, for example carbapenemase gene VIM or IMP, then add a fusion tag to the sequence and transfer it into another bacterial cell. After lysing and purifying, I can have a lot of porin proteins to run experiments.

Why must I use it?

Expressing recombinant proteins can allow me to effectively purify my protein of interest through fusion tags, without using other lengthy or costly processes. Normally it is very difficult to obtain analyzable amounts of proteins from clinical isolates, or it is hard to induce the cells to produce the desired protein without antibiotics with may interfere with the protein. Therefore, I have to use this technique to have a stable way of obtaining proteins.

When will I use it?

After getting the genetic sequence of carbapenemases from clinical isolates, I will use recombinant proteins to get large amounts of carbapenemases to analyze protein-drug interactions or to determine how mutations can affect the hydrolyzing ability of carbapenemases. Since the antimicrobial resistance profiles and concentrations of strains vary widely, comparing the resistance genes between isolates can allow me to gain insights on how these genes and mutations play a role in antimicrobial resistance in these strains.

I can use gene editing to engineer probiotic strains such as Bifidobacterium to improve their effect on host metabolism. For example, I could knock out genes that limit the production of beneficial metabolites (like short-chain fatty acids) or insert new genes under specific promoters to enhance pathways related to weight control. This allows me to design probiotics with more targeted functions.

Why must I use this?

Wild-type probiotics may not have strong or predictable effects on host metabolism. Gene editing gives me precise control to build strains with the desired genetic circuits, making them more reliable and effective. Without gene editing, I could only observe natural variation, but not actively optimize probiotics for metabolic regulation.

When will I use this?

I would use gene editing in the early stages of my research when creating probiotic designs, testing different genetic modifications, and selecting the best-performing strains. Later, I might use it again to improve stability and safety of the engineered Bifidobacterium before moving into animal experiments for weight-control studies.

How can I use this?
By inserting a target gene into cells like bacteria or mammalian cells, I can produce and then purify large amounts of specific proteins. This enables me to perform experiments to understand how these proteins work.

Why must I use this?
This method guarantees pure, consistent proteins in sufficient quantities and allows me to introduce changes in the protein to study or improve its function. Many important drugs rely on this technology.

When will I use this?
Whenever I need high-quality proteins for experiments, diagnostics, or making medicines such as vaccines and therapeutic proteins.

By understanding protein structure, we can do more things than only knowing the aa sequence. As known before, most proteins only gain function after folding to its tertiary structure, so we can denote its function by observing its structure. And we can also find how protein interact with ligands and DNA because we have its structure. We can also modify our protein to enhance its stability or change its activity.

If we produced malfunction protein in experiments, we can often consult its normal structure to see if there is mis-folding or aggregation.

Why must I use this?

In the field of molecular biology, structure really matters a lot, since a change in structure usually means malfunction.

And when reseaching into drugs or molecular interactions, structure indicates if the invent is feasable or not.

When will I use it?

1. to decide or speculate protein function(without carrying out experiment)

2. to spot mis-folding in recombinant protein exoression

I can use protein structure knowledge to understand how key metabolic enzymes regulate B cell activation and differentiation.

By studying the 3D structures of enzymes such as mTOR, PI3K, or hexokinase, I can identify their active sites, binding pockets, or regulatory domains.

This helps me predict how different inhibitors or activators may affect their activity.

For example, analyzing the structural conformation of mTOR can show how energy signals control B cell growth and the possible downstream signaling pathway.

I can also use computational tools to visualize these proteins and explore how structural changes influence B cell metabolism.

Why must I use this?

Because understanding only the metabolic pathway is not enough, I need to know how these enzymes actually work at the molecular level.

Protein structure reveals how small changes, such as mutations or post-translational modifications, can alter enzyme function and thereby influence immune responses.

By learning the structural basis of enzyme regulation, I can connect metabolism and immunity more deeply.

This knowledge is essential for explaining phenomena like the metabolic switch from glycolysis to oxidative phosphorylation during B cell activation.

In addition, it provides the basis for designing metabolic inhibitors that could modulate immune function in diseases or cancer therapy.

When will I use this?

I will use this knowledge when analyzing experimental data or planning new experiments related to B cell function.

For example, when I observe a change in B cell activity after treatment with an inhibitor, I can interpret the result based on the enzyme’s structural mechanism.

I will also apply it when reading scientific papers, designing potential inhibitors, or studying how metabolic signaling pathways (such as mTORC1 or hexokinase, though  both enzymes are well-studied) control immune cell fate.

If I engage in immunology or drug discovery research, understanding protein structures will be a critical skill for linking molecular mechanisms to immune regulation.

Why must I use this?
Because natural tau aggregation in mice is slow and unpredictable. Recombinant tau gives me a controlled, reproducible way to trigger tauopathy, so I can isolate the effects of monocytes and test interventions like CCR2 knockout.

When will I use this?
At the start of the in vivo experiments—once the recombinant tau is validated, I’ll use it for stereotaxic injection into the hippocampus to establish the disease model and monitor tau spread, immune activation, and behavioral changes over time.

Why must I use this?
Because tau’s pathological effects depend heavily on its folded shape, without knowing the structure, I can’t be sure if the recombinant protein triggers the right immune or behavioral responses in mice.

When will I use this?
Before in vivo experiments—after producing recombinant tau, I’ll use structural tools (like CD, TEM, or cryo-EM) to validate its conformation and ensure it’s suitable for injection and mechanistic studies.

Structural biology techniques like X-ray crystallography and small-angle X-ray scattering (SAXS) can help me analyze the 3D structure of proteins. In combination with protein purification, these methods can reveal the structural basis of a protein's function or interaction. Therefore, I could use protein expression and purification to prepare proteins for structural studies of our currently uncharacterized marker genes.

Why must I use this?

To understand the function, stability, and interaction of a protein, one has to understand the protein’s structure. If a protein is potentially involved in cancer development or progression, structural data can reveal active sites, interaction domains, or conformational changes that might not be obvious from sequencing data alone.

When will I use this?

I currently have no plans to use this; however, after learning more about protein structure, I believe it might be a useful tool for me in the future. It could help me better understand the role of our identified marker proteins in the development and progression of ovarian cancer.

I could apply protein structural biology to study how the 3D structure of a protein relates to its function in probiotic metabolism. By using techniques like X-ray crystallography, NMR spectroscopy or cryo-electron microscopy, I could analyze how specific amino acid residues contribute to enzyme activity or substrate binding. Understanding these structural details would help me design or modify proteins that can enhance or regulate metabolic pathways in engineered probiotics.

Why must I use this?

Protein function cannot be fully understood without knowing its structure. For my project, understanding how a protein folds, interacts with other molecules or changes conformation under different conditions is essential for predicting how it behaves in metabolic regulation. Structural biology also allows me to identify key residues for mutagenesis to improve protein stability and design variants with better catalytic efficiency.

When will I use this?

I would use this technique after identifying target proteins involved in metabolic regulation. Once I have purified these proteins, I could determine their structures and compare them with natural or mutated versions to see how structural changes affect activity. Later in the project, structural insights would guide the rational design of modified proteins to optimize probiotic performance and stability in the host environment.

I can use protein structural biology to understand how specific proteins from Lactobacillus interact with the gut environment, especially during inflammation. It helps me analyze how these proteins bind to host receptors, modulate immune responses, or maintain gut barrier integrity. This is key for figuring out how certain strains might help reduce colitis symptoms.

Why must I use this?

Because colitis (my research area) is driven by protein-level interactions—cytokines, receptors, enzymes—so if I want to understand how Lactobacillus strains actually help, I need to look at the structure of both bacterial and host proteins. Without structural biology, I’d be guessing at mechanisms. It gives me a molecular-level view that’s essential for designing better therapeutic strategies.

When will I use this?

I’ll use it when I’m characterizing surface proteins from Lactobacillus, studying how they bind to epithelial cells, or when I’m looking at inflammatory markers like TNF-α or IL-6. Also, if I ever move into strain engineering or drug development, structural biology will be a core part of that work.

I can use protein structural biology to understand how a protein’s three-dimensional conformation determines its biochemical role. This knowledge is obtained mainly through X-ray crystallography, which involves purifying the protein, crystallizing it, and analyzing the diffraction pattern to build an electron density map that reveals atomic details. By growing protein crystals under controlled conditions (temperature, pH, precipitant), I can visualize active sites, binding pockets, and conformational changes that are crucial for function.

Why can I use this?

Because the structure explains function — knowing how a protein folds or interacts with ligands helps us understand disease mechanisms, enzyme catalysis, and drug design. For instance, Hartmut Michel’s Nobel-winning work on the photosynthetic reaction center and Brian Kobilka’s GPCR structures (2012 Nobel) both relied on crystallography to reveal how structural changes enable biological signaling. Therefore, this method is fundamental for rational drug design and biotechnology applications.

When will I use this?

I will use protein crystallography when studying enzymes or membrane proteins where understanding the 3D conformation is critical. For example, if I want to develop inhibitors for a viral protease or study fluorescent protein mutants, crystallization helps compare wild-type vs. mutant structures. This structural insight explains how small amino acid substitutions alter light emission or activity.

How can I use it? 

CRISPR Cas9 can be used to make precise changes in DNA sequences within cells. It allows us to target specific genes, create knockouts, insert new genetic material, or correct mutations. In research it can be used to found and study gene function; by suppressing some specific part of the DNA sequence, it could also allow us to model diseases or even develop new therapies; by correcting genetic mutations or even creating personalized treatments.  

Why must I use this? 

CRISPR Cas9 is a very powerful tool in the gene editing sector, it is a quite practical tool for understanding biological processes and development of medical solutions. It helps researchers explore how genes work, how mutations cause diseases, and how to potentially fix those mutations. Compared to older methods like random mutagenesis or chemical treatments, CRISPR Cas9 is faster, more exact, and easier to design.  

When will I use this? 

It will be used during experiments that require genetic manipulation, such as studying gene regulation. In a lab it might be used when working with cultured cells, animal models, or even in synthetic biology projects. 

How can I use it? 

To use recombinant protein design and purification techniques effectively, we should begin by selecting a gene of interest that encodes the protein we want to study or produce. This gene is then inserted into an expression vector, which is introduced into a suitable host organism such as E. coli, yeast, insect, or mammalian cells. Once the host expresses the protein, we can purify it. This technique allows us to isolate the protein in a functional and stable form. Some other factors should also be considered Related to what we want to do, like codon optimization, fusion tags...  

Why must I use this? 

Recombinant proteins can be used to produce specific proteins in the laboratory. They are useful in research, for example, to generate large quantities of a studied protein in order to investigate its activity. They can also be applied in medicine to develop certain drugs or create vaccines or used for industrial purposes to produce large amounts of therapeutic proteins, such as insulin for individuals suffering from diabetes. It must be used in research because it is essential for understanding how proteins work and for developing new treatments. Natural proteins are often hard to isolate in large amounts, but recombinant methods allow you to produce them efficiently and in high purity. This is an important tool for studies on protein structure and function, for testing drug interactions, and creating therapeutic proteins like insulin or antibodies. 

When will I use this? 

Recombinant protein design and purification can be used when there is a need to study a specific protein, develop a drug, or create a diagnostic tool. It might also be used in biotechnology projects, such as producing enzymes for food processing or biofuels. 

Gene editing allows the study of gene function, modulation of gene expression, or creation of new phenotypes using programmable nucleases such as CRISPR-Cas9, TALENs, or Zinc Finger Nucleases. These systems work by generating a break in the genome, after which the cell repairs its DNA through two mechanisms (NHEJ and HDR), enabling the introduction of a mutation or a DNA fragment from another genome. Thus, this technique can be used to modify a specific gene, introduce a known mutation, correct a defective gene, or insert a transgene. It can also be employed to create cellular and animal models of human diseases to study the molecular functions of a gene or to optimize cell lines for therapeutic antibodies.

2. Why must I use it?

Genetic editing allows for a better understanding of gene function, which is why it is notably used in gene therapy. For example, it enables the correction of mutations responsible for genetic diseases and the reprogramming of immune cells, particularly in the development of cancer therapies, by making cells more effective at recognizing and eliminating tumor cells.

3. When will I use it?

In fundamental research, gene editing is used when it is necessary to determine the function of a gene or analyze the consequences of a specific mutation, while in biotechnology, it enables the production of recombinant biomolecules or the creation of optimized cell lines. Additionally, in biomedical research, this technique is employed to test treatments and understand the molecular mechanisms of pathology by reproducing a human disease in cellular or animal models.

Protein structural biology makes it possible to determine the three-dimensional structure of proteins and to understand the link between their spatial conformation and their biological function. It relies on several experimental methods, including X-ray crystallography, cryo-EM, nuclear magnetic resonance, and SAXS. These approaches allow the analysis of the atomic arrangement of proteins, visualization of their molecular surface, and identification of the interactions they establish with other biomolecules or pharmacological ligands.

2. Why must I use it?

The structural study of proteins is essential, as knowledge of their three-dimensional architecture is key to understanding their functions. This study helps elucidate the mode of action of enzymes or membrane receptors and identify the effects of mutations associated with diseases. Moreover, structural biology is at the heart of drug design by enabling the modeling of active sites and the design of specific inhibitors.

3. When will I use it?

Protein structural biology is used for applications in fundamental research projects in cellular and molecular biology, in the validation of simulation models, or in the design of new therapeutic agents.

How can I use it? 

To apply this technique, we should begin by selecting a target protein and expressing it. After that we should isolate it. Once purified, it should be crystallized. These crystals can then be analyzed using X-ray crystallography to figure out the protein’s three-dimensional structure. 

Why must I use this? 

Proteins structure can lead to understand how proteins work in living organisms. By learning about protein structure, you can predict how a protein will behave, interact with other molecules, or respond to changes. This is useful in many areas such as drug design, enzyme engineering, and disease research. Proteins are essential for almost every biological process. Understanding of their structure helps explain how they function and how mutations can lead to diseases and that information can be used in medicine.  

When will I use this? 

Those knowledges are used in molecular biology, biochemistry, or biomedical research.  

Why must I use this?
These experiments help me connect gene expression to actual protein function in B cells. Using both PCR and western blot gives me a more complete picture of how metabolic pathways are regulated. Cloning and gene knockout experiments can directly show the role of specific enzymes in B cell activation, differentiation, and antibody production, which cannot be confirmed by expression data alone.

When will I use this?
I would use these techniques when exploring how metabolic genes are regulated during different stages of B cell activation or differentiation. They are also useful when validating the results from high-throughput data, or when testing how knocking out certain metabolic enzymes affects B cell function and immune response.

X-ray crystallography and cryo-electron microscopy (cryo-EM) allow visualization of proteins and nucleic-acid complexes in three dimensions at near-atomic detail. Crystallography analyzes ordered crystals to generate electron-density maps and atomic models, ideal for small, rigid proteins and ligand screening. Cryo-EM images vitrified particles to reconstruct 3-D structures, particularly useful for large or flexible assemblies. Together, they reveal mechanisms, ligand interactions, and guide rational drug or mutagenesis design [1–3].

Why must I use this?

Both techniques translate biochemical observations into spatial mechanisms. Crystallography provides atomic precision, whereas cryo-EM exposes native complexes and multiple conformations—essential for any study requiring structural insight [4–5].

When will I use this?

Use crystallography for soluble, crystallizable proteins needing fine ligand details; use cryo-EM for large, heterogeneous, or membrane targets. Combined, they offer complementary resolution and functional context [1–3,6].

References: 1 Kühlbrandt 2014 Science 10.1126/science.1251652 | 2 Nakane 2020 Nature 10.1038/s41586-020-2829-0 | 3 Cheng 2015 Cell 10.1016/j.cell.2015.03.049 | 4 Ilari 2008 Methods Mol Biol PMID 18563369 | 5 García-Nafría 2021 Biochem Soc Trans PMC8589417 | 6 Chua 2022 Front Rev PMC10393189.

I can use gene transfer methods to introduce specific genes or constructs into cells or organoids to study gene function, expression, or regulation. I could use this in my research to overexpress or silence target genes in organoid models to observe their effects on tumor behavior or differentiation.

Why must I use this?

Gene transfer is important for studying a gene's function, modeling genetic alterations, and validating candidate genes. Compared to transient knockdowns or chemical treatments, stable gene transfer allows for long-term expression or suppression, which makes it especially useful for functional assays, lineage tracing, and drug response studies. It is also a good way to introduce fluorescent or selection markers for further analysis.

When will I use this?

I have previously used vector-based cloning and transformation during my udergraduate studies, where I constructed recombinant plasmids and introduced them into bacteria.

I have not used this in my current research yet, but it might be a useful method in the future to manipulate gene expression in ovarian cancer organoids or cell lines, for example to validate marker genes or study tumor-initiating mechanisms.

I use gene transfer and core molecular biology techniques to probe gene regulation in Huntington’s disease models. First, I assess an ATF4-upstream stress-response regulator at both the mRNA (RT-qPCR) and protein (Western blot) levels in my project. If it is reduced in mutant cells, I then clone and overexpress this regulator via gene transfer and re-measure ATF4 by Western blot to test whether elevating the regulator increases ATF4, establishing a causal link in the stress-response pathway. This staged design helps me understand how stress signaling changes across genetic backgrounds.

Why can I use this?

Because these techniques provide a systematic way to link genetic manipulation with functional outcomes. In my project, I analyze transcriptional and translational changes between wild-type and mutant lines to understand stress-adaptive regulation. Later, I can apply gene transfer to overexpress specific regulators upstream of ATF4, testing whether modulating their levels alters the cellular stress response in the Huntington’s model.

When will I use this?

I currently use RT-qPCR and Western blot to quantify mRNA and protein levels striatum mouse cell line. In the next phase, I’ll use gene transfer—by cloning an upstream regulatory gene into an expression vector and introducing it into cells—to study how its overexpression influences ATF4-related signaling. These steps integrate the core wet-lab workflow from gene delivery to functional evaluation.

During my master’s research on the regulation of the NLRP3 inflammasome and cytokine production in THP-1 cells during DENV infection, I used RT-PCR and Western blot (WB) to evaluate gene and protein expression in response to inflammatory stimuli. RT-PCR allowed me to quantify mRNA expression of NLRP3, IL-1β, and protein virus after treatment with lipopolysaccharide or infection, revealing transcriptional activation patterns. Meanwhile, WB confirmed the expression and cleavage of key inflammasome components, such as pro-caspase-1 and mature IL-1β, providing direct protein-level validation. Together, these methods transform biological observations into quantitative molecular data, establishing how signaling activation translates into protein synthesis and post-translational modification [1–3].

Why must I use this?

Both RT-PCR and WB are essential because they validate mechanisms at complementary levels of regulation. RT-PCR offers high sensitivity for detecting early transcriptional changes even in low-abundance genes, while WB determines whether those transcripts are translated and processed into active proteins. In studies of inflammation, relying on one level alone can be misleading; a rise in mRNA does not always predict increased protein abundance. Using both ensures accurate correlation between gene expression, protein function, and inflammatory outcomes [2–4].

When will I use this?

I will use RT-PCR whenever I need to screen expression changes after gene transfer, inhibitor treatment, or immune activation, especially in pathway analysis. WB will be applied to verify protein activation or modification, such as phosphorylation or cleavage, confirming signaling pathway engagement. In future PhD work, combining RT-PCR and WB will remain a core workflow for validating molecular findings before advancing to higher-resolution assays like proteomics or imaging [1,3,4].

References

Nolan T., Hands R. E., Bustin S. A. Quantification of mRNA using real-time RT-PCR. Nat Protoc, 2006; 1: 1559–1582. DOI: 10.1038/nprot.2006.236.

Bustin S. A. et al. The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem, 2009; 55(4): 611–622. DOI: 10.1373/clinchem.2008.112797.

El-Khoury R. et al. Western blotting: Sample preparation to data analysis. Biotechnol J, 2023; 18(1): e2200267. DOI: 10.1002/biot.202200267.

Mahmood T., Yang P. C. Western blot: Technique, theory, and troubleshooting. North Am J Med Sci, 2012; 4(9): 429–434. DOI: 10.4103/1947-2714.100998.

Why must I use this:
These molecular techniques are crucial to connect the observed probiotic activities with underlying genetic mechanisms. By cloning and manipulating genes, I can confirm whether certain factors (like surface adhesion proteins or antioxidant enzymes) directly contribute to probiotic effects. Expression analysis allows me to verify gene regulation during stress exposure or host interaction, while gene transfer helps in creating engineered strains with improved or traceable traits. Together, these methods will strengthen the scientific validity of my findings beyond basic screening results.

When will I use this:
I will use these techniques after completing the initial functional screenings (acid and bile tolerance, adhesion assay). Once I identify promising Lactobacillus candidates, I can perform gene expression analysis and functional cloning around the mechanistic phase of my research to explore how key genes contribute to their probiotic potential and colitis-protective effects.

1. How can I use this?
I can use structural biology techniques like X-ray crystallography or cryo-EM to study resistance-related proteins, such as efflux pumps or porins. By comparing the wild-type and mutant structures, I can see how certain amino acid changes alter drug-binding sites or membrane channel shapes, which may explain the resistance phenotype.

2. Why must I use this?
Phenotypic data alone can’t tell me the molecular reason behind resistance. Structural information reveals how specific mutations or conformational changes affect protein activity, helping me understand the actual mechanism and even design strategies to block or reverse resistance.

3. When will I use this?
I’ll apply these approaches after identifying key genes or mutations from sequencing or expression analysis. Once I know which proteins are important, I can express and purify them, then analyze their structures to confirm how they contribute to antibiotic resistance.

1. How can I use this?
I can use gene transfer methods to introduce or edit genes in Acinetobacter baumannii to study their role in tigecycline resistance. For example, I can use lentiviral vectors or chemical transfection to overexpress resistance-related genes or knock down suspected genes to observe how these changes affect tigecycline susceptibility. This will help identify key genetic factors contributing to resistance mechanistically.​

2.Why must I use this?
Using gene transfer is essential because it allows me to directly manipulate genes that may confer resistance to tigecycline in AB. By experimentally altering gene expression, I can validate whether specific mutations or gene products are responsible for resistance, moving beyond correlation to causation. This is crucial for developing targeted therapeutic strategies against resistant AB strains.

3.When will I use this?
I will use gene transfer when I need to experimentally test the function of candidate resistance genes identified through genomic or transcriptomic analysis. This typically happens after initial bioinformatics identifies resistance-associated genes, and I need to confirm their role in tigecycline resistance through in vitro or in vivo models. It is a key step in verifying the molecular mechanisms behind antibiotic resistance in AB.

How can I use this?

By understanding protein structure, I can predict the protein's function more accurately than by sequence alone. It also helps reveal how the protein interacts with ligands, DNA, or other molecules. Structural data allows me to modify the protein to enhance its stability or activity. If a protein malfunctions in experiments, I can check for misfolding or aggregation using its structure.

Why must I use this?

Protein structure is closely related to function—small changes in structure can lead to major functional issues. In molecular biology, structure-based analysis is essential for understanding protein behavior. For drug development or interaction studies, structure tells us whether binding is physically and chemically possible. Without structural insight, these predictions would be much less reliable.

When will I use it?

I will use protein structure when I want to predict its function without doing experiments. It’s also useful when I suspect misfolding in recombinant protein expression. In drug research, I’ll use it to study how molecules interact with proteins. Anytime function, interaction, or stability is in question, structural analysis becomes necessary.

How can I use this? 
I can use these experimental techniques, like X-ray crystallography or protein purification, to understand how proteins are built and how they work. For example, by analyzing protein structures, I can see how drugs interact with their targets or how mutations affect function. 

Why must I use this? 
I must use these techniques because they are essential to discovering how life works at a molecular level. Without them, it would be impossible to design effective medicines or understand biological processes precisely. 

When will I use this? 
I will use this knowledge in future research projects or in a laboratory career, especially if I work in biotechnology or medical science, where studying protein structures is key to innovation. 

How can I use this? 
I can use gene transfer techniques to give probiotics new abilities that help during chemotherapy. For example, I could add genes that make them support the immune system or protect healthy cells from damage. This way, the probiotics become active therapeutic tools instead of simple gut bacteria. 

Why must I use this? 
I need to use gene transfer because natural probiotics don’t always have the specific functions needed for cancer treatment. By modifying them, I can make them more effective and targeted, so they help patients better and reduce unwanted side effects. 

When will I use this? 
I will use these techniques at the start of my experiments, when I prepare and design the probiotic strain. Once the bacteria are modified, I’ll test them in the lab to see how well they work in supporting chemotherapy and protecting healthy tissues. 

In B cell metabolism research, I can use ChIP-seq to identify transcription factors that bind to the promoters of key metabolic genes involved in glycolysis, oxidative phosphorylation, or other metabolic pathways.

For instance, HIF-1α directly regulates glycolytic genes in IgA-producing B cells, while Notch1 binds to the promoters of LDHA, PKM2, HK2, and GLUT1, recruiting histone acetyltransferases such as p300 to activate transcription.

ChIP can also reveal how histone modifications influence B cell metabolism. For example, H3K27 acetylation is essential for IgA class switching, which depends on acetyl-CoA generated through glycolysis. In lupus B cells, the histone methyltransferase EZH2 increases H3K27me3 modification to repress BACH2, thereby promoting plasma cell differentiation.

Why must I use this?

By integrating ChIP-seq with RNA-seq, I can distinguish between direct and indirect transcriptional targets. For example, STAT3 binding profiles following TLR stimulation identify primary metabolic gene targets that control downstream signaling and differentiation.

Moreover, ChIP allows me to map the hierarchical regulatory network connecting signaling pathways, transcription factors, epigenetic modifications, and metabolic gene expression. For instance, Syk and mTORC1 can activate EZH2, which adds H3K27me3 marks to the BACH2 promoter, suppressing its expression and facilitating plasma cell differentiation.

When will I use this?

I would use ChIP in several research scenarios, such as:

Verifying transcriptional control of metabolic genes — when I observe altered expression of transcription factors like c-Myc, HIF-1α, or STAT3 during B cell metabolic reprogramming.

Studying metabolite-driven chromatin changes — when I detect fluctuations in acetyl-CoA or SAM levels during B cell activation and want to confirm their effects on histone modifications.

Comparing different B cell subsets — for example, analyzing epigenetic differences among regulatory B cells, memory B cells, and plasma cells.

Email: ltmtrang.ls14@nycu.edu.tw

This week I learned how protein–DNA interaction techniques such as ChIP and EMSA can reveal where a protein binds on DNA and how strong that binding is.

I can use them to check if a regulatory protein truly binds to my target gene and to compare the binding between normal and modified proteins.

These techniques are important because many cellular processes depend on such interactions, and without them we cannot understand how gene expression is controlled.

I think I can use them when studying transcription factors or promoter activity in molecular experiments.

In my research, I use lentiviral transduction to introduce engineered receptors like TIM4 into macrophages.

I use these techniques because they allow stable expression of specific genes, which is essential to understand how phagocytic receptors regulate efferocytosis.

I use them when preparing modified cell lines or macrophages to test whether enhanced efferocytosis can improve the clearance of apoptotic cells in lupus models.

How can I use this?

Chromatin Immunoprecipitation (ChIP) allows me to study how proteins interact with DNA in living cells. The process begins with crosslinking protein–DNA complexes using formaldehyde to freeze interactions, followed by chromatin fragmentation and immunoprecipitation with specific antibodies. The associated DNA is then purified and identified through qPCR, microarray (ChIP-on-chip), or next-generation sequencing (ChIP-seq) to map protein binding sites across the genome.

Meanwhile, the SELEX (Systematic Evolution of Ligands by Exponential Enrichment) method enables the selection of DNA or RNA aptamers that bind with high affinity and specificity to a target molecule. It involves iterative cycles of binding, partitioning, amplification, and enrichment from a random oligonucleotide library until strong binders are isolated.

Why can I use this?

ChIP: because it determines how transcription factors and histone modifications regulate gene expression. ChIP reveals dynamic epigenetic regulation that cannot be observed through in vitro assays alone.

SELEX: because nucleic acids can fold into unique 3D structures that recognize specific targets similarly to antibodies. The iterative selection process allows for improving aptamers with precise molecular recognition without requiring immune systems. Aptamers are stable, modifiable, and cost-effective, making them valuable in diagnostics, biosensors, and therapeutics.

When will I use this?

I will use ChIP when I want to explore gene regulation mechanisms, such as identifying transcription factor binding sites or mapping histone modifications under different cellular conditions.

I will use SELEX when I need to generate specific molecular probes or therapeutic tools. For instance, in future projects, I could design RNA aptamers that detect disease biomarkers or inhibit protein aggregation in neurodegenerative diseases such as Huntington’s.

These two methods together would allow me to connect regulatory mechanisms at the chromatin level with the development of molecular tools for disease detection and intervention.

1. How can I use this?
I can apply methods like ChIP or EMSA to investigate whether specific transcription factors bind to promoters of resistance-related genes in A. baumannii. This would help me connect regulatory protein binding with the activation or repression of these genes.

2. Why must I use this?
Many resistance traits are linked to transcriptional regulation rather than just mutations. Studying protein–DNA interactions helps me understand how gene expression is controlled and how the bacteria adjust their transcriptional network in response to antibiotics.

3. When will I use this?
I plan to use these techniques after identifying potential regulatory genes that are differentially expressed in resistant strains. Then I can confirm whether those proteins directly interact with the promoter regions of resistance genes to control their expression.

1. How can I use this?

   • If my probiotic produces a protein that helps protect intestinal cells, I can use ChIP to see which host genes that protein (or a host transcription factor it activates) binds to. This helps me identify whether it turns on protective genes (like those for antioxidants or cell repair) or turns off stress-related genes.

2. Why must I use this?

   • I should use ChIP in this research because it helps in understanding the mechanism behind how the probiotic works, and not just the effects. Although experiments can show that a probiotic protects cells or reduces inflammation, ChIP reveals how that happens at the genetic level by showing which genes are turned on or off when certain proteins bind to DNA.

3. When will I use this?

   • I would use Chromatin Immunoprecipitation (ChIP) after I have enough evidence that the probiotic or its protein affects gene expression. For example, when I see certain protective genes increase or decrease in your treated cells. That’s when I perform ChIP to find out how this happens by checking which genes or DNA regions the probiotic protein (or a host transcription factor it activates) actually binds to.

I can use Microarray-Based Methods (PBMs) to analyze thousands of DNA–protein interactions simultaneously and identify binding motifs across genomic regions. In contrast, EMSA verifies direct binding between a purified transcription factor and a labeled DNA probe by detecting mobility shifts in non-denaturing gels. Together, they reveal both broad binding specificity and precise complex formation [1–3].

Why must I use this?

These methods are essential for validating transcription factor–DNA recognition. Microarrays provide high-throughput motif discovery, while EMSA confirms binding affinity and complex stability. Using both ensures accuracy from large-scale prediction to molecular validation [2–4].

When will I use this?

I will use microarrays for genome-wide mapping or motif screening, and EMSA for confirming specific protein–DNA interactions or comparing mutant and wild-type binding [1,3,4].

References

Berger M. F. et al. Compact, universal DNA microarrays for comprehensive transcription-factor binding site analysis. Nat Biotechnol, 2006; 24: 1429–1435.

Lam K. N. et al. Protein-binding microarrays for rapid characterization of transcription-factor binding specificity. Methods Mol Biol, 2023; 2670: 29–54.

Hellman L. M., Fried M. G. Electrophoretic mobility shift assay (EMSA) for detecting protein–nucleic acid interactions. Nat Protoc, 2007; 2: 1849–1861.

Liu X. et al. High-resolution EMSA analysis of transcription factor complexes. Front Mol Biosci, 2022; 9: 956382.

I can use the techniques of protein–DNA interaction studies, such as ChIP (Chromatin Immunoprecipitation), EMSA (Electrophoretic Mobility Shift Assay), and DNase I or hydroxyl radical footprinting, to understand how host transcription factors or bacterial proteins regulate genes involved in intestinal immunity and inflammation. For instance, ChIP-seq could help identify how certain transcription factors (e.g., NF-κB or STAT3) bind to promoters of cytokine genes in the colon during probiotic treatment. Similarly, EMSA can be used to test whether bacterial components or host nuclear proteins directly bind to specific DNA regulatory regions involved in anti-inflammatory responses.

 2. Why must I use this?

I must use these techniques to uncover the molecular mechanisms behind how probiotic strains influence host gene regulation. While physiological assays show observable effects (like reduced inflammation), protein–DNA interaction studies can prove how these effects occur — by revealing which transcriptional regulators or signaling pathways are directly modulated. Such molecular evidence strengthens the scientific basis of probiotic efficacy and can guide the discovery of key probiotic–host targets for therapeutic use in colitis.

 3. When will I use this?

I will use these techniques during the mechanistic validation phase of my project, after identifying effective Lactobacillus strains through screening and animal studies. For example, after observing reduced inflammatory markers in colonic tissues, I could use ChIP or EMSA to confirm if specific transcription factors (e.g., NF-κB, Nrf2) show altered DNA binding activity in response to probiotic treatment. Such experiments could be part of collaborative mechanistic studies or follow-up experiments once promising probiotic candidates are established.

I can use the techniques of protein–DNA interaction studies, such as ChIP (Chromatin Immunoprecipitation), EMSA (Electrophoretic Mobility Shift Assay), and DNase I or hydroxyl radical footprinting, to understand how host transcription factors or bacterial proteins regulate genes involved in intestinal immunity and inflammation. For instance, ChIP-seq could help identify how certain transcription factors (e.g., NF-κB or STAT3) bind to promoters of cytokine genes in the colon during probiotic treatment. Similarly, EMSA can be used to test whether bacterial components or host nuclear proteins directly bind to specific DNA regulatory regions involved in anti-inflammatory responses.

 2. Why must I use this?

I must use these techniques to uncover the molecular mechanisms behind how probiotic strains influence host gene regulation. While physiological assays show observable effects (like reduced inflammation), protein–DNA interaction studies can prove how these effects occur — by revealing which transcriptional regulators or signaling pathways are directly modulated. Such molecular evidence strengthens the scientific basis of probiotic efficacy and can guide the discovery of key probiotic–host targets for therapeutic use in colitis.

 3. When will I use this?

I will use these techniques during the mechanistic validation phase of my project, after identifying effective Lactobacillus strains through screening and animal studies. For example, after observing reduced inflammatory markers in colonic tissues, I could use ChIP or EMSA to confirm if specific transcription factors (e.g., NF-κB, Nrf2) show altered DNA binding activity in response to probiotic treatment. Such experiments could be part of collaborative mechanistic studies or follow-up experiments once promising probiotic candidates are established.

I can use protein-DNA interaction techniques, such as ChIP or ChIP-seq, to see if specific transcription factors or chromatin modulators bind to promoter regions of genes associated with ovarian cancer. This helps identify regulatory elements and shows how specific genes are transcriptionally controlled during tumor initiation and progression. Methods like EMSA or DNA footprinting can later be used to confirm or map these binding sites.

Why must I use this?

 If we understand protein-DNA interactions, we can see how gene expression is regulated at the chromatin level. Many cancer-related genes are controlled by transcriptional and epigenetic mechanisms, and these methods help us study these regulatory relationships directly.

When will I use this?

I haven’t used this technique yet, but it could be useful to see how transcription factors or chromatin-associated proteins regulate the expression of our target genes.

How I can use this?

I primarily use viruses themselves as tools. I genetically engineer viruses by removing their disease-causing genes and inserting therapeutic or reporter genes instead, creating viral vectors. The most common types I work with are lentiviruses for stable, long-term gene expression and adeno-associated viruses (AAV) for safer, targeted delivery. I use these modified viruses to infect specific cell types, where they efficiently deliver the genetic payload without causing the original disease.

Why must I use this?

I use gene transfer in virology for two main reasons: research and therapy. For research, I use viral vectors to introduce or silence genes in specific host cells. This allows me to meticulously study the function of host factors in viral replication or the function of a single viral gene in pathogenesis. For therapy, I design viral vectors to act as vehicles for delivering correct copies of genes to treat genetic disorders (gene therapy) or to engineer a patient's own immune cells to fight cancer and other diseases.

When will I use this?

I apply gene transfer technologies when I need a highly efficient method to manipulate cellular processes or deliver a genetic cure. Specifically, I use them when creating recombinant viral vaccines, where I insert genes from a pathogenic virus into a safe viral backbone to stimulate an immune response. I also rely on them when developing oncolytic viruses, which are engineered to selectively replicate in and kill cancer cells. Furthermore, it's my go-to method for building robust cellular and animal models to study virus-host interactions in a controlled manner.

How can I use this?

I use ChIP to map where specific proteins, like transcription factors or modified histones, interact with the genome in living cells. The process involves cross-linking proteins to DNA, fragmenting the chromatin, and using specific antibodies to pull down the protein-DNA complexes for sequencing.

I use SELEX to develop DNA or RNA aptamers that bind to a target molecule of interest with high affinity. This involves iterative cycles of incubating a random nucleic acid library with the target, partitioning the bound sequences, and amplifying them to evolve the best binders.

Why can I use this?

I use ChIP because it provides an unbiased, genome-wide view of epigenetic regulation and gene control in a native cellular context, revealing mechanisms that are invisible in simplified in vitro systems.

I use SELEX because it allows me to generate synthetic binding molecules (aptamers) that are stable, cost-effective, and highly specific. These aptamers can be raised against targets for which antibodies are difficult to obtain, making them versatile tools for detection and inhibition.

When will I use this?

I will use ChIP when I need to identify the direct genomic targets of a regulatory protein or map histone modifications during a specific cellular process, such as viral infection or cell differentiation.

I will use SELEX when I need a specific molecular probe for diagnostics or a therapeutic inhibitor. For instance, I could select an aptamer to detect a unique biomarker or to block the function of a critical protein involved in a disease pathway.

Using these methods together would allow me to first use ChIP to discover a critical protein-DNA interaction regulating a disease, and then use SELEX to develop an aptamer that targets that specific protein for detection or therapeutic intervention.

How can I use this?

I use RNA extraction to isolate total RNA from cells or tissues. This process typically involves lysing samples in a chaotropic buffer to inactivate RNases, separating RNA using acid-phenol-chloroform phase separation, and finally purifying and concentrating the RNA, ensuring the integrity of these fragile molecules for downstream analysis.

I use CRISPR-Cas13 to directly target and cleave specific RNA sequences. After designing a guide RNA (crRNA) complementary to my target mRNA, I deliver the Cas13 protein and the crRNA into cells. Upon binding, Cas13 becomes activated and degrades the target RNA, allowing me to knock down its expression without altering the genome.

Why can I use this?

I use RNA extraction because obtaining high-quality, intact RNA is the non-negotiable foundation for any subsequent RNA analysis, whether it's qRT-PCR, RNA-Seq, or Northern Blot. Without a pure RNA template, all downstream results would be unreliable.

I use CRISPR-Cas13 because it provides a highly specific and programmable platform for knocking down RNA. Unlike RNAi, which can have off-target effects, Cas13's cleavage is directed by a precise guide RNA sequence, making it a superior tool for studying the function of specific transcripts or for developing nucleic acid-based diagnostics.

When will I use this?

I will use RNA extraction at the beginning of virtually any experiment aimed at understanding gene expression, such as when I need to analyze how a drug treatment or viral infection changes the transcriptional profile of a cell.

I will use CRISPR-Cas13 when I need to perform a transient, highly specific knockdown of a particular RNA isoform or a non-coding RNA to study its function. I would also use it to develop a diagnostic assay, leveraging its collateral RNAse activity to detect trace amounts of a pathogen's RNA, like SARS-CoV-2.

In my project, I could use gene transfer to introduce synthetic or modified genes into probiotic strains so they can regulate in specific metabolic pathways. Techniques like transformation,conjugation or phage-mediated transduction could be used depending on the strain. For example, I could transfer genes with encoding enzymes, transcriptional regulators or biosynthetic pathways into a probiotic to make it capable of modulating host metabolism.

Why must I use this？

Natural probiotics don’t have the genetic circuits needed for sensing signals or controlling metabolism in a precise way. Gene transfer allows me to add those functions instead of relying on what the bacteria can already do. It also gives me flexibility which I can test different promoters, regulatory elements or enzymes in the same host strain and compare their performance. Without gene transfer, I would only be observing natural behavior rather than engineering the cells to produce, degrade or regulate metabolic compounds in a controlled manner.

When will I use this？

I would use gene transfer at the beginning of my experimental design right after planning the genetic circuit or pathway I want to introduce. It’s the step where I move from theoretical design to an actual engineered probiotic. Later in the process, I might use gene transfer again to modify or optimize the strain such as adding regulatory elements, replacing promoters or integrating genes into the chromosome for stability.

I could use RNA techniques to analyze how gene expression changes in probiotics under different conditions or after genetic modification. For example, I could use RT-qPCR to measure the mRNA levels of metabolic genes. I could also done RNA extraction followed by gel electrophoresis to check the RNA quality. Furthermore, I could use RNA sequencing to see which genes are unregulated or down regulated when the probiotic senses a certain signal or activates a metabolic pathway.

Why would I use this？

Transcription happens before translation and metabolic changes, so if I only measure proteins or metabolites, I’ll miss the earlier regulatory step where the cell actually decides whether to express the gene or not. By analyzing RNA, I can understand the gene regulation process at an earlier stage, before changes appear at the protein or metabolite level. RNA techniques let me check if my engineered circuit is actually being transcribed, whether the promoters are functioning properly or if something inside the cell is preventing expression. They also help me compare different designs or probiotic strains to see which one shows a stronger or more precise transcriptional response.

When would I use this ？

I would use RNA techniques after I introduce the genetic circuit into the probiotic and want to confirm that the genes are being transcribed. Another point where I would rely on RNA analysis is when I need to see how transcription is altered by gut-like conditions including acid stress, fluctuating glucose levels or host immune signals. If the project eventually progresses to in vivo experiments, I could extract RNA from bacteria isolated from the gut to verify whether the metabolic genes are still being transcribed inside the host.

Start by matching the technique to the biological question and the sample I actually have, then turn to X-ray crystallography for molecular detail, SAXS when I need overall shapes in solution, and cryo-EM for large or heterogeneous complexes that resist crystallization. I can plan experiments end-to-end, expression, purification by affinity/ion-exchange/size-exclusion, then crystal growth or grid preparation, so data collection and analysis are the natural culmination rather than an afterthought, and use those insights to sketch transition state analogs or blockers for drug design.

Why must I use this?

Because protein structure anchors function. Without 3D information, models of transport, catalysis, or signaling remain speculative. Solid purification and assay design prevent weeks of trial and error at the bench. Most importantly, translational work, from GPCRs to ion channels and proteases, can routinely turn knowledge of structures into therapeutics, potentially yielding high results.

When will I use this?

Whenever a protein’s phenotype is unclear and I want a structural rationale for loss or gain of function, without utilizing current structure prediction software, or when proposing or validating a drug that mimics a chemical to inhibit a certain ion or substrate pathway of interest.

I can use gene cloning to turn findings from bioinformatics into testable functions. In practice, I can take candidate genes from whole genome analyses, for example carbapenemases, porins, or regulators, and evaluate them in wet-lab experiments. I can rescue a disrupted gene, construct a mutant, or adjust promoter strength to compare phenotypes with an isogenic control. Pairing susceptibility testing (e.g. MIC) with transcripts and, when possible, protein readouts to link genotypes, expression, and resistance levels can help me verify my bioinformatic results.

Why must I use this?

These methods are needed when correlation from whole-genome data isn’t enough to support a mechanism. Controlled introduction or restoration of a single feature separates “gene present” from “gene expressed” and from “gene effective in this host background.” Furthermore, testing gene and protein expression indicates whether an observed phenotype is the same with transcription or translation. Together, these approaches can provide concrete, reproducible evidence that a specific element is correlated to antibiotic resistance in a defined context.

When will I use this?

I will use this immediately after bioinformatic gold digging flags a plausible element and whenever two isolates carry similar genes but show different antibiotic resistance profiles on experimentation. It is also useful during mechanism mapping and when evaluating whether resistance genes in a certain strain can transfect other strains, or by simply constructing a mutant to verify that the gene is highly associated to resistance. Applying the methods can confirm that the proposed determinant changes susceptibility under controlled conditions and that the supporting expression data align with the phenotype.

I can use the RNA methods to connect genotype to functional RNA outcomes in antibiotic resistant bacteria. In practice, I can extract RNA from my target bacteria and run RT-qPCR for resistance associated genes to learn about its gene expression, then validate with RNA sequencing across antibiotic exposure, doses, and time points. Northern blotting can also be used to validate my RNA sequencing results, giving me a comprehensive view of the transcriptional changes of bacteria upon exposure to antimicrobial agents.

Why must I use this?

Whole genome analyses don’t necessarily reflect gene expression, therefore, using methods such as RNA sequencing or Northern blotting can allow me to visualize the amount of RNA in my target cells. Sometimes bacteria small RNAs can also influence mRNA translation, so it is useful when it is important to differentiate whether a change in phenotype is due to genetic mutations, or due to regulations in gene expression. RT-qPCR is also an effective way of measuring gene expression in target cells due to its sensitive nature, and unlike RNA sequencing or northern blotting, RT-qPCR is more efficient and can produce results that can be compared quantitatively.

When will I use this?

I can use RT-qPCR immediately after WGS or plasmid analysis to confirm expression of predicted genes, or during antibiotic time courses to capture induction kinetics. For example, I can measure the amount of porin mRNA in bacterial cells after I expose them to antibiotics using RT-qPCR, then compare the results by timepoints or generations, gaining knowledge of how this strain can evolve or adapt to antibiotic pressure.

How can I use this?

To study B cell metabolism using RT-qPCR, careful experimental design and sample preparation are crucial.
First, I would select the appropriate B cell subsets—such as naïve, activated, germinal center, or plasma cells. The timing of sampling also matters since metabolic reprogramming occurs rapidly after B cell activation, so collecting samples at multiple time points (e.g., 0, 2, 4, 8, 12, 24, and 48 hours) allows me to track dynamic gene expression changes.

Why would I use this?

RT-qPCR offers several advantages in studying B cell metabolism:

• High Sensitivity and Precision: It can detect low-abundance transcripts, even in rare B cell subsets or early activation stages.

• Transcriptional Insight: RT-qPCR provides direct evidence of transcriptional regulation, helping to link signaling pathways (e.g., BCR, TLR, or CD40) with metabolic gene expression.

When would I use this?

RT-qPCR is particularly useful in the following research:

• Dynamic Metabolic Reprogramming: To monitor gene expression changes during B cell activation, differentiation, or antibody production.

• Signaling Pathway Studies: To measure how signaling pathways such as PI3K/mTOR or TLR regulate metabolic enzyme expression.

• Disease-Related Metabolic Changes: To identify abnormal gene expression in autoimmune diseases, B cell cancers, or immune deficiencies.

• Gene Function Validation: After CRISPR or shRNA-mediated knockout/knockdown of a metabolic enzyme, RT-qPCR can confirm gene editing efficiency.

RNA-based technologies can be applied to regulate gene expression and develop therapeutics. mRNA vaccines deliver chemically modified RNA into the cytoplasm using lipid nanoparticles, allowing transient protein production and immune activation. RNA interference (RNAi) uses small RNAs such as siRNA or shRNA, processed by Dicer and loaded into the RISC complex, to degrade target mRNAs. RNA-targeting CRISPR systems like Cas13 act directly in the cytoplasm on mature mRNA after intron removal, providing precise and reversible gene silencing. Although RNA is unstable due to RNases, modern stabilization strategies—including RNase inhibitors, PVSA, and lipid encapsulation - protect it from degradation.

Why can I use this?

I can use these approaches because they are rapid, programmable, and safe. Unlike DNA editing, RNA-based modulation avoids permanent genomic changes and allows temporary regulation of disease-related genes.

When will I use this?

I will use RNA-based methods when investigating diseases or cellular processes that require short-term gene modulation. For instance, RNAi or Cas13 systems are particularly useful for studying cytoplasmic mRNA regulation or for targeting toxic RNA repeats in neurodegenerative diseases. In clinical contexts, mRNA vaccines and RNAi drugs such as Onpattro demonstrate how transient RNA delivery can achieve potent therapeutic effects while maintaining safety through degradation over time.

I can use RNA techniques such as RNA extraction, reverse transcription, RT-qPCR, and RNA-seq to measure changes in gene expression in host cells or colon tissues treated with my Lactobacillus strains. This allows me to see how probiotics affect inflammatory and barrier-related genes.

2. Why must I use this?

I must use RNA techniques because they provide mechanistic evidence of how probiotics work. Phenotypic data alone cannot explain how inflammation is reduced — RNA analysis shows which genes and pathways are up- or down-regulated, proving the strain’s functional impact.

3. When will I use this?

I will use these techniques after initial screening, during:

• Cell assays (Caco-2 or immune cells) to evaluate early gene response.

• Animal studies to analyze colon tissue gene expression and confirm anti-inflammatory effects.

I can use RNA techniques such as RNA extraction, reverse transcription, RT-qPCR, and RNA-seq to measure changes in gene expression in host cells or colon tissues treated with my Lactobacillus strains. This allows me to see how probiotics affect inflammatory and barrier-related genes.

2. Why must I use this?

I must use RNA techniques because they provide mechanistic evidence of how probiotics work. Phenotypic data alone cannot explain how inflammation is reduced — RNA analysis shows which genes and pathways are up- or down-regulated, proving the strain’s functional impact.

3. When will I use this?

I will use these techniques after initial screening, during:

• Cell assays (Caco-2 or immune cells) to evaluate early gene response.

• Animal studies to analyze colon tissue gene expression and confirm anti-inflammatory effects.

Why must I use this? RNA techniques are important for understanding gene expression changes in response to genetic alterations or treatments. Many cancer-related genes are regulated at the RNA level through processes like degradation, splicing, or regulation by RNA-binding proteins and small RNAs like siRNAs.RNA studies help us link RNA expression patterns to functional effects observed in our organoids or mouse models. Although CRISPR is more stable and precise, siRNA knockdown is still a practical and effective method used for transient gene silencing in our experiments.

When will I use this? I already use RNA extraction, RT-PCR, qPCR, and siRNA knockdown experiments regularly to analyze gene expression in organoids. I will soon use RNA-seq for a transcriptome analysis and maybe I will use RIP to explore RNA-protein interactions later on in my study.

I can use gene transfer to manipulate key immune-related genes—like overexpressing CCR2 to enhance monocyte infiltration or knocking down Syk to suppress inflammatory signaling. This helps me test how specific gene changes affect tau pathology and behavior in mouse models.

Why must I use this?

Because tauopathy progression involves complex immune responses, and gene transfer gives me a direct way to validate causality. It lets me go beyond correlation from RNA-seq data and actually prove whether a gene drives tau spread, neuroinflammation, or behavioral deficits.

When will I use this?

After identifying candidate genes from transcriptomic or behavioral results, I’ll design plasmids or viral vectors (like lentivirus) and deliver them into cells or mouse brains—either before tau injection or during disease progression—to test their functional impact.

To explore metabolic dependencies in B cells, I would use a genome-wide CRISPR-Cas9 screening approach to identify synthetic lethal interactions — gene pairs whose simultaneous loss leads to cell death.

1. Establish the background genotype.
B cells with defined metabolic alterations are first generated, such as BCL6 knockout (favoring catabolic metabolism), reduced OXPHOS activity, or constitutive mTORC1 signaling. These changes create specific metabolic vulnerabilities without immediately affecting cell viability.

2. Introduce a pooled CRISPR library.
The modified cells are then transduced with a lentiviral sgRNA library targeting thousands of genes, either genome-wide or metabolism-focused collections.

3. Apply selection pressure and identify lethal hits.
Cells are cultured under selective metabolic conditions. Those harboring both the preexisting mutation and a lethal sgRNA knockout will fail to survive, while others persist.

4. Analyze sgRNA depletion through NGS.
Barcode sequencing reveals which sgRNAs are depleted, pinpointing potential synthetic lethal partners.
For example, in MYC-deficient B cells, loss of PRMT5 leads to synthetic lethality, suggesting that MYC-driven cells rely on PRMT5-mediated protein synthesis for survival.

Why Must I Use This?

B cells exhibit remarkable metabolic plasticity, dynamically shifting between glycolysis, oxidative phosphorylation (OXPHOS), and biosynthetic pathways depending on their activation or differentiation state. This flexibility often limits the efficacy of single-agent therapies.
Synthetic lethal screening provides a systematic way to uncover combinatorial vulnerabilities that cannot be detected through single-gene perturbations.

Representative synthetic lethal relationships include:

A.       BCR–mTORC1 axis: Cells with weak BCR signaling depend on mTORC1; dual inhibition induces apoptosis.

B.       MYC-dependent metabolism: MYC-high B cells require PRMT5, Aurora kinase B, and CHK1/2 to maintain proliferation.

C.       Glycolysis–OXPHOS coordination: Concurrent inhibition of the pentose phosphate pathway and OXPHOS disrupts redox balance and leads to cell death.

D.       MYC–BCL6 regulatory cycle: Dual inhibition of glycolytic and anabolic enzymes is lethal due to metabolic oscillation.

When Will I Use This?

1. Basic Research and Mechanistic Studies
I would apply this approach early in metabolic research to identify hidden gene interactions and understand resistance mechanisms — for instance, how mTORC1 inhibition triggers compensatory pathways.

2. Drug Discovery and Combination Design
After validating synthetic lethal partners, these findings can guide the development of drug combinations.
For example, CRISPR-based screening led to the identification of the BTK inhibitor + mTOR inhibitor + pomalidomide (DTRM-555) combination, which has advanced to Phase I/II clinical trials for CLL and DLBCL.

1. How can I use this?

   • I can use this technique to test various types of engineered probiotics simultaneously. First, I will create a collection of probiotics with different gene combinations that control their impact on the immune system during chemotherapy. Using DNA barcodes and cell analysis, I can determine which probiotic design yields the best immune response.

2. Why must I use this?

   • This technology aligns with my objective because multiple factors interact to influence how probiotics impact the immune system. Testing each design one by one would take too much time. This method lets me quickly identify the optimal combinations and understand how various genetic components interact to produce probiotics that are both safe and effective.

3. When will I use this?

   • I will use this technology during the early screening phase of my research, first in vitro with immune cell co-cultures to narrow down effective probiotic variants, and later in vivo in tumor-bearing mouse models to validate the top candidates.

Why can I use this?
Because these recurring motifs represent fundamental design principles of biological regulation. They transform overwhelming genetic complexity into a limited number of logic structures that are robust, evolvable, and computationally interpretable. Understanding how feed-forward and feedback motifs operate helps reveal why certain regulatory patterns are conserved across species and how cells achieve both stability and adaptability.

When will I use this?
I will use this framework when studying polygenic traits, epistatic interactions, or synthetic gene circuits. For example, in systems like the lac operon or stress-response pathways, identifying feed-forward loops clarifies how multiple environmental signals are integrated into a coherent response.

From this lecture, I learned about key concepts in complex genetics, gene–gene interactions, and synthetic biology circuits such as toggle switches, repressilators, and network motifs. Understanding these systems can help me design experiments to study how different probiotic genes interact to influence functions like stress tolerance, adhesion, or immunomodulation. The lecture’s discussion on epistasis and synthetic lethality particularly inspired me to explore how combining specific gene mutations or deletions might reveal essential pathways for bacterial survival and probiotic function. Additionally, the introduction to high-throughput approaches like PRISM (global transcriptional network reprogramming) and multiplexed screening using yeast models gave me ideas on how such systems-level analyses could be applied to bacterial genetics in probiotic studies.

Why I must use this?

I must use the ideas from this lecture because probiotic functions are rarely controlled by single genes—they depend on complex gene networks and regulatory pathways, similar to what was discussed for yeast and bacteriophage genetic switches. Applying combinatorial and multiplexed genetic screening will allow me to identify interactions between multiple genes or metabolic pathways that contribute to beneficial traits. This systems-level understanding will help me pinpoint the key molecular mechanisms underlying probiotic action more efficiently, instead of relying only on conventional single-gene studies. Moreover, learning from synthetic biology tools like toggle switches and repressilators can help me think about engineering probiotic strains with tunable responses to gut conditions.

When I will use this?

When analyzing Lactobacillus strains for probiotic potential, I can incorporate combinatorial testing—such as evaluating gene expression networks under multiple stress conditions (acid, bile, oxidative). Later, during the mechanistic exploration and validation stage, I could apply ideas from synthetic network design to study how regulatory circuits influence bacterial-host interactions, or even to design engineered strains with optimized probiotic properties.

Why must I use this?  Cancer phenotypes are usually caused by complex genetic interactions. If we understand these interactions, we can understand functional pathways and possible vulnerabilities in tumor cells. High-throughput screening allows us to systematically test gene combinations and identify synthetic lethal pairs, which are important for developing targeted treatments or understanding resistance mechanisms.

When will I use this? I haven’t used multiplex screening in my current research yet, but it might be useful for me in the future when studying dependencies or compensatory pathways. If we identify key genes, we could use combinatory screening to analyze which genes cooperate or counteract each other in tumor initiation and progression.

I can use gene cloning and transfer techniques to turn bioinformatic predictions into functional experiments. For example, if I identify candidate genes, I can clone them into plasmids, rescue disrupted genes or create mutants to compare phenotypes with isogenic controls. This helps me confirm whether these genes truly contribute to antibiotic resistance or other traits. I can also use gene transfer methods to engineer probiotics with therapeutic functions such as enhancing immune support or protecting healthy cells during chemotherapy. This transforms them from passive gut bacteria into active biomedical tools. 

Why must I use this? 

I must use gene transfer and cloning techniques because they are essential for both research and therapeutic innovation. In virology, we rely on viral vectors to introduce or silence genes in specific host cells, allowing us to study the role of host factors in viral replication or the impact of a viral gene on pathogenesis. For therapy, these techniques enable me to design vectors that deliver correct copies of genes to treat genetic disorders or engineer immune cells to fight cancer. I also need gene transfer when natural organisms, like probiotics, lack the desired therapeutic properties. By equipping them with new phenotypes through genetic modification, I can enhance their efficacy and specificity, ensuring they actively support treatment without harming the host. 

When will I use this? 

I can use it to transform theoretical designs and bioinformatic predictions into functional experiments, which could allow me to understand gene functions and develop innovative therapies. IT could help me to link genotypes to phenotypes and confirm the biological relevance of findings. It also allows me to engineer probiotics with therapeutic functions such as enhancing immune support or protecting healthy cells during chemotherapy, turning them into active biomedical tools. 

How can I use it?  

I can use RNA technologies to study and manipulate gene expression at multiple levels. For example, I can apply RNA detection methods like Northern blot, RNA-FISH, and RNA sequencing to measure transcript abundance and localization. I can use RT-PCR and qPCR for precise quantification of RNA, and RNA immunoprecipitation or tethering assays to explore RNA-protein interactions. For functional studies, I can employ RNA interference (siRNA, miRNA) to silence genes or use RNA-targeted CRISPR systems for editing RNA directly. These tools allow me to adapt my experiments and found how RNA regulates cellular processes and to develop therapeutic strategies such as RNA-based drugs or vaccines. 

Why must I use it?  

I must use RNA technologies because RNA is central to gene regulation, protein synthesis, and disease mechanisms. Understanding RNA dynamics transcription, processing, and decay is essential for identifying biomarkers, confirming targets, and creating treatments.  

When will I use it?  

I will use these techniques during different stages of research and development. In the early stages, we can apply RNA extraction and detection methods to profile gene expression. During functional studies we can knock down or edit RNA targets to find their biological function. Later, RNA sequencing or microarrays can be performed for global transcriptome analysis, or design RNA-based therapeutics and vaccines for clinical applications. 

How can I use it?  

I can use these techniques to study how proteins interact with DNA, which is essential for understanding transcriptional regulation, replication, and DNA repair.  

Why should I use it?  

I should use these techniques because they provide direct and reliable evidence of protein-DNA interactions, which cannot be obtained by simple computational predictions or indirect tests. ChIP-based methods allow for in vivo analysis of binding under physiological conditions, while EMSA and footprinting provide accurate information on binding affinity and sequence specificity. These different techniques allow us to learn more about DNA-protein interactions in a precise manner, enabling us to map binding sites and measure interaction strength.  

When will I use it?  

I can use these techniques when I need to confirm whether a transcription factor binds to a specific promoter region or if I would like to know about the presence of new regulatory elements. These methods are essential in genetic regulation studies, drug target validation and epigenetic research.  

How can I use this? 

I can use RNA technologies to study how genes are expressed and regulated after transcription. For example, I can detect RNA with techniques like RNA-FISH or Northern blot, analyze gene expression with RT-PCR or RNA-seq, and even control gene expression using RNA interference. These methods help me understand how cells work and how diseases develop. 

Why must I use this? 

I must use these tools because RNA is central to gene regulation and cell function. DNA tells the story, but RNA makes it happen. By studying RNA, I can see what genes are really active, measure expression levels, and even design RNA-based drugs or vaccines. Without RNA technologies, I would miss a big part of how biology actually works. 

When will I use this? 

I will use RNA technologies whenever I need to study or manipulate gene expression (for example, in medical research, biotechnology, or drug development). If I work on genetic diseases, cancer, or viral infections, I’ll probably use techniques like qPCR, RNAi, or RNA sequencing almost every day. 

How can I use this? 

I can use these methods to study how proteins and DNA interact inside cells. For example, I can apply ChIP or ChIP-seq to find which DNA sequences a protein binds to, or use EMSA and DNA footprinting to measure binding strength and identify exact binding sites. These techniques help me understand gene regulation, transcription, and how mutations affect protein-DNA recognition. 

Why must I use this? 

I must use these techniques because protein-DNA interactions control almost everything in the cell from gene expression to DNA repair and replication. Without studying these interactions, I wouldn’t really understand how genes are turned on or off. It’s also essential for research on cancer, genetics, and biotechnology, since many diseases come from abnormal DNA-protein binding. 

When will I use this? 

I will use these tools when I need to explore how a protein regulates a gene or find new binding sites in the genome. For instance, during a research project on transcription factors, or when testing how a drug affects DNA-protein interactions. In biotech or molecular biology labs, techniques like EMSA, ChIP, and SPR are part of routine experiments. 

How can I use this? 

I can use these strategies to study how multiple genes work together and influence complex traits or diseases. For example, I can perform combinatorial genetic screens to test how two or more mutations interact, or use multiplexed CRISPR approaches to knock out many genes at once. These tools let me explore gene networks, identify synthetic lethal pairs, and design better experiments for understanding non-Mendelian inheritance or cellular pathways. 

Why must I use this? 

I must use these methods because most biological systems are not controlled by a single gene. Complex traits like cancer, metabolism, or aging come from interacting genetic pathways. Studying one gene at a time is too limited. Using combinatorial and high-throughput screens helps reveal hidden genetic relationships, improve drug target discovery, and explain why some mutations only show effects in certain combinations. 

When will I use this? 

I will use these techniques when working on functional genomics, synthetic biology, or disease modeling. For example, if I want to find genes that make cancer cells sensitive to a drug, or to build synthetic circuits like the toggle switch or repressilator, I’ll need multiplexed screening systems. These approaches are useful whenever I need to test many gene interactions efficiently and at large scale. 

How can I use this? 

I can use flow cytometry to analyse and characterise individual cells within a complex mixture. For example, I could label cells with fluorescent antibodies, run them through the instrument, and measure properties like size, granularity, or marker expression. This allows me to answer questions such as “Which cells in my sample express protein X?” or “How many cells are alive vs apoptotic?”  

Why must I use this? 

I must use this technique because it provides high-throughput, single-cell resolution data which is essential when studying heterogeneous cell populations. Standard bulk assays average everything together and can miss rare but important subsets of cells. Flow cytometry overcomes this limitation.  

When will I use this? 

I will use flow cytometry when I need to: 

• Assess the phenotype of cells (for example in immunology, checking T-cell subtypes). 

• Measure functional readouts (such as cell viability, proliferation, apoptosis). 

• Sort or isolate a sub-population of cells for downstream applications (like downstream sequencing or culture). 

• Design multicolour panels to look at many parameters simultaneously 

How can I use this?

Gene transfer is a practical tool for directly manipulating an organism's genetic blueprint. I can use it to introduce a new gene into bacteria, instructing them to produce a valuable protein like human insulin or a vaccine antigen. I can also use it in gene therapy to deliver a functional copy of a gene into a patient's cells to compensate for a defective, disease-causing one. Furthermore, it is a fundamental research technique, allowing me to create genetically modified model organisms to study gene function or disease mechanisms.

Why must I use this?

I must use gene transfer because it is often the only method that addresses the root cause of a problem at the genetic level. For inherited genetic disorders, conventional drugs manage symptoms, but gene transfer offers the potential for a one-time cure by correcting the underlying genetic error.

When will I use this?

I will use gene transfer when I need to engineer an organism to possess a new, heritable trait. Specifically, I will use it when producing recombinant proteins like pharmaceuticals in bioreactors. Another example is when developing a gene therapy treatment for a monogenic disease like Severe Combined Immunodeficiency (SCID).

I can use RNA techniques to directly analyze and manipulate gene expression without altering the permanent DNA code. For instance, I can use Quantitative PCR to precisely measure how much a specific gene is being expressed under different conditions, like in a diseased versus healthy tissue. RNA interference (RNAi) has the ability to "knock down" or silence a target gene's expression to study its function.

Why must I use this?

I must use RNA techniques because they provide a real-time snapshot of cellular activity. DNA is the blueprint, but RNA is the active work order. To understand how a cell is truly responding to a drug, a disease, or an environmental change, I must analyze the RNA profile. Techniques like RNAi are essential for determining gene function because by silencing a gene and observing the consequences. They are often faster, more reversible, and have different therapeutic applications than DNA-based genetic engineering.

When will I use this?

I can use these techniques when I need to diagnose a specific condition at the molecular level, such as detecting viral RNA for an infection. We can also use them in the development of advanced therapies and vaccines that rely on delivering mRNA to produce a desired protein inside human cells.

I can use DNA nanotechnology to build small and precise structures, like tubes, or microrobots, out of DNA they can act as biosensors. For example, we can build a DNA capsule that holds a drug molecule and is programmed to snap open only when it encounters a specific cancer cell marker.

Why must I use this?

I must use this because DNA nanostructures offer a level of programmability and precision that is difficult to achieve with other materials. Their predictable base-pairing rules allow me to design them with atomic-level accuracy. This is crucial for creating biosensors that are highly specific, meaning they only react to the intended target. This specificity minimizes false positives and is essential for accurate medical diagnostics and environmental monitoring.

When will I use this?

I will use this when I need to detect a specific biological target with extreme accuracy and sensitivity. This applies to advanced medical diagnostics, for developing tests that can detect disease biomarkers at very early stages. I will also use it in environmental science to create sensors that can identify minute traces of a pollutant or toxin. Furthermore, as a fundamental research tool, I will use it to study molecular interactions by creating custom-made nanoscale devices that can probe and manipulate other biomolecules.

I can use these novel screening strategies to test the function of thousands of genes simultaneously, rather than one at a time. By employing technologies like CRISPR-pooled libraries and DNA-barcoded guides, I can introduce a complex mix of genetic perturbations into a population of cells. I can then use high-throughput sequencing to read out the barcodes and see which perturbations made cells thrive, die, or change in a specific way, all within a single, highly efficient experiment.

Why must I use this?

I must use this because biological systems are complex and interconnected; most phenotypes are not controlled by single genes but by networks of genes. These multiplexed screens are essential to capture this complexity, allowing me to identify genetic interactions, such as synthetic lethality, where two non-essential genes become essential when disrupted together. This provides a much more realistic and comprehensive view of gene function and disease mechanisms than traditional, single-gene approaches.

When will I use this?

I will use this when my research goal is to uncover the genetic basis of a complex trait or disease in an unbiased, large-scale manner. Specifically, I will use it to identify all genes essential for cancer cell survival or to find genes that confer resistance to a drug. I will also use it to map out complex genetic pathways and interactions on a genome-wide scale, providing a systems-level understanding of cell function.

I can use flow cytometry to analyze the physical and chemical characteristics of thousands of individual cells per second as they flow past a laser. By tagging cells with fluorescent antibodies, it is possible to identify and quantify different cell types in a mixed population—for example, counting specific immune cells like T-cells or B-cells in a blood sample. When combined with cell sorting (FACS), I can not only analyze but also physically isolate specific populations of cells with high purity for further culture or experimentation.

Why must I use this?

I must use this because it provides quantitative, multi-parameter data at a single-cell level, which is impossible with bulk analysis methods. Understanding the immune system requires dissecting its incredible cellular diversity, and flow cytometry is the premier tool for this. It is essential for diagnosing diseases like leukemia (by identifying abnormal blood cells), monitoring immune responses (like T-cell activation in vaccines), and for basic research to understand the roles of rare but critical cell populations.

When will I use this?

I will use this whenever I need to identify, count, or isolate specific cell types from a complex mixture.(not only in the realm in immunology) This is fundamental in both research and clinical settings. I will use it to diagnose and monitor immune disorders, to track the success of a stem cell transplant by analyzing donor cell populations, and in research to isolate pure populations of specific immune cells to study their function in detail.

I can use RNA techniques like RT-qPCR, RNA-FISH, and RNA-Seq to figure out how monocytes react to tau injection. For example, I can check if inflammatory genes like Syk or NF-κB are turned on after tau exposure. These tools help me zoom in on what’s happening at the RNA level—before proteins even show up.

Why must I use this?

Because tau pathology isn’t just about protein aggregates—it rewires gene expression. If I only look at protein levels or behavior, I’ll miss the upstream signals that drive inflammation and tau spread. RNA techniques let me catch those early changes and validate whether monocytes are truly activated or just hanging around.

When will I use this?

After I isolate monocytes from mouse brains by using FACS, I’ll extract RNA and run RT-qPCR to check specific genes, or go broader with RNA-Seq to map the whole transcriptome. I’ll do this at different time points to track how monocyte responses evolve over time.

1.How can I use this?
I can use RNA-based methods like RT-qPCR or RNA-Seq to examine how antibiotic treatment changes the expression of resistance-related genes in A. baumannii. These techniques can help me compare mRNA levels between sensitive and resistant strains.

2.Why must I use this?
Resistance isn’t only about genetic mutations — it also involves transcriptional and post-transcriptional regulation. RNA technologies allow me to understand how the bacteria adjust gene expression and regulatory RNA activity to survive antibiotics.

3.When will I use this?
I plan to apply these techniques after inducing resistance in my bacterial strains. Once I collect samples under different antibiotic conditions, I can extract RNA and analyze expression changes to identify key regulatory genes involved in resistance.

1. How can I use this?
I can apply the idea of combinatorial screening to explore interactions among resistance-related genes in A. baumannii. For instance, by using multiplex CRISPR editing or RNA interference, I could identify gene pairs that work together to enhance or suppress resistance.

2. Why must I use this?
Antibiotic resistance is rarely caused by a single mutation—it often involves complex genetic networks. Studying these interactions helps me understand how multiple genes cooperate or compensate for each other under antibiotic stress.

3. When will I use this?
I plan to use this approach after I identify several candidate resistance genes from my sequencing data. Then I can design combinatorial experiments to test how different gene combinations affect bacterial survival and drug susceptibility.

1. How can I use this?
I can use flow cytometry to measure bacterial viability or host immune cell activation after infection with A. baumannii. For example, staining with live/dead dyes or antibodies could help me quantify infection levels or analyze immune responses in co-culture systems.

2. Why must I use this?
Flow cytometry provides precise single-cell data and allows simultaneous measurement of multiple parameters. This makes it ideal for understanding complex host–pathogen interactions and monitoring how different treatments or mutations affect immune activation or bacterial survival.

3. When will I use this?
I plan to use it when studying immune responses during infection models or when testing how resistant and non-resistant strains of A. baumannii trigger different immune activation profiles. It would also be valuable for collaboration with immunology labs working on host defense mechanisms.

How can I use it? 

Combinatorial and multiplexed genetic screening can be used to study complex interactions between genes and pathways. By introducing multiple genetic mutations or perturbations at once, I can see how genes work together or influence each other. For example, using CRISPR libraries or synthetic gene networks, I can knock out or change several genes simultaneously to identify genetic interactions, such as synthetic lethality or enhancer effects. Manipulation involves designing combinations of gene edits, monitoring the resulting phenotypes, and analyzing the data using computational tools to detect interaction patterns. 

Why must I use this? 

I should use these techniques because they allow for a deeper understanding of complex biological systems that cannot be explained by studying one gene at a time. Combinatorial and multiplexed screens reveal hidden relationships and help identify potential drug targets, especially diseases caused by multiple genetic factors like cancer. Their main advantages include high throughput, precision, and the ability to uncover non-linear or epistatic interactions that are essential for understanding complex traits. 

When will I use it?  

These methods are especially useful when studying complex traits, synthetic biology circuits, or genetic networks in model organisms such as yeast or bacteria. I would use them in research focused on disease mechanisms, metabolic engineering, or synthetic gene design, where multiple genes must be tested together to understand their combined effects.  

Why must I use this?  Flow cytometry offers a fast and quantitative method for analyzing complex cell mixtures. It allows us to measure multiple markers simultaneously, which is important when studying tumor heterogeneity and identifying specific subpopulations. FACS sorting enables the purification of these populations for molecular and functional assays, with precision and reproducibility.

When will I use this? I already use FACS and fluorescent-based staining to isolate and analyze specific tumor cell populations. It is an important method for me when establishing organoid cultures or validating marker expression, and I will most likely use it for future experiments.

For exploring the presence or epidemiology of virulence or resistance genes in clinical bacterial isolates. Some genes may have a mutated allele with little difference to the original gene, thus I can use techniques like EMSA or ChIP to differentiate one genotype from the other, especially when differential primers are difficult to design or other methods such as PCR are unsatisfactory for this particular gene.

•Why must I use this?

Proteins can be designed to bind to specific DNA sequences and differentiate between minimally mutated genomes so EMSA and ChIP can be used when conventional methods cannot be used. Furthermore, ChIP has many variants allowing for more flexible utilization.

•When will I use this?

When I encounter a set of virulence or resistance genes I want to study, but primers for these genes cannot be used or are hard to design. I can also design a recombinant gene regulatory protein to study how these proteins interact with the bacterial genome.

I can adapt combinatorial screening to my bacterial clinical isolates by building dual-sgRNA CRISPRi libraries (and/or barcoded transposon pools) that perturb pairs of resistance modules, such as porins (OmpK35/OmpK36), efflux pumps (AcrAB-TolC system), or beta-lactamases (KPC/NDM). Exposing pooled isolates to antimicrobial gradients and sequencing barcodes lets me quantify pairwise epistasis, then confirm top hits with following experiments.

Why must I use this?

Resistance outcomes and profiles, especially those with multidrug resistance, are sometimes shaped by gene-gene interactions, not single genes. Porin loss, efflux pump upregulation, and enzyme activity can compensate or amplify each other under drug stress. Combinatorial screens can reveal synthetic vulnerabilities and antagonistic couplings that single-gene approaches miss, helping adjuvant target selection and screening suitable drug-combination choices before bench experiments.

When will I use this?

I can use this when I discover candidates for comparative genomics, such as after whole genome analysis of isolates. I can run focused pairwise CRISPRi screens to test their interactions under the intended therapy. Before advancing a drug pair or an efflux or porin adjuvant, I’ll verify synergy and exclude antagonism across representative clinical isolates, and rescreen emerging plasmid backgrounds to anticipate how new elements influence the resistance network and profile.

Why must I use this?
Bulk MICs average away critical heterogeneity; flow resolves whether a “resistant” phenotype is widespread killing failure or a small, resilient subpopulation. Sorting those survivors turns observation into mechanism by linking phenotype to genotype and regrowth kinetics. Barcoding collapses many conditions into one tube, slashing staining variance and reagent noise while boosting power, exactly what’s needed when comparing multiple isolates, drug doses, and adjuvants side-by-side.

When will I use this?
Right after comparative genomics nominates candidates (porins, efflux, β-lactamases), I’ll run barcoded time-kill panels across the intended drugs to see if the tolerant tail collapses with an adjuvant or combination. I’ll also deploy it whenever MIC and clinical response diverge, or when a new plasmid or gene appears in surveillance, re-measuring single-cell kill, sorting survivors, and verifying that proposed combinations still clear the rare, hard-to-kill cells across representative clinical isolates.

Why can I use this?
Because flow cytometry combines hydrodynamic focusing, laser excitation, and fluorescence detection to measure multiple parameters from each cell simultaneously. This technology allows rapid and quantitative analysis of complex cell populations, giving reliable and reproducible data for immunological or molecular studies.

When will I use this?
I will use flow cytometry when studying immune responses, comparing marker expression between samples, testing drug effects, or sorting live cells for further experiments. It is especially useful when I need single-cell resolution and multiparametric data from a large number of cells.

Why must I use this?
Because flow cytometry provides single-cell resolution, enabling me to detect metabolic heterogeneity among B-cell subsets that bulk assays would mask.
It’s also quantitative, high-throughput, and compatible with multiparameter immunophenotyping, making it ideal for linking metabolism to immune function.

When will I use this?
I will use this when studying B-cell activation (e.g., after TLR or BCR stimulation), germinal center responses, or disease conditions (autoimmune diseases, infection, or cancer) to understand how metabolic pathways regulate B-cell fate and function.

Why must I use this?
Flow cytometry provides high-throughput and quantitative data on multiple immune markers simultaneously, which is essential to understand the detailed immunological effects of candidate probiotics. Since ulcerative colitis involves dysregulated immune responses, using this technique will allow me to verify whether the probiotics restore immune balance or suppress inflammation at a cellular level. It offers more reliable and detailed insights compared to conventional assays alone.

When will I use this?
I will use this method during the later phase of my research, after preliminary screening of Lactobacillus strains for their in vitro properties. Specifically, I plan to apply flow cytometry during animal studies to evaluate immune cell profiles in colon tissue or spleen samples from colitis models treated with the probiotic strains.

I can build DNA-based biosensors—like aptamer-integrated nanostructures—that specifically recognize phosphorylated tau or inflammation-related molecules released by monocytes. These sensors could light up or send a signal when they detect their target, allowing me to monitor tau spread or immune activation in real-time.

Why must I use this?

Traditional methods, such as ELISA or IHC, are useful but somewhat slow and not always sensitive enough. DNA nanotechnology provides a faster and more precise way to detect small changes—such as tau uptake or monocyte activation—especially in early stages or low-abundance conditions. Moreover, aptamers are super customizable and stable, which makes them great for brain tissue or CSF analysis.

When will I use this?

I’ll use it during tau injection experiments—either to track tau movement across brain regions or to see how monocytes respond. I might also use it to validate therapeutic effects in a more dynamic and sensitive way.

Protein-binding microarrays (PBMs) allow simultaneous interrogation of thousands of DNA sequences to map transcription factor binding preferences with high throughput. Practically, purified protein is incubated on a microarray containing diverse oligonucleotides, followed by fluorescent detection to quantify binding intensity and generate motif profiles [1,2]. This enables rapid discovery of consensus sequences and binding selectivity.

Why must I use this?

PBMs provide genome-scale evidence of sequence specificity that single-target assays cannot deliver, minimizing bias and enabling quantitative affinity comparisons across many variants [2,3]. The technique directly links DNA sequence patterns to binding strength, forming a foundation for regulatory network modeling.

When will I use this?

I will apply PBMs during early screening of DNA-binding preferences for transcription factors, especially before validating key targets with lower-throughput assays like EMSA or ChIP [1,3].

References

1. Berger M.F., et al. Compact, universal DNA microarrays for comprehensive transcription-factor binding site analysis. Nat Biotechnol, 2006.

2. Lam K.N., et al. Protein-binding microarrays for rapid characterization of transcription factor binding specificity. Methods Mol Biol, 2023.

3. Weirauch M.T., et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell, 2014.

How?

A synthetic gene oscillator is built by wiring transcriptional regulators into a feedback loop that produces rhythmic gene expression rather than static ON/OFF states. In the yeast longevity oscillator, two opposing regulators controlling nucleolar vs. mitochondrial aging were rewired into a coupled feedback architecture, generating autonomous oscillations without external induction. The design relies on balanced activation/repression kinetics and tunable degradation rates, validated through single-cell fluorescence tracking and mathematical modeling to confirm stable periodic behavior (1).

When to use it?

Oscillators are ideal when a biological process requires temporal control rather than constant expression for instance, pacing metabolic states, delaying cell fate commitment, controlling cyclic drug sensitivity, or distributing cellular stress over time. They outperform simple switches when rhythmic regulation prevents pathway exhaustion, desynchronizes damage accumulation, or preserves homeostatic flexibility (1,2).

Why use it?

Synthetic oscillations introduce a programmable “biological clock,” enabling dynamic phenotypes that static circuits cannot achieve. In the aging model, oscillatory switching delayed irreversible commitment to decline, extending lifespan without modifying core aging genes (1). Because oscillators regulate timing rather than intensity, they minimize chronic pathway burden, reduce toxicity risk, and add a new dimension-time as an engineering parameter—to cellular programming (1–3).

References:

1. Zhou, Zhen, Yuting Liu, Yushen Feng, Stephen Klepin, Lev S. Tsimring, Lorraine Pillus, Jeff Hasty, Nan Hao. “Engineering Longevity—Design of a Synthetic Gene Oscillator to Slow Cellular Aging.” Science, 2023.

2. Elowitz, Michael B., Stanislas Leibler. “A Synthetic Oscillatory Network of Transcriptional Regulators.” Nature, 2000.

3. Bugaj, Luke J., Joshua E. Toettcher, Wendell A. Lim. “Programmable Dynamics in Synthetic Cell Signaling Circuits.” Science, 2016.

High-throughput screening (HTS) allows me to rapidly identify active compounds or genetic modulators by testing thousands of samples in parallel. I can design a diverse library of small molecules, proteins, siRNA/shRNA, or cDNA, then build either target-based assays to measure specific protein interactions or phenotype-based assays to observe cellular outcomes such as viability or cytotoxicity. After validating the assay with reliable positive/negative controls and an acceptable Z-factor, automated liquid-handling systems enable large-scale screening. I can then analyze hit compounds through SAR analysis or deeper phenotypic evaluation using cell-based assays and high-content imaging.

Why can I use this?

I can use HTS because it provides a quantitative, scalable, and reproducible framework for discovering bioactive molecules efficiently. Validated assays with strong Z-factors ensure high data quality, while automation minimizes human error. The method accommodates both biochemical and phenotypic readouts, uses diverse libraries, and works with cell lines or model organisms, making it versatile for drug discovery, pathway identification, and functional genomics.

When will I use this?

I will use HTS when screening large chemical or genetic libraries to identify initial hits, when exploring unknown pathways using phenotype-based assays, or when validating signaling activity through reporter systems. I will apply it in toxicity studies using ATP or cytotoxicity assays, and in high-content imaging when morphological or multiparametric cellular responses are required.

I can use HTS by preparing a structured strain library, running reporter assays, and using 96/384-well microplates, automated liquid handling, plate readers, and high-content imaging to test many Lactobacillus strains in parallel. These techniques let me quickly measure growth, stress responses, and functional activity across all candidates.

2. Why I must use ?

I must use HTS because my research involves screening a large library of Lactobacillus strains, and methods like high-throughput reporter assays, parallel microplate screening, and automated analysis make the process faster, more reproducible, and more efficient. HTS helps me identify the most promising probiotic candidates early while saving time, effort, and resources.

3. When I will use ?

I will use HTS during the early and mid phases of my project, when I need to rapidly evaluate my entire strain library to narrow it down to the best-performing candidates. Techniques like library preparation, reporter-based screening, and automated plate reading will be applied before moving on to slower, detailed mechanistic experiments later in the project.

I can use high-throughput screening to systematically identify genes, pathways, or small molecules that regulate B cell metabolism by combining CRISPR libraries or compound libraries with metabolic assays such as glycolytic activity, mitochondrial function, or proliferation under metabolic stress. This approach allows me to rapidly map metabolic dependencies that would be difficult to uncover with targeted experiments alone.

Why must I use this?

I must use HTS because B cell metabolism is governed by highly interconnected and redundant networks, making low-throughput methods insufficient to capture the full landscape of metabolic regulators. HTS provides the scale and unbiased power needed to discover unexpected metabolic factors, prioritize functional targets, and efficiently advance mechanistic or therapeutic studies.

When will I use this?

HTS help define the baseline metabolic features of B cell subsets. When identifying which metabolic pathways support specific B cell functions, these platforms are useful for gene or drug screening. They are also applied when validating candidate genes, testing drug combinations, or studying activation mechanisms. Single-cell platforms are needed when linking metabolism to receptor sequences or cellular functions, and they are helpful for tracking metabolic changes before and after vaccination or treatment.

1. How can I use this?
I can use HTS to screen large chemical or genetic libraries and look for factors that affect bacterial growth, host responses, or other phenotypes relevant to my research. By designing either a target-based assay or a phenotype-based assay and validating it with solid controls and a good Z-factor, I can run large-scale screens using automated systems and then analyze the hits for follow-up studies.

2. Why must I use this?
HTS is useful because it provides a scalable and quantitative way to discover active molecules quickly. Automation reduces variability, and the method supports many types of readouts—from biochemical assays to cell-based imaging—making it versatile for drug discovery and functional genomics.

3. When will I use this?
I would use HTS when exploring unknown pathways, screening for new inhibitors, or evaluating toxicity across many samples. It is also helpful when I need multiparametric data from cell-based assays or high-content imaging.

How can I use this?

High-throughput screening (HTS) allows rapid identification of active compounds or genetic modulators by testing thousands of samples in parallel. I can design libraries of small molecules, peptides, siRNA/shRNA, or cDNA, then run target-based assays for specific protein activities or phenotype-based assays to monitor cellular responses. After validating the assay with controls and an acceptable Z-factor, automated platforms enable large-scale screening, and hits can be analyzed through SAR studies or follow-up cell-based and high-content imaging assays.

Why can I use this?

HTS provides a quantitative, scalable, and reproducible framework for discovering bioactive molecules. Validated assays with high Z-factors ensure data reliability, while automation reduces human error. Its compatibility with biochemical and phenotypic readouts across diverse libraries and model systems makes it versatile for drug discovery, pathway mapping, and functional genomics.

When will I use this?

I will use HTS to screen large chemical or genetic libraries, explore unknown pathways via phenotype-based assays, or validate signaling with reporter systems. It is also useful for toxicity studies and high-content imaging when detailed cellular responses are needed.

Why must I use this?  Since cancer development and treatment are often influenced by complex gene and signaling networks, a low-throughput approach, such as single-gene knockdown, often misses important factors. HTS provides an unbiased and scalable way to discover gene dependencies, synthetic lethal partners, or compounds that selectively affect certain cancer populations. It enables efficient identification of important regulators and offers subsequent validations in organoids or mouse models.

When will I use this? I haven’t used HTS in my current research; however, it could be useful in future projects when testing large numbers of siRNAs/shRNAs, CRISPR modifications, or small-molecule inhibitors to identify regulators of specific genes and/or pathways involved in tumor initiation.

I can integrate DNA nanostructures or DNA-based sensing modules into engineered probiotic strains to detect specific metabolites or microenvironmental signals in the gut. For example, DNA aptamers, DNAzymes and hybrid DNA–protein structures can be designed to respond to small-molecule metabolites such as short-chain fatty acids, bile acids or amino-acid-derived compounds. These DNA sensors can trigger downstream genetic circuits such as activating metabolic pathways, regulating secretion of beneficial compounds or switching on safety mechanisms. Additionally, DNA nanostructures can serve as stable, programmable scaffolds to improve spatial organization of enzymes inside probiotics, increasing metabolic efficiency.

Why must I use this?

DNA biosensors offer high specificity and tunability, they can be engineered to recognize metabolites that traditional protein-based sensors struggle to detect. DNA nanostructures are highly modular which mean that they can be redesigned quickly without altering core probiotic physiology or reducing the burden on engineered strains. Next, DNA-based sensors often operate under mild conditions and are less immunogenic which make them suitable for in vivo applications like the human gut. DNA nanotechnology also enables rapid prototyping and precise control at the nanoscale, which is essential when designing probiotics that must respond dynamically to fluctuating metabolic environments.

When will I use this?

I will apply DNA nanotechnology at multiple stages of the project. During early development, DNA aptamer screening and DNA-based detection systems can help me quantify key metabolites, which allow me to characterize the host gut environment and identify metabolic targets for engineering. During strain construction, I can incorporate DNA biosensors into the probiotic genome or plasmids to establish metabolite-responsive regulatory circuits. Later, in testing and optimization, DNA nanodevices can be used to monitor how engineered probiotics behave in vitro and in vivo, providing real-time feedback on metabolite changes. In future clinical or translational phases, DNA-based biosensing modules will enable next-generation probiotics to function as smart living therapeutics which capable of sensing, deciding and responding to metabolic cues with high precision.

Why must I use this?
Organoids are essential because classical 2D cell lines or mouse models cannot fully capture patient-specific tumor genetics and the spatially organized host–microbe interface, or are difficult to maintain. Tumor organoids maintain the architecture, heterogeneity, and many functional properties of the original tumor. Organoids also let me combine genetic manipulation of the host with microbiota perturbations, which is essential to dissect mechanisms rather than relying only on correlative microbiome profiling.

When will I use this?
I will use organoid–microbiota systems when I move from association to mechanism and from mechanism to intervention. After identifying microbial signatures linked to tumor subtype, prognosis, or therapy response from sequencing studies, I can bring those candidate taxa or consortia into organoid co-culture to validate their functional impact. Later, when I have potential microbiota-targeted strategies, I can test them first in tumor organoids colonized with relevant microbes, to see whether they respond to procedures before considering in vivo or clinical translation.

Why must I use this?  Organoids recapitulate in vivo tumor behavior, including cellular diversity and structure, and reflect the patient- and mouse-specific genetic backgrounds. This is important because cancer is highly heterogeneous, and many phenotypes are not fully captured when working with standard cell-line models. Organoids offer more reliable tests of gene function, drug response, or pathway alterations. They can be expanded and maintained over time, which makes it easier to reproduce molecular and functional assays.

When will I use this? I already use organoids in my research. We generate them from mouse tumor samples, and they serve as the basis for most of my experiments, including siRNA knockdown, RNA-seq, FACS, and many more.

1. How can I use this technology?

   - I can use HTS to quickly test thousands of probiotic strains or bacterial metabolites to find which ones activate immune cells, enhance chemotherapy responses, or reduce side effects. Instead of testing bacteria one by one, HTS helps me rapidly identify which probiotic candidates have the strongest and safest immune-modulating effects.

2. Why must I use this?

   • HTS guarantees that I don't overlook crucial strains or chemicals, enabling me to find the best probiotic options without having to guess. Other approaches are complex and tedious. On the other hand, HTS provides dependable, high-quality data quickly, which could help me identify the most promising NGP-based adjuvants for further testing.

3. When will I use this?

   • I will use this technology when I want to screen a variety of bacterial strains or their metabolites to determine which ones enhance immune function or improve chemotherapy results. Once I've determined which options are the best, I can test them further in subsequent studies.

1. How can I use this?

   • I can assess how my next-generation probiotic strains influence immune activation and tumor behavior during treatment using organoid technology. I can determine if these bacteria increase medication sensitivity, boost immune responses, or decrease cancer cell viability by subjecting tumor organoids to my NGPs or their metabolites in combination with chemotherapeutic treatments. I can also assess safety using organoids by seeing how they react to normal tissue organoids.

2. Why must I use this?

   • Mainly because organoid technology is more accessible and ethically controllable than animal models, and provides a degree of physiological realism that 2D cell cultures cannot.

3. When will I use this?

   • Organoids will be utilized in the mid-stage validation of my project, following the initial bacterial screening but prior to animal testing. To find out if my NGPs do improve immune activation and chemotherapeutic efficacy, I currently need a realistic model. When in vivo models are too expensive or too early, but simple cell culture is too limiting, organoids would be the best option.

To study B cell metabolism, I would use germinal center (GC) organoids, because they can recreate a 3D lymphoid environment that normal 2D cultures cannot provide. Experimentally, I would embed B cells in a 3D hydrogel matrix and include supporting cells that express CD40L and BAFF, allowing the organoids to maintain GC-like activity for several days. After establishing the system, I would analyze metabolic changes using flow cytometry for glycolysis- or OXPHOS-related markers and use LC-MS or GC-MS to measure key metabolites. This setup would help me observe how B cell activation, class switching, and differentiation are linked to specific metabolic pathways.

Why must I use this?

I would choose organoids because 2D cultures cannot accurately maintain germinal center B cell metabolism. GC B cells are short-lived and strongly influenced by spatial organization (such as differences between dark-zone and light-zone B cells) which only a 3D system can model. Organoids also allow more reliable analysis of metabolic transitions during B cell activation and plasma cell differentiation, since they generate enough cells for metabolomics and single-cell profiling.

When will I use this?

I would use organoids when I need to explore how B cell metabolism shifts during activation and differentiation, because organoids can generate GC-like responses in just a few days. They are also useful when screening multiple metabolic inhibitors or pathway modulators, since the high-throughput format allows many conditions to be tested at once. In later stages of research—such as identifying metabolic biomarkers, comparing donor-specific metabolic differences, or evaluating vaccine or immunotherapy responses—organoids remain valuable because they closely reflect human biology.

I can use organoid systems to model human tissues and diseases in a controlled, three-dimensional environment. By deriving organoids from adult stem cells or pluripotent stem cells, I can recreate key structural and functional features of organs. This allows me to study development, genetic diseases, cancer, infections, and to perform drug testing or toxicity assays. Organoids can also be combined with single-cell sequencing, organ-on-chip platforms, and genetic engineering tools for deeper mechanistic studies.  

• Why must I use this? 

I should use organoids because they represent human physiology more accurately than traditional 2D cell lines or some animal models. They are fast to establish, genetically tractable, scalable for drug or genomic screens, and can be personalized from patient-derived cells. Organoids enable disease modeling that captures human-specific features—such as CFTR defects in cystic fibrosis or neural progenitor vulnerability to Zika—while reducing ethical and experimental limitations of in vivo systems.  

• When will I use this? 

I will use organoids when I need human-relevant models for development, disease mechanisms, or therapeutic discovery. This includes studying cancer evolution, testing drug responses, modeling genetic disorders, analyzing host–pathogen interactions, or investigating tissue development such as cerebral organoids for microcephaly studies. I will also use organoids for personalized medicine, toxicity assessments, and high-throughput or high-content screens that require tissue-like complexity.

2.Why must I use this?
This method is indispensable to understand the function of a gene, to validate bioinformatic hypotheses, to produce recombinant proteins, or to develop therapeutic vectors. It makes it possible to introduce targeted mutations, to create cellular or animal models, and to test biological mechanisms. Without cloning, it is impossible to manipulate gene expression in a controlled and reproducible way.

3. When will I use this?
It is used whenever gene expressions must be modified in a biological system. Cloning is involved in functional studies, protein production, validation of therapeutic targets, or the creation of experimental models. It is also employed in laboratories of molecular biology, genetics, virology, or translational medicine.

RNA technologies bring together a set of methods that make it possible to detect, analyze, and manipulate RNA molecules. They include classical techniques such as Northern blot, EMSA, RT-PCR, and RNA-FISH, as well as modern approaches like RNA-Seq, RNA interference (RNAi), RNA vaccines, and CRISPR systems targeting RNA. These tools make it possible to study the expression, stability, localization, and interactions of RNA in cells.

2. Why must I use this?

These methods are indispensable to understand post-transcriptional regulation, the dynamics of gene expression, and the mechanisms of RNA degradation. They offer powerful means to identify biomarkers, to develop innovative RNA-based therapies, and to explore genetic correction strategies. They are also crucial for the design of modern vaccines and targeted treatments against genetic or infectious diseases.

3. When will I use this?

RNA technologies are used in research projects on gene expression regulation, in transcriptomic studies, and in the development of new therapies. They are involved in viral RNA detection, vaccine design, expression profiling by RNA-Seq, or treatments using RNAi. They are mobilized whenever it is necessary to explore the role of RNA as a central molecule of biology and medicine.

2. Why must I use this?
This makes it possible to understand how a protein interacts with DNA, which is essential to decipher transcriptional regulation, to identify genomic targets, and to explore epigenetic mechanisms. These methods make it possible to characterize regulatory networks, to develop diagnostic tools, and to design targeted therapies. They offer fine and quantitative resolution of molecular mechanisms.

3. When will I use this?
These techniques are used in research projects on transcription factors, repair enzymes, or regulatory proteins. They are involved in studies of cell differentiation, tumor transformation, or immune response. They are mobilized whenever the function of a DNA-binding protein must be analyzed.

Combinatorial and multiplexed genetic strategies make it possible to test many gene interactions simultaneously using high-throughput screening approaches. They rely on the creation of synthetic genetic networks, the study of epistatic interactions, or the analysis of phenomena such as synthetic lethality. These methods use models such as yeast or artificial genetic circuits to map functional networks and to understand the logic of interactions.

2. Why must I use this?

These approaches are essential to decipher the complexity of human diseases, which often depend on multiple interactions between genes and metabolic pathways. They make it possible to identify essential genes, to reveal therapeutic targets, and to understand the structure of biological networks. They also provide a basis for synthetic biology, making it possible to design artificial genetic circuits capable of new functions such as cellular memory or oscillators.

3. When will I use this?

These strategies are used in research projects on complex diseases, in screening genes involved in cancer or metabolic diseases, and in designing targeted therapies based on genetic interactions. They are also involved in synthetic biology to create artificial regulatory circuits, and in network studies to map cellular functions. They are mobilized whenever it is necessary to explore or manipulate genetic complexity beyond Mendelian models.

2. Why must I use this?
This method is essential to characterize complex cell populations quickly and precisely. It makes it possible to obtain robust quantitative data, to detect rare events, and to analyze dynamic processes. It is indispensable in immunology, oncology, cell biology, and experimental medicine. It offers unmatched multiparametric resolution for the study of cells in suspension

3. When will I use this?
It is used in immunological analyses, signaling studies, treatment monitoring, or biomarker screening. It is applied in stimulation protocols, intracellular staining, or cell sorting. It is mobilized whenever fine, rapid, and multiparametric cell characterization is required.

Organoids are three-dimensional structures derived from stem cells that reproduce the architecture and functions of human organs. They can be used to model development, to study genetic or infectious diseases, to test drugs, and to explore regenerative therapy strategies. Their culture makes it possible to generate mini-organs such as intestine, brain, liver, or lungs, offering a relevant and manipulable experimental model.

2. Why must I use this?

This method is essential because it offers a faithful representation of human physiology, much more than 2D cell cultures or animal models. Organoids make it possible to understand pathological mechanisms, to develop personalized medicine approaches, and to reduce dependence on animal models. They provide a robust platform for drug screening, tissue repair, and the study of cellular diversity.

3. When will I use this?

Organoids are mobilized whenever it is necessary to reproduce the complexity of human tissue in vitro. They are used in fundamental research on development, in modeling diseases such as cystic fibrosis or cancer, in studies of viral infections (such as Zika or SARS-CoV-2), and in regenerative medicine projects. They become essential whenever an experimental approach must combine physiological relevance with the possibility of genetic or pharmacological manipulation.

I can use organoids as a three-dimensional, physiologically relevant human model to study development, disease mechanisms, and therapeutic responses. By differentiating pluripotent stem cells into brain, gut, I can recreate layered architecture and multicellular interactions that are impossible to capture in 2D culture. In practice, I can apply organoids to model neurodevelopmental defects, perform genetic manipulation at the iPSC or organoid stage, combine them with single-cell sequencing to validate cellular composition, and use them for drug testing or toxicity screening in a more realistic tissue environment.

Why can I use this?

I can use organoids because they are human-derived and capable of capturing key cellular interactions that 2D cultures cannot. It offers strong advantages such as human physiological relevance, scalability once established, compatibility with modern genome engineering tools, and the ability to generate personalized disease models from patient-derived iPSCs. These features make organoids a suitable model when my research requires a higher level of biological complexity than conventional 2D systems.

When will I use this?

I will use organoids when my research question requires tissue-level organization or multicellular interactions. These contexts benefit from organoids’ ability to mimic aspects of human brain architecture that are absent in 2D culture.

However, after discussing with my PI, I also realized that organoids are not the optimal choice, especially for Huntington’s disease research. Although recent protocols can generate cortical or striatal-like organoids, these 3D models still do not reproduce the full architecture, signaling environment, or connectivity of the human brain, and lack standardized protocols. In addition, organoid culture requires specialized matrices, long differentiation timelines, and higher consumable usage, making it significantly more expensive than maintaining 2D cultures. These limitations make organoids far less reproducible than 2D iPSC-derived neuronal cultures, which routinely achieve high consistency. Nevertheless, I still keep in mind that this is an early stage of 3D organoid technology. As protocols become more standardized and costs progressively decrease, these models will likely mature into a far more reliable and powerful system that can eventually mimic human physiology with much greater fidelity.

I can use intestinal organoids as an ex vivo model to test how my probiotic candidates influence epithelial health, inflammation, and barrier function. Their 3D structure and multiple cell types allow me to study host–microbe interactions in a system that closely resembles the human gut.

2. Why must I use this?

I must use organoids because traditional 2D cell lines cannot fully replicate the architecture or cellular diversity of the intestine. Organoids provide a more accurate and translational model, helping me better predict whether my Lactobacillus strains will have protective or therapeutic effects in colitis before moving to animal studies.

3. When will I use this?

I will use organoid experiments after completing basic in vitro screening assays (acid/bile tolerance, Caco-2 adhesion). This will serve as a functional evaluation step before beginning my in vivo mouse colitis experiments.

1. How can I use this?

I can use combinatorial and multiplexed genetic techniques to test many gene interactions at once by creating multiple genetic variants or synthetic circuits. These methods let me observe how different genes affect each other and help build functional maps of genetic networks in models like yeast or engineered cells.

2. Why must I use this?

I need to use these approaches because complex traits and diseases depend on interactions among many genes. They help identify essential genes, uncover therapeutic targets, and clarify how biological pathways work together. They also support synthetic biology by enabling the design of genetic circuits with new functions.

3. When will I use this?

These techniques are used in research on complex diseases, in high-throughput gene screens, and in developing targeted therapies. They are also applied in synthetic biology projects that require constructing artificial regulatory circuits or studying network-level cellular functions.

1. How can I use this?

I can use flow cytometry to measure the physical and chemical properties of thousands of cells per second as they pass through a laser. By labeling cells with fluorescent markers, I can identify and quantify different cell types in a mixed sample. With FACS, I can also sort and isolate specific cell populations with high purity for further experiments.

2. Why must I use this?

I must use this because it provides rapid, quantitative, single-cell analysis that bulk methods cannot offer. Flow cytometry is essential for detecting abnormal cell populations in diseases like leukemia, monitoring immune responses, and studying rare but important cell subsets. It gives detailed, multi-parameter information necessary for both clinical diagnostics and research.

3. When will I use this?

I will use this whenever I need to identify, count, or separate specific cell types from complex samples. This applies in immunology, cancer diagnostics, stem cell tracking, and basic research where pure cell populations are required to study their functions.

1. How can I use this?

I can use high-throughput screening to systematically identify genes, pathways, or small molecules that regulate cellular metabolism by combining CRISPR libraries or compound libraries with metabolic assays such as glycolytic rate, mitochondrial function, or cell viability under stress. This allows me to rapidly uncover metabolic dependencies in a way that targeted, low-throughput experiments cannot.

2. Why must I use this?

I must use HTS because cellular metabolism is controlled by complex and interconnected networks. Low-throughput methods cannot capture the full range of regulators involved. HTS provides an unbiased, large-scale approach to discover unexpected metabolic factors, prioritize meaningful targets, and efficiently support mechanistic research or therapeutic development.

3. When will I use this?

I will use HTS when defining the metabolic features of different cell types, when screening genes or compounds that influence cellular function, and when validating candidate pathways or testing drug combinations. HTS is also valuable for studying how metabolism changes during activation, differentiation, disease progression, or treatment responses, especially when combined with single-cell platforms.

1. How can I use this?

I can use organoid cultures to study tumors ex vivo by growing 3D structures derived from tumor tissue. Because organoids preserve many architectural and functional features of the original tumor, I can use them to analyze gene function, examine tumor heterogeneity, assess pathway activity, and test drug responses in a system that more closely reflects in vivo conditions than traditional 2D cell lines.

2. Why must I use this?

I must use organoids because they better replicate the complexity of real tumors, including cellular diversity, structural organization, and patient-specific genetic backgrounds. Since cancer is highly heterogeneous, organoids provide more accurate and reliable platforms for evaluating gene perturbations, pathway changes, and therapeutic responses compared to standard cell-line models. Their ability to be expanded long-term also supports reproducible molecular and functional assays.

3. When will I use this?

I will use organoids whenever I need a model that closely mimics in vivo tumor biology. They are valuable for experiments such as gene knockdown, transcriptomic profiling, functional assays, and drug testing. As a core system in my research, organoids serve as the foundation for many of my studies using mouse-derived tumor samples.

1. How can I use this?
I can use high-throughput screening (HTS) to systematically identify compounds or genetic factors that influence A. baumannii survival or antibiotic response. By designing either a target-based assay—such as monitoring efflux pump activity—or a phenotype-based assay like viability under tigecycline or imipenem exposure, I can screen large chemical or genetic libraries in parallel. After validating the assay with good controls and a strong Z-factor, automation allows me to test thousands of samples efficiently and select promising hits for follow-up studies.

2. Why must I use this?
HTS provides a scalable and quantitative framework that helps reveal important modulators of antibiotic resistance that small-scale experiments might miss. It improves reproducibility through automation, supports both biochemical and cell-based readouts, and accommodates many types of libraries. This makes it especially useful for identifying novel drug candidates or discovering pathways involved in heterogeneous or spontaneous resistance in A. baumannii.

3. When will I use this?
I would use HTS when I need to screen large compound or genetic libraries to find potential inhibitors of resistance pathways, or when exploring genetic interactions that contribute to resistance development. It will also be helpful after generating resistant mutants so I can test their responses to many antibiotics or stress conditions at once. High-content imaging or phenotypic assays can further provide multiparameter data on bacterial behavior or host–pathogen interactions.

1. How can I use this?

I can use organoid-based infection models—such as airway, lung, or intestinal organoids—to study how A. baumanniiinteracts with human tissues under more realistic physiological conditions. These models would allow me to examine epithelial damage, inflammatory responses, cytokine secretion, or cell death patterns caused by resistant versus non-resistant strains. Organoids also provide a controlled system for testing antibiotic efficacy or potential adjuvant therapies directly on human-like tissue structures.

2. Why must I use this?

Standard cell lines often oversimplify host–pathogen interactions, which can limit understanding of clinically relevant resistance mechanisms. Organoids offer better tissue architecture, multiple cell types, and more accurate signaling environments. This makes them valuable for capturing the complex ways in which A. baumannii affects human tissues, especially when evaluating virulence factors or antibiotic responses of resistant mutants. Using organoids can help generate data that more closely reflects how infections behave in real patients.

3. When will I use this?

I would consider using organoids after identifying specific resistance-associated mutations or phenotypes from my bacterial evolution experiments. Once I have resistant and sensitive strains to compare, organoids would be useful for testing whether these variants differ in their ability to invade tissue, trigger inflammation, or withstand antibiotic treatment in a more realistic model. They would also be helpful if I aim to explore potential therapeutic strategies or host-directed treatments.

Why must I use this?  This is important because in vitro studies alone are often not sufficient to investigate cancer-related genes. Conditional knockout systems enable me to control where and when a gene is deleted, thereby helping to avoid early lethality or developmental defects. Temporal controls such as the Tet-O-Cre are also valuable when gene deletion should occur at a later life stage. These models better reflect in vivo disease mechanisms and provide organoids with the correct genetic background, making downstream assays (e.g., siRNA knockdown, RNA-seq, drug testing,…) more physiologically relevant.  

When will I use this? I already work with my own Cre/loxP mouse colonies, and they are a central part of my current research. These include both constitutive (Amhr2-Cre) and inducible systems (Pax8-tetO-Cre and K8-Cre). They are necessary for us to generate tumor-derived organoids that serve as the basis for our later analyses.

I can use combinatorial and multiplexed genetic screening to map gene–gene interactions, find epistasis, identify synthetic lethal pairs, and understand complex traits that don’t follow simple Mendelian rules. It’s essentially a toolkit for understanding how genes interact rather than acting independently.

Why must I use this?

Because most real biological systems—metabolism, signaling, disease pathways—are not controlled by single genes. They’re networks. If I only study one gene at a time, I miss the real biology. These strategies let you uncover hidden interactions, parallel pathways, and functional modules that traditional genetics can’t reveal.

When will I use this?

I’ll use it whenever you need to understand complex phenotypes, such as drug resistance, cancer metabolism (like the Warburg effect), aging circuits, or regulatory networks (toggle switches, repressilators). It’s also essential when designing synthetic biology circuits or doing large‑scale functional genomics.

Why must I use this?
Because I need clean, well-defined cell populations to really understand who is responding to tau and how. Bulk tissue data can’t tell me which cell type is changing; flow and sorting let me link specific immune subsets to cytokine profiles, RNA-Seq data, or functional assays.

When will I use this?
I’ll use it after in vivo experiments—at key time points after tau or vector injection—to analyze immune infiltration, activation, and to sort monocytes or microglia for downstream RNA, protein, or ex vivo functional studies.

Why must I use this?
Because tau‑driven immune responses involve many pathways, guessing one target at a time is slow. High‑throughput screening lets me rapidly narrow down which pathways or compounds are actually worth following up in vivo.

When will I use this?
I’ll use it early in the project—right after identifying candidate genes or signaling pathways—to screen for hits in cell‑based assays before moving the most promising ones into mouse experiments.

Why must I use this?
Because tauopathy is a complex, multicellular process, and simple cell lines can’t capture the architecture, signaling gradients, or immune–neuron interactions that happen in vivo. Organoid-based models provide a more accurate platform for validating mechanisms before moving into animal studies.

When will I use this?
I’ll use these models after initial in vitro assays—once I’ve identified key pathways or genes from monocyte responses. Organoids serve as an intermediate step, where I test whether those findings still hold in a more physiologically relevant system before committing to mouse experiments.

Why must I use this?
Because tauopathy is a complex in vivo process, and cell culture alone can’t capture the full immune–brain interaction. Genetically modified mice provide me with precise and controlled methods to determine whether a gene is truly required—or sufficient—for driving inflammation or tau transmission.

When will I use this?
I’ll use these models once I’ve identified promising targets from RNA‑Seq or in vitro assays. These mice serve as the backbone of my in vivo experiments, particularly when comparing disease progression between wild-type, knockout, and inducible gene-controlled lines.

1. How can I use this?

I can use genetically modified mice to study how specific host genes influence susceptibility to A. baumannii infection. Knockout or CRISPR-edited mice would allow me to test how changes in immune pathways affect the response to resistant versus non-resistant strains.

2. Why must I use this?

Mouse models provide whole-organism context that cell cultures can’t. Using targeted gene modifications helps isolate the role of individual host genes in inflammation, bacterial clearance, or antibiotic response—factors that are crucial for understanding resistance mechanisms.

3. When will I use this?

I would use these models after identifying host pathways that seem important from in vitro experiments. Once I have candidate genes, transgenic or knockout mice can help confirm their roles during infection and compare how different A. baumannii strains behave in vivo.

I can use this system by creating floxed mice for genes like G6PD, TALDO1, or TKT, and crossing them with CD19-Cre or AID-Cre mice to make B cell-specific knockouts. Then I isolate their B cells and compare their development, antibody responses, and metabolic activity. If needed, I can add immunization (like NP-KLH), metabolic tracing, RNA-seq, or flow cytometry to study how the deleted gene changes B cell function in vivo.

Why must I use this?

I need this approach because whole-body knockouts often cause early death or non-B cell effects, making results unclear. Using a B cell-specific deletion lets me see the direct role of the gene in B cells without interference from other tissues. It also gives more reliable in vivo data than in vitro CRISPR or shRNA. This helps me understand how pathways like the PPP support B cell activation, antibody production, and disease processes.

When will I use this?

I will use this system when I want to study the function of a metabolic gene specifically in B cells—such as during immunization, infection, tumor growth, or autoimmune conditions. It is also useful when exploring how gene loss affects antibody responses or when searching for metabolic targets for future therapies.

What impressed me most is that modern combinatorial and multiplexed screening actually provides a practical way to uncover these hidden interactions at a scale impossible to reason about intuitively. It made me realize that if we want to understand complex diseases or find new therapeutic strategies, we really need these high-throughput genetic methods, because they're the tools that can actually handle the complexity of real biology.

I can use these mouse-genetics methods to change a gene, add a reporter, or control when a gene is turned on or off. Techniques like transgenesis, CRISPR, or Cre/loxP let me test the function of specific sequences or regulatory elements directly in a living organism, instead of only relying on cell culture results.

Why can I use this?

I can use them because mice allow precise and stable genetic manipulation, and their physiology is close enough to humans for disease studies. These systems also give me control over timing and cell-type specificity, which is important when a full knockout or early misexpression would be lethal or misleading.

When can I use this?

I will use these tools when my project needs in vivo confirmation. For example, when I want to check whether a regulatory variant truly changes gene expression in the brain, or when I need to delete or activate a gene specifically in striatal neurons to see how it affects pathways relevant to HD. This is the stage where cell models are no longer enough and I need evidence from an intact neural system.

I can use transgenesis and gene targeting in mice to understand the molecular mechanisms by which probiotics reduce inflammation in colitis. By using knockout or conditional mouse models, I can test whether specific inflammatory genes such as iNOS, TNF-α, or IL-10 are required for the anti-colitic effects of my Lactobacillus strains. This will help me connect my in vitro findings (NO and cytokine suppression) with real biological outcomes in a living organism.

Why must I use this?

I must use genetically modified mouse models because in vitro cell culture systems cannot fully represent the complexity of immune regulation, gut barrier function, and host–microbe interactions in colitis. Gene targeting allows me to prove causation, not just correlation, by showing whether a specific gene is necessary or sufficient for disease progression or probiotic action. This is essential for producing scientifically credible and translationally relevant results.

When will I use this?

I will use transgenic and gene-targeted mouse models during the animal study phase of my Master’s research, after completing in vitro probiotic screening. At that time, I will move from cell-based assays to in vivo validation of probiotic efficacy and immune mechanisms in colitis.

The methods discussed in this lecture provide the technical framework for designing and executing large-scale biological experiments. I can implement Automation and utilize liquid handling robotics and automated readout systems to process thousands of samples efficiently, minimizing the human error associated with manual pipetting. Also, this method is great for analyzing big data, filtering out false positives and identifying genuine "hits."

2. Why must I use this?

High-throughput screening (HTS) is indispensable in modern biomedical research and drug discovery for several reasons:

• Unbiased Discovery

• Efficiency and Speed

• Cost-Effectiveness

3. When will I use this?

I will likely encounter and utilize these methods during specific phases of research, for example, early-stage drug discovery: This is the primary application. I will use HTS at the very beginning of a project after a therapeutic target has been identified but before lead compounds exist. And also drug repurposing: If I am working on finding new uses for existing, FDA-approved drugs (screening a library of known drugs against a new disease model), I will use these screening methods to quickly identify potential treatments.

I can utilize the concepts from this lecture by establishing and manipulating advanced biological models that go beyond standard cell lines. Practically, this involves learning to culture three-dimensional organoids derived from pluripotent stem cells or patient tissues to mimic organ architecture. I can also employ gene-editing technologies, such as CRISPR-Cas9, within these complex models to introduce specific mutations and observe their effects on development or tumorigenesis in a spatially accurate context.

2. Why must I use this?

I must use next-generation modeling because traditional two-dimensional cell cultures often fail to predict clinical outcomes accurately. Standard cell lines grown on plastic lack the structural complexity, cellular heterogeneity, and crucial microenvironmental interactions, that exist in actual human tissues. Relying solely on older methods risks generating data that is reproducible in the lab but irrelevant to the patient. Therefore, adoption of these advanced models is essential to capture the true biological behavior of cancer and development.

3. When will I use this?

I will use these techniques primarily during the translational phase of research or when investigating complex developmental mechanisms that require tissue-level organization. Specifically, this becomes relevant when I need to validate a potential drug target in a physiologically relevant setting before moving to clinical trials. I will also deploy these models when studying personalized medicine, such as testing a battery of drugs on an individual patient’s tumor organoids to determine the most effective treatment strategy.

I can use the knowledge gained from this lecture to design and generate sophisticated mouse models that manipulate specific sequences within the genome. Practically, this involves utilizing techniques such as homologous recombination or CRISPR-Cas9 to create knockout or knock-in mice, allowing me to remove a gene’s function or introduce a specific mutation. By understanding the breeding strategies required to maintain these lines, I can effectively manage colonies to produce the specific genotypes needed for experimentation, ensuring that the genetic background remains consistent and reliable for analysis.

2. Why must I use this?

I must use transgenic and gene-targeting approaches because in vitro cell culture models often fail to capture the systemic complexity of an entire organism. While cells in a dish can show molecular mechanisms, they cannot replicate the interactions between different organ systems, the immune response, or complex behavioral phenotypes. Mice share a high degree of genetic homology with humans, making them the gold standard for studying gene function in a physiological context.

3. When will I use this?

I will use these methods when I have identified a candidate gene or pathway in preliminary studies and need to validate its function in a living system. This often occurs after initial high-throughput screens or cell-based assays have highlighted a potential target, and the research moves into a pre-clinical phase. Specifically, I will rely on these techniques when studying developmental biology to observe how gene loss affects embryogenesis, or when modeling complex human diseases like cancer or autoimmunity that require a functional immune system and tissue microenvironment.

I can utilize Caenorhabditis elegans as a powerful platform for conducting rapid genetic screens and in vivo imaging. Practically, this involves employing techniques such as RNAi by simply feeding the worms bacteria that express dsRNA, allowing for easy and scalable gene knockdown without complex injection protocols. I can also take advantage of the organism's natural transparency to use fluorescent protein reporters to visualize protein location, cell migration, and organelle dynamics in a living, intact animal. Furthermore, I can use the detailed maps of its cell lineage to trace the developmental fate of single cell, manipulating pathways to observe how they alter the invariant developmental program.

2. Why must I use this?

It is essential for research that requires high-throughput analysis in a whole-organism context, which is often prohibitively expensive or time-consuming in mouse models. The worm's short life cycle of about three days and its large brood size allow me to generate statistically significant data on genetics and longevity in a fraction of the time required for vertebrate models. Additionally, because the wiring diagram of its nervous system is fully mapped, I must use this model if I want to understand how neural circuits drive behavior at a single-neuron resolution.

3. When will I use this?

I will use this model primarily when I need to dissect conserved biological pathways, such as apoptosis, aging, or insulin signaling, before validating them in mammalian systems. It is particularly useful when I am investigating the genetics of aging and longevity, as the worm's short lifespan allows for survival studies that would take years in mice to complete in just a few weeks. I will also turn to this model during the early discovery phase of a project to perform forward genetic screens—mutating the genome to find the genes responsible for a specific phenotype—thereby identifying novel genetic players that can later be studied in humans or other higher organisms.

Why must I use this?  Many fundamental biological mechanisms, such as apoptosis, developmental signaling and cell-fate determination, were first discovered in C. elegans. Its short life cycle and relatively easy genetics make it ideal for quick functional screens or for studying pathways that would be difficult to analyze directly in mice. Worm studies can provide foundational mechanistic insights that might help interpret conserved processes in higher organisms.

When will I use this? I do not expect to use C. elegans in my current work, since my research relies heavily on mouse models and organoid cultures. However, it could be useful in the future for preliminary genetic screens to study conserved pathways at a basic level before validating them in mammalian systems.

The tools we learned from C. elegans research can actually be applied directly to B cell metabolism. For example, RNAi lets me quickly knock down metabolic genes to see what changes, and CRISPR can create stable knockout B cell lines for deeper studies. I can also use genetic libraries to screen many genes at once and find the ones that really matter for metabolism. With techniques like flow cytometry and metabolic dyes, I can even track metabolic states at the single-cell level.

Why must I use this?

Because B cell metabolism is too complex to figure out by looking at one gene at a time. Genetic tools give me a systematic and unbiased way to pinpoint which genes truly drive metabolic changes, not just correlate with them. Plus, many metabolic pathways discovered in C. elegans are conserved in mammals, so these methods help me build solid, reproducible findings that are more likely to apply in real immune systems.

When will I use this?

I’ll use these methods throughout the whole research process. In the beginning, genetic screens help me generate hypotheses and narrow down key genes. In the middle stage, CRISPR or RNAi allows me to test which genes actually affect metabolism. Later, techniques like RNA-seq, ChIP-seq, or metabolomics help me figure out the mechanism behind those effects. And finally, in disease-related studies, I can use mouse models or primary human B cells to see whether these metabolic genes play roles in autoimmune disease, lymphoma, or infections.

I can apply high-throughput screening when I need to test many variables (e.g., compounds, gene knockdowns) in my project quickly and in parallel. HTS allows me to evaluate multiple conditions under consistent experimental settings, which increases efficiency and comparability.

Why must I use this technique?

I must use HTS because manual, one-by-one testing is too slow and may miss hits. HTS brings automation, higher throughput, and better control over variables, helping to identify significant modulators of immune responses reliably.

When will I use this technique?

I will use HTS at the early discovery stage of the project, when screening many candidates (small molecules, antibodies, gene edits) for their effect on an immune outcome. Once hits are identified, I will switch to focused validation and mechanistic follow-up.

I can utilize gene targeting in embryonic stem cells to generate Upk1a-deficient mice, selectively inactivating the gene responsible for the urothelial receptor for FimH from Klebsiella pneumoniae. Instead of relying on cellular or molecular adhesion assays, I can challenge these mice with K. pneumoniae and perform longitudinal analysis of bacteriuria and tissue bacterial load. By comparing these knockouts to wild-type mice, I can directly test how the absence of the specific mannose-presenting scaffold alters the formation of Intracellular Bacterial Communities and the recruitment of neutrophils to the bladder mucosa in a living, physiologically complete system.

Why must I use this?

Transgenic (specifically gene-targeted) mice are essential because cell cultures and organoids cannot fully capture the systemic innate immune response and the complex hydrodynamics of micturition that define urinary tract pathogenicity. Klebsiella infections triggers a "scorched earth" defense called exfoliation, where infected cells detach to flush out bacteria; this process relies on a signaling cascade that requires the structural integrity of the whole bladder wall. The Upk1a knockout mouse reveals a critical paradox unavailable in 2D cultures: without the receptor, the host fails to sense the infection (blunted TLR4 signaling), leading to reduced bacterial clearance despite the lack of binding targets, which is a mechanism that requires a whole-organism model to dissect.

When will I use this?

I will use this mouse model when moving from identifying adhesion inhibitors to validating host-response mechanisms. After discovering potential anti-adhesive agents in vitro, I must test them in the Upk1a knockout model to distinguish between simple blocking of attachment and the complex modulation of the host's immune system. This allows me to determine if a therapy effectively clears the infection or merely masks it, preventing the immune activation necessary for long-term resolution before considering clinical translation.

I can utilize CRISPR/Cas9 gene editing or microinjection to generate transgenic C. elegans strains carrying fluorescent reporters that light up when the innate immune system is triggered. Instead of complex procedures with mice, I can simply infect these worms with bacteria on agar plates or in liquid culture. By using RNA interference by feeding, I can also systematically silence thousands of host genes to identify exactly which pathways are required to survive the bacterium induced oxidative stress and colonization.

Why must I use this?

C. elegans is essential because it allows for high-throughput, whole-organism screening that is impossible in mice, organoids, or cellular models. Because the worm is transparent, I can visually track the accumulation of bacteria in the worm and the simultaneous activation of immune reporters in a living host without dissection or complex imaging. This model isolates the innate immune response, allowing me to dissect the evolutionarily conserved innate defense mechanisms against bacteria without the confounding variables of the adaptive immune system.

When will I use this?

I will use the C. elegans model at the start of the discovery pipeline, specifically for high-volume screening of antimicrobial compounds or bacterial virulence factors. After identifying a library of potential drug candidates that rescue the worms from bacterial virulence, or pinning down specific bacterial genes that drive cellular stress responses, I will then select the most promising few candidates to validate in the more labor intensive murine models or complex organoid systems.

1. How can I use this?

   Flow cytometry allows me to analyze thousands of individual cells within seconds by giving detailed information about their surface markers, internal proteins and overall functional state. Using fluorescent antibodies or dyes, I can identify which cells are activated and which belong to specific immune populations. Cell sorting extends this capability by physically separating selected cell types from a mixed sample. This lets me isolate pure populations of T cells, B cells, macrophages or other subsets for further experiments, such as gene expression analysis or functional assays. Together, these methods help me understand cellular diversity and immune responses with precision and speed.

2. Why must I use this?

   These techniques are essential because the immune system is highly complex and bulk measurements often hide important differences between individual cells. Flow cytometry provides quantitative and single-cell resolution, which is critical for distinguishing subtle immune changes that may be missed in traditional assays. Cell sorting is equally important when I need clean and well defined cell populations to study specific mechanisms or to perform downstream experiments without contamination from unrelated cell types. Both methods are standard in immunology because they offer accuracy, scalability and deep insight into how immune systems function in health and disease.

3. When will I use this?

   I will use flow cytometry when I need to measure immune cell composition, activation states, cytokine expression or cell cycle progression with high precision. It is especially valuable when studying complex samples, such as blood, lymphoid tissues or immune stimulated cultures. I will use cell sorting when I need to purify a specific immune subset for detailed analysis or controlled experimental manipulation. These methods are particularly important during experiments that require clear identification of immune phenotypes or functional validation of specific cell populations.

1. How can I use this?

   • I can create mouse models with specific genetic alterations related to immunological pathways, cytokines, or gut microbiome interactions through this technology. I can evaluate whether my next-generation probiotics actually improve chemotherapy outcomes, such as boosting immune cell activation, lowering inflammation, or increasing treatment sensitivity, by creating mice with modified immune responses or tumor microenvironments.

2. Why must I use this technology?

   • Unlike conventional animal models, transgenic and gene-targeted mice offer precise control over specific genes related to immunity, cancer progression, and host-microbe interactions. They aid in determining the precise mode of action of my probiotic strains and prevent findings that are confusing due to biological differences. Compared to other models, such as cell lines or wild-type animals, this technology provides me with a clearer and more mechanistic understanding of the process.

3. When will I use this technology?

   • This technique will be used after my in vitro data reveal that my probiotic candidates have promising immunomodulatory or chemo-enhancing properties. At that point, I need an in vivo system to evaluate the mechanism and ensure its safety and efficacy. When I want to test particular pathways, like removing a receptor that my bacteria are meant to stimulate, gene-targeted mice are particularly helpful. This is often the preclinical validation stage before proceeding to more advanced animal experiments.

1. How can I use this?

I can use C. elegans infection assays to compare how my resistant and non-resistant A. baumannii strains affect host survival or colonization. Worm mutants or RNAi lines can also help identify host pathways involved in responding to infection.

2. Why must I use this?

Cell culture alone cannot capture whole-organism level responses like innate immunity, stress signaling, or behavioral changes. C. elegans provides a simple but multicellular host with conserved pathways, making it a useful bridge between in vitro assays and more complex animal models. Using worms can help me evaluate whether my resistant strains show altered virulence or trigger different host responses, which is important for understanding the broader consequences of resistance evolution.

3. When will I use this?

I would use C. elegans models after generating resistant mutants or identifying bacterial genes that might influence virulence. Once I have strains I want to compare, worms allow me to quickly test infection outcomes, survival differences, or immune-related phenotypes. This would be especially helpful before moving into more resource-intensive mammalian systems.

2. Why must I use this?

HTS is indispensable for drug discovery, functional genomics, and biomarker identification. It provides large-scale data that help select promising compounds or genes for further study. Without HTS, biomedical research would be slower and less efficient. It also ensures that potential therapies can be evaluated early, reducing the risk and cost of later clinical trials.

3. When will I use this?

These methods are applied in pharmaceutical research, genetic studies, and biotechnology projects. They are mobilized whenever large numbers of samples or targets must be tested quickly and systematically. HTS is especially important when researchers need to compare many different molecules or genetic variants under standardized conditions.

2. Why must I use this?
These methods are essential to understand gene function in living organisms, to model human diseases, and to test therapies before applying them to humans. They also allow the creation of animals with useful traits, such as producing therapeutic proteins or serving as organ donors. Without these approaches, it would be impossible to study gene expression in a controlled and reproducible way. Moreover, they provide a bridge between basic genetic research and translational applications in medicine.

3. When will I use this?
They are used in biomedical research whenever gene function must be studied in vivo. Applications include disease modeling (cancer, diabetes, cystic fibrosis, Alzheimer’s), functional genomics, and translational medicine. They are mobilized in genetics laboratories, molecular biology, and biotechnology. In addition, they are often chosen when researchers need reliable animal models that closely mimic human physiology.

2. Why must I use this?
C. elegans is a powerful model because it shares 50–80% of its genes with humans, yet it is easy and cheap to maintain. Its invariant cell lineage and compact genome make it ideal for genetic studies. Discoveries in C. elegans have revealed conserved pathways, such as apoptosis, that are directly relevant to human biology and disease. This means that results obtained in worms often provide insights that can be applied to higher organisms, including humans.

3. When will I use this?
This organism is used in projects on genetics, neurobiology, developmental biology, and aging. It is mobilized when researchers need a simple multicellular model with strong genetic tools, short generation time, and reproducible results. It is particularly useful when large-scale genetic screens or functional studies must be performed quickly and at low cost.

Protein structure biology provides the tools and concepts needed to understand how a protein's 3D conformation determines its function. In practical research, this allows me to examine how mutations alter protein folding, stability, and active-site geometry. For example, if I am studying an enzyme implicated in a disease pathway, determining its structure through X-ray crystallography, cryo-EM, or NMR spectroscopy enables me to map functional domains, locate catalytic residues, and visualize how ligands or inhibitors bind. With this information, I can rationally design experiments to test structure-function relationships, create targeted mutations, and screen for small molecules that may modulate the protein's activity.

• Why must I use this?

Protein behavior cannot be fully understood from its amino-acid sequence alone. Because many biological processes-signal transduction, metabolism, transcriptional regulation-depend on highly specific molecular interactions, knowing the structure is essential for explaining the mechanism at the atomic or near-atomic level. Structural information also provides insight into misfolding diseases, conformational changes, and protein-protein interfaces that are otherwise invisible using standard biochemical assays. Therefore, protein structure biology is necessary when the research question requires mechanistic clarity, such as determining how a mutation disrupts function, why an inhibitor works, or what conformational states exist during a protein’s activity cycle.

• When will I use this?

I will use protein structure biology whenever I need to visualize a protein's architecture to answer functional or mechanistic questions. For example, if I am working on drug development, structural data will guide rational design of molecules that fit precisely into a binding pocket. If I am studying a protein complex involved in immune signaling, cryo-EM can reveal how multiple subunits assemble and interact. Additionally, when mutations produce unexpected phenotypes, solving the structure can help explain how subtle changes reshape the protein’s stability or interaction surfaces. In short, I will use protein structure biology in any project where understanding the shape of the molecule is key to understanding its biology.

Gene transfer allows me to introduce specific DNA sequences into cells or organisms so I can express new genes, silence existing ones, or gene modifications. For example, I can use viral vectors or plasmids to deliver a reporter gene into mammalian cells to study signaling pathways or to test how certain regulatory elements affect gene expression.

• Why must I use this?

To study gene function, I need a way to precisely manipulate genetic material inside living cells. Many biological questions such as how a mutation alters phenotype, or how a therapeutic gene can correct a defect, cannot be addressed without introducing new genetic functions. Gene transfer provides an effective and efficient method to achieve this.

• When will I use this?

I will use gene transfer whenever an experiment requires changing what a cell expresses. This includes overexpressing proteins to study their roles, introducing CRISPR components for genome editing, creating stable cell lines that carry specific constructs, or delivering therapeutic genes in translational research.

Methods in C. elegans can be used to study multicellular biology in a simple, easily manipulatable organism. I can use tools such as RNAi feeding, transgenic reporter strains, and cell-specific promoters to observe how genes regulate development, neural circuits, and behavioral patterns.

• Why must I use this?

Some biological processes like tissue development, cell-cell communication, and organism-level phenotypes, cannot be studied accurately in cell culture. C. elegans provides a transparent body, well-mapped cell lineage, and established genetic tools, making it ideal for linking gene function to physiological outcomes in a complete multicellular organism.

• When will I use this?

I will use these methods when I need an in vivo model to test how genetic changes affect development, behavior, or aging. For example, if I want to study how a mutation alters neuronal wiring, C. elegans methods allow me to observe these effects directly in a living organism.

Flow cytometry analyzes single cells suspended in fluid by measuring fluorescence as they pass through a laser beam. It quantifies surface or intracellular markers, while fluorescence-activated cell sorting (FACS) physically separates cells based on signal intensity [1,2]. This allows simultaneous measurement of multiple parameters at high speed and resolution.

Why must I use this?

It is essential for defining immune cell phenotypes, activation states, and cytokine production. Compared with bulk assays, flow cytometry provides single-cell precision and quantitative population distribution, while sorting yields pure subsets for downstream genomic or functional assays [2,3].

When will I use this?

I will use flow cytometry during immune profiling or infection studies, especially to analyze neutrophil or macrophage activation and to isolate specific subpopulations for transcriptomic or proteomic analysis [1,3].

References

1.Saeys Y., et al. Computational flow cytometry: Helping to make sense of high-dimensional immunology data. Nat Rev Immunol, 2016; 16: 449–462.

2.Herzenberg L.A., et al. The history and future of the fluorescence activated cell sorter and flow cytometry: A view from Stanford. Clin Chem, 2002; 48(10): 1819–1827.

3.Chattopadhyay P.K., Roederer M. A new era in cytometry: Multiparameter analysis of the immune system. Nat Rev Immunol, 2012; 12: 451–455.

How can I use this?

I can use high-throughput screening to test large chemical or genetic libraries in parallel using miniaturized assays, automated liquid handling, and plate readers. By building either target-based or phenotype-based assays, I can quantify enzymatic activity, signaling responses, viability, or morphological changes. A validated assay with a strong Z′-factor provides confidence that thousands of conditions can be screened reproducibly, allowing rapid identification of hits that modulate a pathway or phenotype [1,2].

Why must I use this?

HTS is essential when the biological question involves many potential regulators or compounds. It provides scalability, statistical robustness, and automation that manual experimentation cannot achieve. HTS also reduces bias by enabling unbiased discovery of unexpected targets, and it integrates seamlessly with downstream confirmation assays such as imaging or transcriptomics [2,3].

When will I use this?

I will use HTS in the early discovery phase screening chemicals, CRISPR libraries, or reporter systems to reveal initial hits. Later, I will apply it when comparing toxicities, optimizing dose–response behaviors, or prioritizing candidates for mechanistic studies [1,3].

References

1.Macarron R. et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov, 2011; 10: 188–195.

2.Arkin M.R., Whitty A. The road less traveled: high-throughput screening in academia. Nat Chem Biol, 2009; 5: 15–17.

3.Pushpakom S. et al. Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov, 2019; 18: 41–58.

How can I use this?

I can use next-generation cancer and developmental models such as organoids and organ-on-chip systems to recreate human tissue architecture in vitro, allowing me to analyze tumor evolution, lineage specification, drug responses, and developmental signaling with far greater physiological relevance than 2D cultures. Using patient-derived organoids or iPSC-derived structures, I can model crypt–villus organization, airway differentiation, or brain development, These platforms can be combined with CRISPR editing, single-cell sequencing, and microfluidics to resolve dynamic behaviors at cellular and tissue scales.

Why must I use this?

These systems capture human-specific features that animal models often miss, including genetic diversity, self-organization, and clinically relevant drug sensitivity. Their scalability, compatibility with high-content imaging, and integration with omics make them essential for precision oncology and developmental research [1–3].

When will I use this?

I will use these models when validating patient-specific mutations, testing therapeutic candidates, mapping developmental defects, or studying host–pathogen interactions, especially where 2D or animal systems lack fidelity [2,3].

References

1.Clevers H. Modeling development and disease with organoids. Cell, 2016; 165: 1586–1597.

2.Sachs N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell, 2018; 172: 373–386. 3.KimJ., Koo B.-K., Knoblich J.A. Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol, 2020; 21: 571–584.

How can this be used?

Transgenesis and gene targeting in mice enable controlled manipulation of the genome to study gene function in vivo. Pronuclear injection introduces exogenous transgenes under defined promoters, while embryonic stem (ES) cell targeting and CRISPR-assisted homologous recombination generate precise knockouts, knock-ins, or reporter alleles, as outlined in the lecture slides. These methods create genetic models that reflect developmental, physiological, or disease-relevant contexts.

Why must this be used?

Mouse models reveal phenotypes and regulatory mechanisms that cannot be captured in cell culture. They allow analysis of tissue specificity, developmental timing, systemic interactions, and compensatory pathways critical factors for understanding gene function and modeling human disorders [1–3].

When will this be used?

These approaches are applied when validating pathogenic mutations, constructing cancer or immunology models, evaluating therapeutic strategies, or studying developmental processes that require an intact mammalian system before translational progression [2,3].

References

1.Capecchi M.R. Gene targeting in mice: functional analysis of the mammalian genome. Nat Rev Genet, 2005; 6: 507–512.

2.Yang H. et al. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell, 2013; 154: 1370–1379.

3.Platt R.J. et al. CRISPR–Cas9 knock-in mice for genome editing and cancer modeling. Cell, 2014; 159: 440–455.

How can this be used?

C. elegans enables controlled genetic and developmental studies because it is transparent, has an invariant cell lineage, and supports CRISPR editing, RNAi, and live imaging. Its short generation time and high fecundity make it suited for large-scale genetic screens, neuronal mapping, and studies of behavior, stress responses, and aging [1].

Why must this be used?

The worm shares extensive conservation with human disease pathways and allows mechanistic questions to be tested in an intact organism at single-cell resolution. Its simplicity, low cost, and compatibility with high-throughput phenotyping make it uniquely powerful for linking gene function to system-level outcomes [1,2].

When is this used?

C. elegans is selected for projects requiring rapid in vivo genetics, functional genomics, neurobiology studies, drug or toxicity testing, or modeling conserved signaling pathways before transitioning to vertebrate systems [2,3].

References

1.Calahorro F., Ruiz-Rubio M. Caenorhabditis elegans as an experimental tool for molecular neuroscience. Front Mol Neurosci, 2021.

2.Hunt P.R. The C. elegans model in toxicity testing. J Appl Toxicol, 2017.

3.Markaki M., Tavernarakis N. Modeling human diseases in Caenorhabditis elegans. Biotechnol J, 2020.

1. How can I use this?

   • During chemotherapy-like stress, I can easily assess if my next-generation probiotics can enhance survival, lessen toxicity, or alter host immune responses using C. elegans. For example, I can treat worms with my probiotic candidates after exposing them to chemotherapeutic treatments to see if they increase longevity, lower oxidative stress, preserve gut integrity, or alter immune-related signaling pathways. This provides me with an early indication of whether my germs have protective or damaging effects on the entire organism.

2. Why must I use this?

   • Compared to mammalian models, C. elegans allows me to look at host-microbe-drug interactions in a living multicellular organism much more quickly and ethically. It is affordable, genetically well-characterized, and scalable, providing me with biological complexity that cell culture cannot. Additionally, it enables me to effectively screen various probiotic strains and conditions for my study before proceeding with more expensive mouse experiments.

3. When will I use this?

   • C. elegans will be used in the early-stage screening phase, before moving on to mammalian cell tests and animal studies. It is ideal for determining which probiotic strains are worthwhile, evaluating toxicity, monitoring effects throughout the body, and choosing the most promising candidates to proceed to more complex in vitro or in vivo research.

How can I use this?
You can use these techniques to change the mouse genome in a precise way. For example, you can add a transgene by pronuclear injection, or you can delete or modify a gene using gene targeting or CRISPR/Cas9. You can also control when and where a gene is active using systems like Cre/loxP or inducible promoters. Basically, these tools let you study gene function directly in a living organism.

Why must I use this?
Because mice are very similar to humans genetically, and we cannot do genetic experiments on humans for ethical reasons. Using genetically modified mice helps us understand how genes work, model human diseases, and test new therapies. It’s also one of the best ways to see the real effect of a gene in a whole organism, not just in cells.

When will I use this?
You will use these methods when you need to study the effect of a specific gene, create a disease model, or test how changing a gene influences development or physiology. For example, if a gene causes early lethality, you might use conditional or inducible systems to delete it only later or only in one tissue. In general, anytime you need to explore gene function in vivo, these techniques become essential.

How can I use this?

You can use C. elegans as a model organism to study many biological processes in a simple and efficient way. For example, you can observe development because the worm is transparent, or analyze gene function using tools like mutants, RNAi, or CRISPR. You can also use transgenics to see where a gene is expressed or what happens when you overexpress it. Basically, the worm lets you test ideas about genetics, cell biology, or behavior in a whole organism.

Why must I use this?

Because C. elegans is one of the easiest organisms to work with, while still sharing many conserved pathways with humans (about 50–80% of genes). It grows fast, is cheap to maintain, and has a fully mapped cell lineage and nervous system. It’s perfect when you want to understand fundamental mechanisms like development, cell death, aging, or behavior. And since it’s transparent and small, experiments are simple and reproducible. So, it’s a very practical and powerful model for research.

 When will I use this?

You will use C. elegans when you need a fast, simple and reliable system to study gene function or biological pathways. For example, when you want to screen for mutants, test RNAi effects, analyze neuronal circuits, or explore aging in a short time. It’s also useful when you need large populations, or when working with mammals would be too slow, expensive, or ethically complex. Basically, anytime you need a genetic or developmental model that gives quick and clear results.

How can I use this?

I can use transgenesis and gene-targeting methods in mice to introduce precise genetic changes, add reporters to visualize gene activity, or control when and where a gene is expressed. Techniques such as CRISPR knock-in/knock-out, ES-cell targeting, pronuclear injection, and Cre/loxP allow me to test the function of specific regulatory elements, coding mutations, or gene networks directly in a whole organism. These approaches let me study gene function in a physiological setting that reflects real tissue complexity.

Why can I use this?

I can use these methods because mice are a genetically tractable model with strong biological similarity to humans. Their genome can be modified in a stable and heritable way, making them ideal for disease modeling and functional testing. Mouse lines also offer temporal and cell-type specificity through inducible or tissue-specific Cre drivers, which is essential when global knockouts or early misexpression would cause lethality or mask the true phenotype. This flexibility allows me to study genes under conditions that more accurately reflect human biology.

When can I use this?

I can use these approaches when my research questions require in vivo validation rather than just cell-culture results. This includes situations where I need to confirm whether a regulatory variant truly affects expression in a specific tissue, or when I want to activate or delete a gene in defined neuronal or developmental populations. These tools become necessary when the biological process I’m studying, such as neural circuitry, development, or disease progression, depends on interactions that only occur within an intact mammalian system.

How can I use this?

I can use multicellular organism methods in C. elegans to study development, tissue interactions, and whole-body responses in a controlled and genetically tractable system. Because the worm is transparent and has a fully mapped cell lineage, I can easily visualize how cells divide, migrate, and differentiate during growth. By combining fluorescent reporters, CRISPR-based editing, RNAi, and tissue-specific promoters, I can observe how genetic changes affect the nervous system, muscles, immune pathways, metabolism, or stress responses across the entire organism. This gives me the ability to test hypotheses about multicellular coordination, organ function, and gene regulation in vivo, rather than relying only on isolated cell culture systems.

Why must I use this?

I must use C. elegans for multicellular studies because it provides a whole-organism context that simpler models cannot offer. Unlike cell lines, the worm allows me to observe interactions between tissues, developmental timing, and systemic physiological responses, all of which are essential for understanding how a gene or pathway functions within a complete biological network. The worm is also ethical, inexpensive, and genetically well-annotated, enabling rapid screening and mechanistic studies that would be too slow, costly, or complex in mammals. In addition, the high evolutionary conservation between C. elegans and humans means that discoveries made in worms often translate into insights about human development, aging, immunity, and disease.

When will I use this?

I will use these methods when my research requires whole-organism evidence, such as determining how a mutation affects multiple tissues, whether a signaling pathway influences development, or how different organs coordinate during stress or infection. This is especially important when cell culture models fail to capture systemic effects or long-range communication between tissues. C. elegans is ideal for the early and intermediate phases of my project, when I need to evaluate multicellular phenotypes, perform genetic screens, or monitor organism-wide outcomes before moving on to more complex vertebrate models. It helps me identify which genes, pathways, or conditions are worth pursuing in higher organisms.

I can use C. elegans to study developmental and physiological processes in a whole organism because its transparency, invariant cell lineage, and mapped nervous system allow direct observation of tissues and behavior. With genetic tools such as mutants, RNAi, CRISPR, and transgenics, I can perturb gene function and efficiently connect molecular mechanisms to organism-level phenotypes.

Why must I use this?

Because C. elegans combines high genetic conservation with experimental simplicity. Its short lifecycle, small cell number, and low maintenance cost make it ideal for rapid studies of development, stress responses, apoptosis, and aging. The ability to perform large-scale genetic screens and apply RNAi conveniently provides advantages that many other systems cannot offer.

When will I use this?

I will use C. elegans when I need a fast and tractable model to evaluate gene function, perform genetic screens, or analyze behavior linked to defined neural circuits. It is especially useful for aging research: in my previous Aging course, I saw how its short lifespan and clear aging markers make lifespan and healthspan assays highly efficient. This makes the worm a practical first model before moving to more complex systems.

Why must I use this? 

Flow cytometry is essential because it provides rapid, quantitative, and multiparametric analysis of thousands or even millions of cells in a very short time. It allows me to study the immune system in great detail, identify rare cell types, and analyze functional properties such as cytokine production, proliferation, or apoptosis. Compared to traditional microscopy or ELISA, it offers higher precision, speed, and the ability to analyze multiple markers at once. Technology can also be combined with fluorescent barcoding or bead-based assays to study many samples or cytokines simultaneously, saving both time and reagents. 

When will I use it? 
I will use flow cytometry in research that involves immunology, cell biology, or biomedical studies. It is particularly useful for characterizing immune cell populations, watching responses to infection or vaccination, and studying diseases like cancer or autoimmune disorders. In clinical or translational research, flow cytometry helps diagnose immune deficiencies, leukemia, or lymphoma by identifying abnormal cell markers. I would also use it when I need to track cell proliferation, detect apoptosis, or measure protein phosphorylation. Overall, this technique is necessary whenever I need to analyze complex cellular systems quickly and accurately at the single-cell level. 

You can use High-Throughput Screening (HTS) to quickly test many thousands of different substances, like small chemical compounds or genetic materials, to see if they affect a specific biological target, such as a protein or enzyme. The core methods rely on optical assays, meaning the result is measured by light, often using fluorescence or luminescence techniques because they are sensitive and easy to automate. These tests are done in tiny wells of specialized plates. The main steps involve: developing a test that works well on a small scale, using robotic systems to automatically move the target, test compounds, and reagents into the plates, reading the result in every well using a specialized plate reader and finally analyzing the massive amount of data to find the active compounds, known as "hits." 

Why Must I Use HTS? 

You must use HTS primarily to find new starting points for drug development or to identify crucial biological mechanisms that control cell function. It is necessary when the task involves analyzing hundreds of thousands or even millions of samples contained in modern chemical libraries. HTS is highly favored over traditional, manual lab methods because it offers enormous advantages in speed, scale, and cost-effectiveness. Traditional techniques could only test a few compounds per week, while HTS uses sophisticated robotics and automation to test tens of thousands of compounds per day. This speed drastically accelerates the discovery process, minimizes human error, and saves money by using much smaller volumes of expensive reagents. 

When Will I Use HTS? 

You will typically use HTS at the very beginning of a research or drug discovery project, specifically when you need to explore a very large number of potential solutions or effectors. The necessary condition for using HTS is having a well-defined target and a large, diverse library of compounds or genetic materials to screen against it. Essentially, HTS is needed whenever the sheer volume of samples makes manual testing impractical, too slow, or too costly. 

You can use this modeling technique by generating microscopic, self-organizing, three-dimensional organoids from stem cells. The foundational method involves taking either adult stem cells or pluripotent stem cells and culturing them to guide their self-assembly into structures that biologically and structurally resemble miniature human organs. Once these systems are established, the scale-up process is usually possible to allow for large-scale genomic screening or drug screening. Furthermore, you can apply most modern genetic engineering tools directly to these stem cells or organoid systems to study gene function or disease mechanisms. 

Why Must I Use This? 

You must use this modeling approach to create a better representation of human biology in a dish, as organoids offer the best recapitulation of human physiology compared to simple two-dimensional cell culture, animal models like C. elegans or fish, and PDX models. They are highly favored because they enable personalization, meaning they can be grown from an individual's stem cells to test tailored therapies or study patient-specific disease progression. Additionally, while they are more costly than traditional cell lines, they provide a valuable, physiologically complex alternative that is generally less expensive than using mouse or others models for screening. 

When Will I Use This? 

We should use next-generation modeling when your research requires a complex, multi-cellular structure that more accurately mimics the natural conditions of a human organ. This method is ideal when you need to perform large-scale genomic or drug screening where a high-throughput format is necessary, but the simplicity of 2D cell lines would lead to irrelevant or misleading results. Furthermore, organoids are chosen when the primary objective is personalized medicine, using models derived from an individual patient to precisely study disease and test drug efficacy for that specific person.  

You can use these techniques through two principal methods: classical transgenesis and precise gene targeting. In transgenesis, the major method is pronuclear injection, where a DNA construct is manually injected into the male pronucleus of a one-cell embryo. The process involves collecting embryos, injecting the transgene, and implanting the embryos into a surrogate mother to guarantee the gene's presence in all cells of the resulting founder animal. Alternatively, gene targeting in Embryonic Stem Cells is used to create specific modifications like a knock-out or knock-in via homologous recombination. This involves modifying ESCs in vitro, selecting for the correctly targeted cells, injecting them into a host blastocyst to produce a chimeric mouse, and screening for germ-line transmission. 

Why Must I Use This?  

You must use genetically manipulated mice to accurately model the complex dynamics of human physiology and disease, which cannot be fully replicated in simpler organisms or cell cultures. Mice are favored because they share approximately 95% of their genes with humans, and their body systems function similarly, allowing researchers to study gene function, establish causation, and test therapies in a relevant mammalian context.  

When Will I Use This?  

You will use these methods whenever your research requires the comprehensive physiology of a whole mammal to investigate a gene’s function or model a complex human condition like diabetes or Alzheimer’s. You will use gene targeting when precision is critical, for instance, when creating an exact knock-in of a human disease-causing mutation. This system allows you to control the gene's deletion or expression spatially or temporally , thereby revealing its function in adult animals. 

I can use the nematode Caenorhabditis elegans for multicellular research by employing methods such as microinjection and biolistic transformation to introduce foreign DNA. Microinjection is a common and efficient method where DNA is injected into the syncytial gonad to produce transgenic lines, often using a visible marker as a co-injection marker to identify transgenic worms. A major limitation of this technique is that the expression of the transgene can sometimes be silenced in germ cells. Alternatively, biolistic transformation involves shooting DNA coated gold particles into the worms, which generally results in stable, chromosomally integrated transgenes that do not undergo germline silencing, though this method is more labor-intensive. 

Why Must I Use This?  

I must use C. elegans to study biological principles due to its combination of simplicity, genetic tractability, and well-characterized development. It is highly favored over other multicellular models because it is transparent, allowing for easy visualization of all its internal structures, and has a fixed and fully mapped cell lineage from egg to adult. This complete cellular map is unavailable in any other animal. Furthermore, C. elegans is a hermaphrodite, which greatly simplifies genetic crossing and mutant isolation. Compared to more complex models like mice, C. elegans offers a fast and cheap system for large-scale genetic screenings.

When Will I Use This? 

I will use C. elegans when your research question can be addressed with a model that is evolutionarily distant from humans but still shares fundamental biological processes. This is especially true when you need to study developmental biology, aging, neurobiology, or programmed cell death, as the core mechanisms of these processes are conserved. I will select this model if you need a fast lifecycle and high reproduction rate for efficient genetic screening or if you need a cost-effective alternative to mammalian models.  

I can use recombinant protein design to produce specific bacterial or host proteins in a clean, controlled form. By cloning a gene of interest into an expression vector and purifying the protein with tags like His-tag, I obtain the exact molecule I need for functional or interaction studies related to my research.

Why must I use this?

I need this technique because natural proteins are often difficult to isolate in large, pure amounts. Recombinant expression allows me to study how individual microbial or immune-related proteins function, interact, or contribute to processes like inflammation and sepsis—key topics in my thesis.

When will I use this?

I will use recombinant protein design whenever I need to test a protein’s activity outside the whole organism, such as examining how a bacterial factor binds to a host receptor or affects immune signaling. It is especially useful for biochemical assays and validation experiments in my Master’s research.

I can use protein structural biology to understand how a protein’s three-dimensional shape determines its function, binding specificity, and stability. By analyzing structures obtained from X-ray crystallography, cryo-EM, or computational models, I can identify key residues important for enzyme activity or host–microbe interactions relevant to my research. This knowledge helps me interpret how a protein behaves, predict its role in biological pathways, and detect structural problems such as misfolding in recombinant protein expression.

Why must I use this?

Protein structure is essential for explaining function at the molecular level. Small structural changes can completely alter activity, binding, or regulatory mechanisms. For my thesis, structural information is necessary to understand how bacterial or host proteins interact during infection or immune signaling. It also allows me to identify residues for mutagenesis, evaluate the effects of pathogenic variants, and design more stable or more active protein variants for experimental studies.

When will I use this?

I will use structural biology whenever I need to infer a protein’s function, evaluate binding interactions, or troubleshoot recombinant protein experiments. It becomes especially important after purifying a target protein, when I want to compare wild-type and mutant forms or understand how structural changes influence biological outcomes related to host–microbe interactions.

I can use gene transfer to introduce specific genes, reporters, or regulatory elements into bacterial or mammalian cells so I can study how they influence GLP-1 expression. For example, I could transfer plasmids into Bifidobacteria to express candidate enzymes or metabolites, or use viral vectors to deliver GLP-1–related reporter constructs into intestinal cell models. This allows me to test how bacterial genes or secreted factors affect host signaling pathways involved in glucose regulation.

Why must I use this?

To understand how Bifidobacteria regulate GLP-1, I need a precise way to modify genes in both the bacteria and the host cells they interact with. Gene transfer is essential for validating whether a bacterial gene contributes to GLP-1 stimulation, for creating knockout or overexpression strains, and for testing regulatory elements in host intestinal cells. Without gene transfer, it would be impossible to dissect mechanisms or confirm causality in microbe–host metabolic interactions.

When will I use this?

I will use gene transfer whenever I need to alter gene expression in my experiments—for example, when engineering Bifidobacteria strains, testing mutants, creating GLP-1 reporter cell lines, or introducing CRISPR components to study pathway regulation. It will be especially useful during functional validation and mechanistic studies directly related to my thesis.

I can use RNA-based techniques—such as qRT-PCR, RNA-seq, and small RNA profiling—to measure how Bifidobacteria or their metabolites influence GLP-1 expression in host intestinal cells. qRT-PCR allows me to quantify changes in GLP-1 mRNA after treating cells with bacterial supernatants, while RNA-seq helps identify broader transcriptional changes in pathways related to metabolism, inflammation, or enteroendocrine cell function. I can also analyze bacterial RNA to understand which genes are active when Bifidobacteria interact with the host.

Why must I use this?

RNA techniques are essential because gene expression changes are the most direct indicators of how Bifidobacteria regulate GLP-1. Without measuring RNA, I cannot determine whether bacteria enhance transcription, affect mRNA stability, or modify signaling pathways involved in diabetes control. RNA-seq is especially important for discovering new bacterial factors or host genes that mediate GLP-1 induction, providing mechanistic insight into microbe–host metabolic communication.

When will I use this?

I will use RNA techniques whenever I need to evaluate how bacterial treatments affect host gene expression—for example, after co-culturing Bifidobacteria with intestinal cells, testing engineered strains, or validating pathway activation. These methods are also crucial during hypothesis generation (RNA-seq screens) and during targeted validation steps (qRT-PCR) in my thesis project.

I can use DNA nanotechnology to design highly programmable biosensors based on predictable base-pairing and precise structural assembly. DNA can be engineered into 2D or 3D nanostructures—such as DNA origami, tiles, or nanomachines—that respond to specific biomolecules. For example, DNA aptamers can be integrated into these nanostructures to recognize glucose, inflammatory markers, or microbial metabolites. When a target binds, the DNA structure changes conformation or produces a measurable signal, enabling sensitive detection.

Why can I use this?

I can use DNA nanotechnology because DNA is remarkably stable, easy to synthesize, and capable of self-assembly with high precision. These properties allow me to build customizable sensing platforms that are cheaper and more adaptable than antibody-based systems. DNA sensors also support multiplex detection, rapid signal generation, and integration with optical or electrochemical readouts, making them suitable for biomedical diagnostics and point-of-care applications.

When will I use this?

I will use this approach when I need to detect low-abundance biomarkers or design highly specific recognition systems. In metabolic or microbiome-related research, I could apply DNA aptamer-based sensors to monitor bacterial metabolites, inflammatory cytokines, or hormones such as GLP-1. This is especially useful for studying host–microbe interactions or developing diagnostic tools for metabolic diseases.

I can apply combinatorial and multiplexed genetic screening to systematically investigate which genetic features of Bifidobacteria drive GLP-1 induction in host cells. Instead of modifying one gene at a time, I can create a pooled library of Bifidobacterium variants—each carrying different combinations of metabolic genes, surface proteins, or regulatory elements suspected to interact with host enteroendocrine pathways.
By introducing DNA barcodes into each variant and co-culturing the entire library with intestinal organoids or GLP-1–reporter cell lines, I can track which genetic combinations most strongly activate GLP-1 production. This allows me to map synergistic or antagonistic gene interactions that shape how Bifidobacteria influence incretin signaling.

Why must I use this?

GLP-1 regulation by gut bacteria is not controlled by a single factor. It depends on complex metabolic processes such as SCFA production, bile acid modification, carbohydrate utilization pathways, and bacterial surface molecules that interact with host receptors. These factors often act in combination rather than isolation.
Using single-gene approaches would be too slow and would miss synergistic effects. Multiplex genetic screening gives me a high-throughput and unbiased strategy to pinpoint which combinations of bacterial genes—rather than individual ones—are necessary and sufficient to stimulate GLP-1.
This is essential for my research goal, because identifying the right gene networks will help engineer or select probiotic strains with maximal antidiabetic function.

When will I use this?

I will use this approach during the discovery and optimization phase of my project, when I need to identify which bacterial pathways contribute most to GLP-1 induction. Initially, I can perform in vitro screening using GLP-1 reporter intestinal organoids to rapidly narrow down candidate gene combinations.
After selecting the top-performing variants from the pooled screen, I will test them individually in vivo in diabetic mouse models to validate their effect on GLP-1 levels and glucose metabolism.
In the long term, combinatorial screening will be helpful if I work on engineering next-generation Bifidobacteria probiotics or uncovering compensatory pathways that determine which strains are most effective for diabetes prevention.

Why must I use this?
Protein function often depends on correct folding and interactions. For my project, understanding the structure of key bacterial proteins is crucial to predict how they influence GLP-1 signaling and metabolic regulation. Structural knowledge also helps identify residues for targeted modifications to improve probiotic efficacy.

When will I use this?
I will use structural biology after purifying proteins from selected Bifidobacteria strains. Comparing natural and engineered proteins will show how structural changes affect activity, helping optimize probiotic strains for controlling GLP-1 expression.

Why must I use this?
GLP-1 regulation is controlled by complex interactions among bacterial genes and metabolites. Low-throughput approaches would be too slow to capture all potential contributors. High-throughput screening provides a scalable, unbiased way to discover key regulators and prioritize candidates for further study.

When will I use this?
I will use HTS during the early discovery phase to identify bacterial genes or compounds that modulate GLP-1. Hits from these screens can then be validated in functional assays and used to design engineered probiotics with enhanced metabolic benefits.

Why must I use this?
Organoids retain the architecture, heterogeneity, and functional properties of human intestinal tissue, which are essential to study complex host–microbe interactions. They allow testing probiotic effects in a physiologically relevant setting before moving to animal models, reducing uncertainty and improving translational relevance.

When will I use this?
I will use organoid co-cultures in the mid-stage of my project, after identifying promising Bifidobacteria strains from initial screenings. This platform will help validate their impact on GLP-1 regulation and host metabolism before testing in vivo.

Why must I use this?
Mouse models are essential for validating findings from in vitro or organoid experiments. They allow me to observe systemic effects of probiotics on metabolism, GLP-1 regulation, and glucose homeostasis in a whole-organism context, which cannot be fully captured in cells or organoids.

When will I use this?
I will use transgenic or gene-targeted mice after identifying key Bifidobacteria strains and their target pathways in vitro and in organoids. These models will help confirm mechanisms and evaluate the therapeutic potential of probiotics in regulating GLP-1 and reducing diabetes-related phenotypes.

Why must I use this?
C. elegans provides a fast, cost-effective, and genetically tractable system to study host–microbe interactions in vivo. Its conserved metabolic pathways allow me to model aspects of human GLP-1 regulation and predict the systemic effects of probiotic interventions before moving to more complex models.

When will I use this?
I will use C. elegans in the early-to-mid stages of my project, after in vitro screening of bacterial strains. This system will help identify promising probiotic candidates and their mechanisms of action, guiding subsequent studies in organoids or mouse models.

RNA techniques, such as RT-PCR and RNA sequencing, allow me to detect and quantify gene expression in cells. These methods can be applied to study how genes respond to different treatments or during development by analyzing mRNA levels, providing insight into cellular functions and regulatory pathways.

• Why must I use this?

Understanding gene expression helps reveal which genes are active under specific conditions. RNA techniques provide sensitive and precise ways to measure the RNA transcripts, which is key to linking gene activity with specific cellular responses, or disease states.

• When will I use this?

I will use RNA techniques when I want to analyze gene expression changes, validate gene knockdown or overexpression, or profile transcriptomes to discover new RNA sequences or investigate alternative splicing patterns in various biological contexts.

DNA biosensing can be used in many different ways in bioscience research. From the earliest and simplest use of probes such as FISH, to modern multi-parameter large scale single cell or tissue genomics studies, DNA biosensing allows either focused or wide ranging studies with high throughput.

• Why must I use this?

Sometimes genome wide observations must be made in order to understand the whole picture in regards to the genomic profile either at the tissue level or at the cellular level. DNA probes or DNA sensing techniques allow this to be done in a high precise and specific manner.

• When will I use this?

When I want to see multi-parameter data using DNA probes. For example, in my lab, there has been projects in the past that try to find the most ideal conditions for differentiating iPSCs into specific tissue organoids. By designing a DNA aptamer biosensor to measure the growth factor release, I can also learn more about the signaling patterns of differentiated cells during organoid development.

These strategies allow me to simultaneously test multiple gene perturbations or interactions within gene circuits by using high-throughput genetic manipulation tools like CRISPR libraries. This helps identify key genes or pathways involved in complex biological processes or phenotypes.

• Why must I use this?

Traditional one-gene-at-a-time screens are time-consuming and miss combinatorial effects. Multiplexed screens enable efficient discovery of gene interactions and synthetic genetic relationships, which is critical for understanding gene networks and designing engineered gene circuits.

• When will I use this?

I will use these methods when studying complex traits influenced by multiple genes, mapping interaction networks, or optimizing synthetic biology constructs that require coordinated regulation of several genes simultaneously.

I can use C. elegans to study genetics, development, aging, and neural circuits because it’s transparent, easy to manipulate, and has powerful genetic tools like RNAi and CRISPR.

Why must I use this?

Because C. elegans gives you fast, cheap, and reliable insights into biology that often translate to humans—its genome shares 50–80% homology, and many pathways (like apoptosis) are conserved.

When will I use this?

I’ll use it when I need a simple but powerful system to test gene function, model human diseases, or run large-scale genetic screens—especially in projects where speed and cost matter.

Where I work, biotech or pharmaceutical companies often use high-throughput screening with automated imaging systems to process multi-well plates of cell cultures, in order to test drug or compound effects on cellular responses, such as viability, morphology, or signaling, enabling rapid evaluation of thousands of conditions simultaneously.

• Why must I use this?

Manual screening is too slow and labor-intensive for large compound libraries, while automated imaging provides quantitative, reproducible data on diverse phenotypes, uncovering subtle drug responses that low-throughput methods might miss. Automated systems also allows for the removal of human error as a factor.

• When will I use this?

I will use these methods when screening chemical libraries for hits in drug discovery, validating compound toxicity or efficacy across cell types, or assessing genetic perturbations' effects on cellular behavior in a scalable and reproducible way.

By growing tissue organoids, 3D self-organizing structures derived from stem cells, I can model complex tissue structures and functions, allowing me to simulate cancer progression, tumor microenvironments, or developmental processes in vitro for drug testing and bio-pathway studies.

• Why must I use this?

Traditional 2D cell cultures fail to capture spatial organization, cell-cell interactions, and heterogeneity seen in vivo, while organoids provide physiologically relevant models that bridge the gap between simplistic monolayers and animal studies.

• When will I use this?

I will use organoids when investigating cancer metastasis, screening therapies for patient-specific tumors, or studying embryonic development, especially to predict drug responses or dissect genetic regulatory networks in a human-relevant context.

How can I use C. elegans?

I will use C. elegans as an in-vivo model to validate and extend findings obtained from in-vitro cell-based assays. Specifically, it will help me evaluate organism-level effects such as survival, stress resistance, oxidative stress response, immune modulation, and lifespan after treatment with bioactive compounds or probiotic-derived factors. Using C. elegans allows me to connect molecular and cellular mechanisms (e.g., antioxidant or anti-inflammatory effects) with physiological outcomes in a whole organism.

Why I Must Use C. elegans?

While cell culture models provide mechanistic insights, they cannot fully represent systemic biological responses. C. elegans is essential because it offers a simple yet genetically conserved organism in which key pathways related to inflammation, oxidative stress, metabolism, and aging are shared with humans. It is cost-effective, ethically favorable, and enables rapid experimentation, making it an ideal intermediate model before moving to complex mammalian systems. Using C. elegans therefore strengthens the biological relevance, credibility, and translational value of my research.

When I Will Use C. elegans?

I will use C. elegans:

• After obtaining significant results from in-vitro assays (e.g., antioxidant, cytotoxicity, or anti-inflammatory studies)

• During mechanistic studies to evaluate whole-organism responses such as stress tolerance and lifespan

• In preclinical validation of probiotics or bioactive compounds

• While preparing publications or research proposals that require in-vivo evidence to support cellular findings

I can use mouse models for cancer research. In the past my lab had used a mutant mouse prone to develop diabetes, along with another mutant prone to develop pancreatic cancer, to conduct research into the relationship between diabetes, chronic high blood glucose, and the development of pancreatic cancer. The diabetes prone strain of mouse was an established mutant strain with a mutation in it's leptin receptor, named db mice. The pancreatic cancer prone strain of mouse used transgenic methods to produce a mouse line carrying the Kras G12D mutation. The two strains of mice were then crossed to produce mice that were both diabetic and carrying a mutation making them prone to develop pancreatic cancer. In this way, experiments for obtaining insights into the relationship between diabetes and pancreatic cancer could be carried out. Transgenic mice can also have "reporter genes" engineered into their genome, so that colors or patterns in their fur coat can be used to discern if they are indeed carrying the gene of interest, in the event they are crossed with another strain of mouse. This can partially save time in regards to genotyping the mouse.

• Why must I use this?

In many areas of research, especially in topics related to a clinical setting, experiments need to be conducted on systemic models rather than on individual component units such as cells. For example in the study of cancer a researcher may be interested in finding out the time frame in which metastasis occur. This type of observation is hard to reproduce accurately without animal models. When mere cell culture experiments are insufficient, animal models are required, and mice are both similar enough to humans, while being easy to maintain to make them one the most suitable model organisms.

• When will I use this?

I will use mouse models, or any other animal models, when mere cellular level experiments are insufficient for the research topic at hand. If my research is trying to demonstrate biological phenomena whose data will later to be extropolated to humans, and which can only be observed in a systemic setting, then mouse or animal models will be indispensable if I want my experiments to be convincing.

I use these methods because each reveals a different layer: quantity (qPCR), authenticity (Northern), spatial distribution (FISH), and mechanism (RIP/EMSA).

I will apply this toolkit when designing future experiments: first, screening with high-throughput data, then confirming expression with qPCR, and finally moving to structural and mechanistic assays only when necessary. This strategy saves time, reduces cost, and produces solid, believable data.

I use C. elegans when the question is about conserved cell biology or signaling pathways. The apoptosis pathway discovered in worms and later confirmed in humans is a real example of why data from worms can translate. Also, the transparent body and invariant cell lineage mean that if I want to track cell division or neuron behavior, worms are more informative and realistic than cultured cells.

I will use this model especially at early phases of a project: screening candidate genes, checking phenotypes, and doing rapid loss-of-function (RNAi/CRISPR) before committing to expensive mammalian work. In short, C. elegans is a practical decision—cheap, fast, genetic-powerful—and helps me fail early or succeed early.

Flow cytometry allows for very fast accumulation of quantitative data in cellular analysis. In the past I have used flow cytometry for immune profiling of mouse and human blood samples, as well as cell cycle experiments. Flow cytometry is an essential tool in immunology research as well as in many other fields. For example, in the field of stem cell or tissue regeneration research, flow cytometry can be used to quickly determine the surface marker expression profiles of cells, which in turn can be used to determine things such as differentiation efficiency.

• Why must I use this?

There are times when large scale quantitative data must be presented in order to provide more compelling evidence for trends or status of cell populations. In times when other techniques, such as imaging methods, can only provide a narrow view of the situation, flow cytometry is required to provide a macro view of the phenotype of cells.

• When will I use this?

Flow cytometry is used when requiring relatively fast and high volume acquisition of data on cell populations. When I want to see the expression profiles of a group of cells and how this changes during my experiments.